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As the global threat of antibiotic resistance grows the approval rate of new antibiotics falls. Pharma 
companies are dropping their antibiotic research programmes at the time when new antibiotics are 
needed the most due to antibiotic resistance. Paradoxically antibiotic resistance is one of the many 
reasons that the discovery of new antibiotics is not lucrative enough for it to be a financially viable 
pursuit. Promising high-throughput technologies have been unsuccessfully employed to streamline 
drug discovery due to the lack of novel chemicals within libraries. Natural products have contributed 
massively to drug discovery in the past although its contribution to the declining number of 
antibiotics discovered recently has also diminished. To revive the drug discovery pipeline invasive 
weeds were targeted as a potential source of novel chemical compounds. Three species; Fallopia 
japonica, Impatiens glandulifera and Rhododendron ponticum were collected. Each species was 
extracted and fractioned to discover any potential antimicrobial compounds. A particularly active 
compound 2-methoxy-1,4naphthoquinone (MNQ) was discovered. This compound was found to 
have a broad range of activity against clinically relevant bacteria. The methoxy group was found to 
be crucial for the potent antimicrobial activity of this compound. It was also a potent inhibitor of 
Schistosoma mansoni. Cytotoxicity of this compound was found to be a potential issue with mixed 
results. High throughput metabolomic methodologies were developed to understand the 
mechanism by which MNQ inhibits the growth of MRSA. The metabolomic effect of MNQ was 
compared to other antibiotics, it was found that MNQ had a distinctive metabolomic effect. This 
unique effect was further investigated with in-depth metabolic pathway analysis using statistical 
methods twinned with KEGG metabolomics pathway database. Once a tentative mode of action was 
identified transmission electron microscopy and specific antimicrobial assays were used to support 
this theory.   
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 This research project has discovered a promising antimicrobial and anthelminthic 
compound and the developed metabolomic methodology yielded a large amount of useful data 
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Chapter 1 - Natural Products; Invasive weed species as a 
potential source of antimicrobials  
1.1 – Introduction – Natural Products  
1.1.1 - Chapter Aims 
 Natural products have been used to treat disease for thousands of years yet traditional 
approaches to drug discovery have been declining with the modernisation of the drug discovery 
pipeline. With an emphasis on synthetic methods and high throughput screening in recent research 
there has been a decline in the number of novel drugs being discovered. The effectiveness of drug 
discovery is critical especially in the face of antibiotic resistance. The contribution of natural 
products and alternative methods to drug discovery will be discussed as well as the issue of 
antibiotic resistance. Invasive weeds are a problematic yet could potentially be a plentiful source of 
novel antimicrobial compounds. Three particularly plentiful and aggressive invasive weed species 
were chosen for analysis. A bioactivity led purification process will be carried out to identify 
compounds which have the potential to treat MRSA infections. 
1.1.2 - History of natural products  
 Humans have always been dependant on nature to cater for their basic needs such as food 
and shelter but also medicines. Initially medicines were in the form of crude treatments such as 
tinctures, teas, poultices, powders and other herbal formulations. There is evidence that 
Neanderthals living 60,000 years ago used plants from the Alcea genus to treat infections (Stockwell, 
1988), this plant genus is widely used in ethnomedicine and there are current research efforts 
attempting to identify active compounds within this genus (Seyyednejad et al., 2010; Ghasemi and 
Atakishiyeva, 2016; Azab, 2017). More recent approaches involved the isolation of a single active 
compound (Balunas and Kinghorn, 2005). The first active compound to be isolated in this way was 
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morphine from opium by Friedrich Setürner in 1804 (Schmitz, 1885). Morphine was used as a potent 
analgesic at this time and became the first of the opioid drug class. Current semi-synthetic opioid 
drugs, such as oxycodone, are all derived from the initial research on Papaver somniferum 
commonly known as the breadseed or opium poppy. Much natural product research at this time 
was based on plants linked to known medicinal properties and this led to discoveries such as aspirin, 
quinine, and pilocarpine (Butler, 2004). The analgesic aspirin is synonymous with the willow tree 
because in the 18th century willow extracts were used to relieve pain. The active components of 
the willow tree were identified as salicilin and salicylic acid (Mahdi, Mahdi and Bowen, 2006). The 
salicylic acid synthetic derivative acetylsalicylic acid (aspirin) is a Nonsteroidal anti-inflammatory 
drug (NSAID) which is a drug class which reduces pain, fever and inflammation. It also reported to 
have a range of other beneficial health benefits being said to have, antiproliferative, anticancer 
properties (Ridker et al., 1997; Mahdi, Mahdi and Bowen, 2006). Pilocarpine, a treatment for 
intraocular pressure and xerostomia, is another example of an effective natural product isolated 
from Pilocarpus jaborandi in 1874 which is still in use today (Sneader, 2005). Quinine has origins as 
far back as the 1600s when the bark of the cinchona tree was used to treat malaria.  Later the active 
component was identified as quinine and the use of which to treat malaria marked the first 
successful treatment of an infectious disease. It was replaced as the frontline treatment for malaria 
in 2006 yet it remains as an alternative if artemisinin fails and is still the favoured antimalarial drug 
in pregnant patients (Achan et al., 2011). The replacement frontline treatment for malaria is now 
artemisinin which is a natural product derived from Artemisia annua. It was discovered in 1972 
although the medicinal properties of the herb have been known for over 2000 years. The herb 
immersed in 2 L of water was prescribed between 284-346 CE and the handbook remains (Tu, 2011). 
From these examples isolated natural products alone or with some synthetic variation have made 
major contributions to medicine even before the causes of diseases were understood.   
  It was not until the late 19th century that microorganisms were known to causes disease, 
despite microorganisms being discovered by Robert Hooke and Antoni Van Leeuwenhoek in 1665. 
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The link between microorganisms and disease was not made until Louis Pasteur between 1860-
1864. With the definition of Koch’s postulates (basic criteria for demonstrating a disease was caused 
by an organism) the discovery of the causative bacterium enabled drugs to be disease/bacteria 
specific. However, up to this point toxic substances were used to treat such diseases where the 
“drugs” being used were just as poisonous to human as to the bacteria causing the disease. For 
example, mercury was used to treat syphilis. Using the insights gained from discovery of 
microorganisms Paul Ehrlich developed approaches to detect specific substances which would kill 
microbes without harming human cells using dyes. He also coined the term ‘chemotherapy’ and 
’magic bullet’, which is the best description for modern day medicines. The first successful ‘magic 
bullet’ was arsphenamine which was able to treat syphilis, sold under the trade name salvarsan in 
1910. This was synthesised, opposed to the traditional method of searching for the active compound 
from plant extracts (Ehrlich and Hata, 1910; Williams, 2009). This systematic screening approach 
developed by Ehrlich became the cornerstone for drug research in pharmaceutical industry leading 
to the identification of thousands of drugs, not only antimicrobials.   
 Around the same time in 1928 was possibly the most famous discovery made in the 
antibiotic era, the discovery of penicillin. Its discovery was serendipitous and contrasted with the 
methodical systematic approaches laid down by Ehrlich a few years earlier. Its discovery was 
unplanned, untargeted and it was a purely natural origin rather than being (semi) synthesised.  
 The discovery of a potent antimicrobial compound was desperately needed at the time of 
World War II and led to the discovery of many more antimicrobial agents. Given the example of 
penicillin there is no absolute correct way to carry out drug discovery.  It should use of historical 
knowledge and the technological advances available at the time, while also taking advantage of 
unforeseen opportunities which may arise at the time.   
 Research into natural products has diminished in the past two decades due to a lack of 
interest by major pharmaceutical companies. Caused by the laborious nature of natural product 
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discovery and its incompatibility with high throughput screening (HTS) directed at molecular targets 
(Harvey, Edrada-Ebel and Quinn, 2015). HTS have many benefits; they provide large amounts of 
high-quality data in relation to standard techniques, it is high throughput (as the name suggests) 
therefore large volumes of samples can be tested in small duration of time, increased cost-
effectiveness. The increase popularity of HTS has also led to the development of underlying 
technologies such as automation, miniaturisation, data capture, data analysis, and new bioassay 
formats. However, the results of HTS large chemical libraries have been disappointing in practice 
(these libraries containing a range of compounds from many diverse sources) and so natural 
products have emerged with a significantly higher hit rate compared to fully synthetic and 
combinatorial libraries (Sukuru et al., 2009). Furthermore, it has been shown that 83% of core ring 
scaffolds present in natural products are not represented in commercially available screening 
libraries leading to fewer drug leads (Hert et al., 2009). This stated HTS should be considered as a 
tool to be used alongside other drug discovery methods and should not be the only means for drug 
discovery (Macarron et al., 2011).   
  Even with the recent neglect of natural products as a source of drugs, plants have been the 
single most productive source of leads, particularly as anti-cancer agents and anti-infectives (Harvey, 
2008). Using the most recent Newman and Cragg paper results tracking the number of new 
antimicrobial agents approved between 1981 and 2002 and then in 4-year intervals up to 2014 
(Figure 1). There are three main trends in approved antimicrobials between 2002-2014: i) the new 
biological compound, ii) the sharp rise in the number of vaccines iii) and the consistent performance 
of natural and synthetics. (Newman, Cragg and Snader, 2003; Newman and Cragg, 2007, 2012, 




Figure 1: Total number of antibacterial drugs approved in different ways from 01/01/1981 to 
Recent Years (data adapted from Newman, Cragg and Snader, 2003; Newman and Cragg, 2007, 
2012, 2016) 
 
 Biologicals as defined by Newman & Cragg are “usually large (>50 residues) peptides or 
proteins either isolated from an organism/cell line or produced by biotechnological means in a 
surrogate”. The example given is Raxibacumab; a recombinant human monoclonal antibody 
developed against inhalation of Bacillus anthracis. A part of B. anthracis pathologic process it 
produces the anthrax toxin, which is composed of two binary combinations, each containing a 
protective antigen (PA) responsible for binding, which can combine with either an oedema factor or 
a lethal factor to form the respective toxin. Raxibacumab binds the PA preventing the formation of 
either toxin. Raxibacumab therefore does not have any antibacterial activity but works by 
preventing the internalisation of toxins and the progression of infection. As such it should be used 
alongside other antibiotic treatments (Kummerfeldt, 2014). The treatment of bacteria with non-
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pathogen could potentially have a lower selective pressure compared to targeting critical molecular 
targets that result in death and lead to a slower onset of resistance (Hentzer and Givskov, 2003; 
Rasmussen and Givskov, 2006).  
  Similarly, there has been a sudden increase in the number of vaccines between 2010-2014, 
almost doubling from 14 to 27. Most of the new vaccines treat meningococcal vaccines, but also 
include most notably the first vaccine for typhoid fever (Newman and Cragg, 2016).   
  One new natural compound, fidaxomicin was the first in a new class of narrow spectrum 
macrocyclic antibiotics used to treat Clostridium difficile. The original discovery of this compound 
from Actinoplanes deccanensis ATCC 21983 dates to 1975, with the structure elucidated in 1988, 
approval for use as a drug in 2011 and the mode of action revealed in 2012. This compound inhibits 
RNA polymerase, but unlike other antibiotics such as rifampicin, fidaxomicin binds to and prevents 
the movement of the switch regions of RNA polymerase (Parenti, Pagani and Beretta, 1976; Cavalleri 
et al., 1988; Artsimovitch, Seddon and Sears, 2012). Other new natural derivatives and synthetic 
compounds have also been approved. For example, natural derivatives have included ceftaroline 
(cephalosporin), cetolozane (cephalosporin with tazobactam β-lactams inhibitor), dalvabancin 
(glycopeptide), and oritavacin (glycopeptide). There were no new classes of antibacterial 
compounds. One synthetic drug of interest, bedaquiline is a quinolone-based antibacterial. The first 
tuberculosis drug in 40 years with a unique activity which inhibits proton pumps of mycobacterial 
ATP synthetase enabling efficacy against multidrug resistant TB (Matteelli et al., 2010).   
 The pharmaceutical industry has been deemphasising its natural products since before 2002 
even though they also provide a platform for synthetic derivatisation to take place and enhance the 
pharmacophoric spaces available in HTS libraries. In 2013 there were 14 classes of antibiotics, of 
these 4 had a synthetic origin and the remaining 10 were all from natural sources (Lewis, 2013). 
Therefore, due to the vast diversity of natural products and wide possible applications means that 
their isolation and characterisations for medicinal purposes remains of importance today.  
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1.1.3 - Antimicrobial Resistance  
 Antimicrobial efficacy is highlighted following their introduction; circa 1930 pre-antibiotic 
hospitals were populated with patients suffering from pneumonia, meningitis, bacteraemia, typhoid 
fever, endocarditis, mastoiditis, syphilis, tuberculosis, and rheumatic fever. While in the post-
antibiotic era wards of the 1980s were filled with patients with cancer, heart disease, or 
complications from diabetes or hypertension (McDermott and Rogers, 1982; Cohen, 1992). 
Therefore, antibiotic resistance will have a profound effect and was forewarned when penicillin was 
first used to treat disease:  
“The time may come when penicillin can be bought by anyone in the shops. 
Then there is the danger that the ignorant man may easily underdose 
himself and by exposing his microbes to non-lethal quantities of the drug 
make them resistant. Here is a hypothetical illustration. Mr. X. has a sore 
throat. He buys some penicillin and gives himself, not enough to kill the 
streptococci but enough to educate them to resist penicillin. He then infects 
his wife. Mrs. X gets pneumonia and is treated with penicillin. As the 
streptococci are now resistant to penicillin the treatment fails. Mrs. X dies. 
Who is primarily responsible for Mrs. X’s death? Why Mr. X whose negligent 
use of penicillin changed the nature of the microbe. Moral: If you use 
penicillin, use enough”  
(Fleming, Chain and Florey, 1945).  
 Even with this forewarning we have been unable to prevent the global propagation of 
antibiotic resistance, due to a range of factors. The inappropriate prescription of antibiotics is a 
completely avoidable contributing factor to antimicrobial resistance. Antibiotics are not 
recommended for coughs, colds, and viral sore throats however, half of these conditions were 
incorrectly provided with an antibiotic prescription in the UK between 1995-2011 (Hawker et al., 
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2014). Antibiotics are provided in these situations in fear of a suppurative complication or to ease 
the severity or duration of the illness, but these concerns are not supported by data.  For example, 
it has been shown that the risk of serious complications following a sore throat, otitis media, and 
upper respiratory tract infections is low and the number of antibiotics needed to prevent one 
serious complication is over 4,000 prescriptions (Petersen et al., 2007). Furthermore, there is little 
evidence that antibiotics significantly reduce duration or severity of a sore throat (Little et al., 2013) 
and the inappropriate use of antibiotics has no clear benefit to the patient and will only act to further 
propagate antibiotic resistance. This has been evidenced by randomised double-blind placebo-
controlled study for the macrolides, azithromycin and clarithromycin, which showed a significant 
increase in the proportion of macrolide-resistant Streptococci in healthy patients (Malhotra-Kumar 
et al., 2007). A future consequence of this increased carriage of resistant bacteria may include the 
spread of bacteria which could also cause a resistant infection to develop. The inappropriate 
prescription of antibiotics is widespread, but the variations can vary significantly in relatively small 
area. There is a marked variation in antibiotic prescriptions between clinical commissioning groups 
in England, with, 8.4% of patients provided antibiotics in Newcastle West compared to only 4% in 
Camden with a national average of 6.4% (Shallcross and Davies, 2014).   
 When compared to rest of the European Union, UK consumption was slightly lower with 
18.8 defined daily doses per 1000 habitants (DID) compared to the EU average of 14.9 DID. France 
reported the highest antibiotic consumption (32.2 DID) and the Netherlands with the lowest (10.0 
DID) (Goossens et al., 2005). Most countries are now taking further measures against antibiotic 
resistant bacteria such as isolating MRSA and multi-drug resistant (MDR) Staphylococci colonised 
patients in specialised and have been key in reducing MRSA (Cooper et al., 2004). Similar approaches 
are taking for other serious drug resistant bacterial infections such as C. difficile (Hsu et al., 2010), 
Klebsiella pneumoniae, E. coli, Enterobacter cloacae (Gupta et al., 2011) infections. However, no 
matter how well individual countries perform in prevention, prescriptions and isolation, resistant 
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bacteria do not respect international boundaries with active infections and colonising drug-resistant 
bacteria being spread throughout the globe by population movement.  
 Therefore, this is a global issue which needs coordinated antibiotic controls between all 
countries however, this can be challenging due to limited coordinated action at political, 
governmental and international levels (Laxminarayan et al., 2013). Self-medication with antibiotics 
is common in many parts of the world (Väänänen, Pietilä and Airaksinen, 2006; Plachouras et al., 
2010; Morgan et al., 2011). This is unacceptable when the repercussions of not completing a course 
of antibiotics have been known since they were first discovered.  
  Another source of antibiotic resistance is the millions of kilograms of antibiotics used for 
agricultural. Whereby, approximately 80% of antibiotics sold in the US are used animal agriculture 
and 60% of which are medically important for human disease. These antibiotics are administered 
through animal feed to marginally improve growth rates and prevent infection and are predicted 
according to the FDA to increase overall in the next 15 years (Martin, Thottathil and Newman, 2015). 
Tracking the recent total use antibiotics over the past few years from 2009-2016 based on US Food 
and Drug Administration (FDA) figures submitted over consecutive years (Figure 2) there has been 
steady increase in the antibiotic use in the agricultural industry up to 2015, with a significant drop 
in 2016.  
 The impact of non-action or lack of action over the misuse of antibiotics could result in a 
return to pre-antibiotics conditions in hospitals. Where the contraction of a relatively harmless 
bacterial infection by modern standards this could result in a death sentence. Although currently 
unimaginable, if resistance spreads globally current antibiotics will become obsolete. If effective 
controls are not placed on antibiotic use, the fate of future antibiotic efficacy will depend on new 





Figure 2: Bar chart showing percentage of medically important and unimportant antibiotics used 
for agricultural use over time and line showing the total mass of antibiotics used in the agricultural 
industry annually (Cvm, 2017) 
 The rise in antimicrobial resistance in bacterial is compounded by a decrease in the number 
of new classes of antibiotics being developed, with only two new classes: fidaxomicin and 
bedaquiline introduced in 2011 and 2012, respectively. This slight upward trend in novel 
antimicrobial discovery, although encouraging, is unlikely to solve the problems of resistance. Figure 
3 is a timeline of antibiotic discovery from 1936 to 2012, during this time 14 classes antibiotics were 
discovered. Five of which; tetracyclines, streptogramins, lipopeptides, fidaxomicin, and bedaquiline 
(diarylquinolines class), resistance was detected before they were approved for use as an 
antimicrobial agent. A combination of a slow discovery rate and lengthy approval processes the 
antibiotic discovery pipeline has run dry. The market is crowded with many versions of the same 
class, neglecting to risk the potential benefits of discovering new modes of action. The development 
of new antibiotics is high risk and expense, the development process can be separated into 5 
sections: Lead compound identification, Lead compound optimisation, preclinical testing, phase I 
clinical trials and phase II clinical trials. The associated cost of each stage can vary massively; lead 
compound identification can range for € 100,000 to more than € 1 million and can take between 6 
months and 4 years. Optimisation is far more costly, estimated to cost between € 1-5 million and 
expected to take between 6 month and 4 years.  Preclinical testing would be expected to take one 
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trials ranges from less than € 1 million to as much as € 15 million, taking around 1 year to complete. 
Phase II costs are likely to be higher ranging from less than € 1 million to over € 20 million (Årdal et 
al., 2018). Additionally, obtaining regulatory approval is often a significant obstacle for drugs 
attempting to make it to market (Gould and Bal, 2013; Ventola, 2015).  
 
Figure 3: Column cluster graph showing the number of years taken to approve antimicrobial class 
for use in humans from the first point of discovery compared to the time taken for resistance to 
develop. With the first approved antimicrobials on the left to the newest approved on the right. *-
indicate instances where resistance developed before approval. (Graph made using data from 
Lewis, 2013).  
 The nature of antibiotics is that they are “singe use”, only required when there is an 
infection and once the course is complete, they are not needed. This reduces their profitability 
compared to other drugs for chronic conditions which are required to be taken over a long period 
of time or drugs can be taken sporadically as and when needed. The single use nature of antibiotics, 
the significant expenditure required to take a new drug to market, the inevitability of resistance, 
and a global lack initiative to prevent misuse of antibiotics are all contributors which have led to big 
23 
 
pharmaceutical companies reducing their interest in antibiotic discovery. This is especially true for 
early phase interest which are vital for discovering novel compounds yet are extremely unlikely to 
make it to market. Of tens of thousands of drug candidates which have found to be active can be 
whittled down to just one approved medicine afters years of investment.  
1.1.4 - Invasive Weeds  
 Invasive non-native species (INNS) are organisms that have been introduced into a new 
environment once established are able to outcompete the native flora/fauna. These species have 
generally been introduced by humans into areas outside their natural range and can have drastic 
effects on the ecosystem. These INNS can also incur economic cost due to control and eradication, 
structural damage to infrastructure and loss of crop production with impact to the UK estimated to 
be between £200-300 million (Williamson, 2002). However, it can be proposed that INNS may 
provide an alternative source in the discovery of new pharmaceuticals. (Williams et al., 2010).   
  When INNS are introduced into a new environment, they may be eaten by native insects 
which can result in a reduce their likelihood of survival (Singer, Thomas and Parmesan, 1993). The 
INNS could be phytochemically like the native species herbivores often switch to novel hosts 
compared to their traditional host (Strong, Lawton and Southwood, 1984). Conversely, if the INNS 
have a different phytochemical make up this could deter insect feeding; referred to as the enemy 
release hypothesis (ERH). Reduced feeding by herbivores and other natural enemies can result in a 
rapid increase in distribution and abundance (Keane and Crawley, 2002). However, it is not only 
herbivory which could influence the success of the INNS but the outcome of interaction with soil 
microbiological communities (Kourtev, Ehrenfeld and Häggblom, 2002) and other plant species 
through allelopathy (Callaway and Ridenour, 2004). For example, 57.5% of phytochemicals from 
invasive plants have shown activity against more than one type of microorganism and several had 
general biocidal effects (Cappuccino and Arnason, 2006). The increases in novel phytochemistry and 
bioactivity were linked to invasive plants which benefit from the ERH. These plants can produce a 
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plethora of novel compounds in their new environment as the herbivorous, bacterial and 
allelopathic pressures are avoided and may provide a continually evolving source of novel 
antimicrobial compounds. For this study three invasive weeds were used and explained in detail 
below. There were chosen since they are currently widespread throughout the UK as a result would 
be a plentiful source of biomass for extraction of bioactive compounds. They are also problematic 
therefore their removal in large amounts will be beneficial to the environment.  
1.1.4.1 – Impatiens glandulifera  
 Impatiens glandulifera or Himalayan balsam is a tall annual herb with explosive seed heads 
native to west and central Himalayas. It has pink-purple flowers, fleshy stem and finely serrated 
leaves. It was first introduced in the early 19th century as an ornamental and nectar producing plant 
and later recoded in the growing wild in 1885 becoming widespread in the UK and throughout the 
norther hemisphere (Beerling and Perrins, 1993). It is currently widespread and common across the 
UK, primarily on riverbanks and in other damp areas (NNSS, 2018). Due to the height of I. 
glandulifera it casts shade reducing the germination and establishment of other species beneath its 
canopy, resulting in a 25% reduction in the richness of diversity (Hulme and Bremner, 2006). I. 
glandulifera has an estimated annual cost of £1,000,000 on the UK economy (Williams et al., 2010). 
I. glandulifera is native to high altitude meadows and fringe woodland and have been found to grow 
taller in non-native sites. The invasive plants within the UK show clear signs of the EHS, where 
generalist natural enemies are not inflicting as much damage as the specialists within the native 
environment (Tanner et al., 2014). 
1.1.4.2 – Fallopia japonica  
  Fallopia japonica or Japanese knotweed is a tall herbaceous perennial with bamboo-like 
stem which grows into dense thickets. It was introduced into the UK from Japan as an ornamental 
garden plant in the 19th century and has now become widespread in a range of habitats particularly 
on roadsides, riverbanks and derelict land displacing native flora. It causes serious structural damage 
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to buildings and infrastructure due to its rapid growth rate and ability to push through tarmac, 
concrete and drains. The presence of Japanese knotweed can devalue housing, damage roads and 
rail networks, displace of local flora to impact on leisure and tourism. The costs linked to its presence 
and removal can be considerable, estimated to be £165, 609,000 within the UK in 2010 (Williams et 
al., 2010).   
1.1.4.3 – Rhododendron ponticum  
  Rhododendron ponticum is a large evergreen shrub with attractive purple to pink flowers, 
leathery leaves and solid stems. R. ponticum is extensively naturalised throughout the British Isles 
with very few natural enemies facilitating its widespread growth (Judd and Rotherham, 1992) and 
adverse impact on forestry (Cross, 1981). It is unclear from which area R. ponticum originated prior 
to introduction into the UK, as well as the extent of introgression which has altered British species 
(Cross, 1975). The total cost of R. ponticum to the UK in 2011, which includes public, charities, 
private and forestry related cost, was calculated to be £670,924 (Dehnen-Schmutz, Perrings and 
Williamson, 2004) yet the annual cost has also been estimated to be £8,621,000 on the UK economy 
by Williams et al., 2010. 
1.1.5 – Liquid Chromatography 
1.1.5.1 – Overview  
 The term chromatography was first coined in 1906, when coloured constituents of leaves 
were separated using a column of calcium, alumina, and sucrose. The International Union of Pure 
and Applied Chemistry’s (IUPAC) definition of chromatography is:  
“Chromatography is a physical method of separation in which the 
components to be separated are distributed between two phases, one of 
which is stationary (stationary phase), while the other (the mobile phase) 
moves in a definite direction.” 
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 The two principle types of chromatography are gas chromatography and liquid 
chromatography. Gas chromatography separates gaseous substances based on adsorption on or 
partitioning in a stationary phase. Liquid chromatography includes a range of techniques based on 
molecular size, charge, adsorption or partitioning from a liquid phase. All chromatography is based 
upon the establishment of an equilibrium between a stationary phase and a mobile phase. The 





Equation 1: The distribution constant (Kc). Where [X]s is the concentration of component X in the 
stationary phase at equilibrium and [X]m is the concentration in the mobile phase.  
 This is dependent upon temperature, type of compound, and the stationary and mobile 
phases. A larger Kc value will result in a stronger affinity to the stationary phase moving slowly along 
the column and those with lower values have a stronger affinity to the mobile phase and move 
quickly along the column. (Christian, 2003). Pre-1970s liquid chromatography was based on the use 
of large columns with large particles under gravity feed and fractions collected manually for 
measurement in a spectrophotometer. With the advancements of increased flow pressure and small 
silanized silica particles resulting in improved peak dispersion becoming known as high powered 
liquid chromatography (HPLC). In addition to conventional HPLC columns, Ultra High-Pressure Liquid 
Chromatography (UHPLC) is also an option, which as the name suggests, operates at a higher 
pressure then HPLC. This higher pressure results in more rapid chromatography (typically <10 min) 
with better resolution and efficiency due to smaller particle size (<3 µm). The conventional 
maximum operating pressure of HPLC is around 400 bar (6,000 psi), whereas UHPLC operates at 
pressures as high as 1300 bar (19,000 psi) (Fekete et al., 2014). As well as smaller particle sizes 
Superficially Porous Particles (SPP) are an alternative to smaller particles sizes, comprised of a solid 
core coated with porous silica layer, offering increased efficiency and speed comparable to HPLC. 
The most important measure of successful chromatography is the resolution of the peaks, this is 
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vital whether chromatography is being used for purification of analysis. In order to obtain good 
resolution three key factors, retention, selectivity and efficiency need to be considered. There is a 
visual summary of these in Figure 4. 
 
Figure 4: Typical chromatography highlighting the major measurable factors of chromatography. 
 Retention is the time an analyte spends on the column compared to unretained compounds 
which pass through the column unaffected by the stationary phase. Analytes are retained on a 
column based in their affinity with the stationary/mobile phase. There are many different stationary 
phases available which retain analytes based on their polarity in the case of normal and reversed 
phase but also charge in the case of ion-exchange chromatography and size-exclusion 
chromatography. In order to obtain desired retention, the correct stationary phase is the most 
important first step. Once a relevant column is selected then mobile phase selection and 
composition need to be considered carefully. Each type of column is only suitable with certain 
solvents and the most effective way to alter retention is to change mobile phase composition.  
 The retention of peaks needs to be controlled so analytes are clearly defined from one 
another, this is selectivity. The selectivity factor is the ability of a chromatographic system to 
distinguish between different components. This can be visualized as the distance between two peak 
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and measured as a ratio of the retention time of two peaks.  Selectivity factor is calculated by 
dividing the latest retaining peak by the earlier retaining peak, the larger the selectivity factor the 
better the separation between peaks. The space between peaks is dependent on the retention, if 
too strong mobile phase is used peaks will elute quickly and there will be poor separation between 
the peak causing them to coelute. The pH of the mobile phase effects the retention and particularly 
the selectivity of certain analytes which have ionisable groups. The pH has a significant effect on the 
ionization state of the analyte, for successful chromatography. For example, when pH = pKa the 
analyte can be in both ionized and neutral states, these two forms will have different retention 
properties and lead to broad, tailing or splitting peaks. If an acidic analyte is present within acidic 
mobile phase which has a pH below the pKa there will be sufficient protons to maintain a neutral 
analyte which will retain for longer on the column. If this acidic analyte is in a basic environment the 
analyte dissociates into its ionized conjugate base, resulting in less retention. However, if an analyte 
is particularly polar or ionic then ion pairing agents can be added to the mobile phase which will 
bind to ionized molecules increasing their retention (Berg et al., 2009).  
 Efficiency is the ability to obtain the correct peak shape, which is as thin as possible. This is 
vital for good chromatography and the efficiency of a column is measured using a plate count 
equation (Equation 2) 
𝑁 = 5.54 (𝑡𝑟/W0.5) 
Equation 2: Where tr is the retention time and W0.5 is the peak width at half height. There are 
other plate count calculations, but this is the most widely used.  
The larger the number of plates the more efficient the column. The length of the column as well as 
the particle size and pore size have a significant effect on efficiency of a column. Smaller particles 
and pores result in higher number of plates due to reduced eddy diffusion, which is the lateral 
movement through column packing. Longer columns result in poor peak shape due to longitudinal 
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diffusion. Both lateral and longitudinal diffusion are key factors within the Van Deemter equation 
(Equation 3):  




Equation 3: Van Deemter equation is a measure of the resolving power of a column (H). Where A is 
eddy diffusion, B is longitudinal diffusion, C is equilibration time and u is linear flow rate.  
Each of these factors have an effect in the efficiency of the column and can be used to calculate the 
flow rate required to obtain the ideal chromatography (Van Deemter, Zuiderweg and Klinkenberg, 
1956).  
1.1.5.2 – Normal Phase  
 Normal phase as the name implies is the original form of chromatography. The columns are 
made from silica, which is an ideal material for chromatography. These rigid particles resist 
compaction due to flow and have a large surface area. This has been the main packing material for 
HPLC columns for decades. The surface of the silica is covered with strongly polar silanol groups (Si-
OH) which form hydrogen bonds, π- π bonds and dipole-dipole interactions with analytes in a 
nonpolar mobile phase. Typical normal phase stationary phases include bare silica, cyano, diol and 
amino bonded phases. Cyano bonded silica is the most robust of all normal phase options with the 
ability to retain dipolar compounds such as chloro, nitro and nitrile substituents more strongly than 
other normal phases. Diol is the most polar and retains amines, ethers, ester and ketones more 
strongly. Amino being the least robust of the boned phases and have similar properties to that of 
diol but have the ability to separate vitamins A and D. Silica alone is the least convenient for stability 
and reproducibility reasons but it does have the ability to separate isomers and particularly useful 
for large scale applications due to its simplicity. Normal phase works well with analytes which are 
insoluble in water and can even separate isomers, due to separation selectivity being greatly 
influenced by altering the mobile phase constituents and solvent ratios. Another advantage of 
normal phase is that organic compounds are highly soluble in normal phase solvents and these 
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solvents have a low viscosity therefore allowing higher flow rates increasing sample throughput 
(Jandera, 2011)  
1.1.5.3 – Reversed Phase 
 Reversed phase chromatography was chronologically the second mode of chromatography 
after normal phase. It is named reversed because the mobile phase used is more polar than the 
stationary phase, effectively the reverse of normal phase. Reversed phase stationary phases are 
silica at their core but with the addition of hydrophobic groups. Typically, these groups include 
differing lengths of carbon chains, C4, C8 or C18. Reversed-phase columns do not suffer for poor 
reproducibility from solvent usage resulting in reversed-phase becoming the main HPLC technique. 
The retention of an analyte on a column is primarily dependent on its hydrophobicity. Linear carbon 
chains of increasing length result in higher retention.  
1.1.5.4 – Other Liquid chromatography and their uses 
 Ion exchange chromatography is particularly useful for proteins, nucleotides and other 
macro biomolecules. It is based on the attractive forces between the charged solute molecules and 
immobilized groups of the opposite charge. This method is not compatible with MS and other 
analytical equipment and is solely used as a purification technique (Kopaciewicz et al., 1983). 
Similarly, size exclusion chromatography is also a technique used for protein analysis rather than 
small molecules. This chromatography is based on the observation that zeolites could act as a 
molecular sieve to exclude molecules based on their size (Barrer, 1944). 
 Hydrophilic interaction liquid chromatography (HILIC) provides a chromatography approach 
to separate small polar compounds which combine characteristics from normal, reversed phase and 
ion exchange chromatography. HILIC uses polar stationary phases like those of normal phase but 
utilizes mobile phases like those used in reversed phase. HILIC overcomes reversed phase solid 
phases which are unable to retain particularly polar molecules and overcomes the polarity limits of 
normal phase mobile phases which are unable to solubilize very polar molecules. HILIC is also able 
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to separate ionic analytes without the addition of ion paring agents required by ion exchange 
chromatography. In contrast to reversed phase, HILIC gradients begin with organic solvents such as 
acetone and increase in polarity up to high aqueous content mixtures to elute increasingly polar 
analytes (Guo and Gaiki, 2005).  
 Solid phase extraction (SPE) is a sample preparation technique which allows samples to be 
extracted, concentrated and cleaned prior to other purification techniques or analysis. SPE 
cartridges are available in a range of sizes from small scale < 1 mL to over 1 L and a range of phases: 
normal, reversed, ion exchange and adsorption (Thurman and Mills, 1998). Flash purification is a 
cost-effective high-throughput alternative to chromatography purification. It requires less 
optimization and offers a range of columns options and sizes depending on the scale of the sample. 
Like HPLC solvent is forced through a column under pressure resulting in fast flow rates in 
comparison to HPLC but at far lower pressure. The columns used for flash purification tend to be 
much larger and wider than HPLC allowing purification of several grams of sample in a short time 
with moderate resolution (Andrews, 1986). 
1.1.6 – Mass Spectrometry 
 Mass spectrometry is an analytical technique which measures the mass-to-charge ratio of 
compounds and fragments. The invention of mass spectrometry began in 1858 when Julius Plucker 
attempted to pass electricity through a vacuum and discovered cathode rays (Plucker, 1858) and 
later the discovery of electrons by J.J. Thomson. Thomson went on to construct a parabola mass 
spectrograph which is was the forerunner to modern mass spectrometer (MS). The original MS 
released a beam of positive ions through parallel magnetic and electrical fields which would deflect 
the beam onto a fluorescent screen or photographic plate. It was observed that the extent of 
deflection was related to the mass-to-charge ration of the positive ion (Thomson, 1913). In 1918 
Dempster constructed the first true MS which ionized a salt by electron bombardment and 
accelerated the ions through a magnetic field into a mass analyser (Dempster, 1918). MS 
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instrumentation can be broken down into three parts: ionization source, mass analyser and the 
detector. Each of these underwent rapid development following 1918 to obtain the various 
ionization sources, mass analysers and detectors available for modern MS. 
 There are a wide variety of ionization sources available, Electrospray Ionization (ESI) being 
one of the most popular, as well many others; Electron Ionization (EI), Chemical Ionization (CI), Field 
Ionization (FI), Fast Atom Bombardment (FAB), Field Desorption (FD), Plasma Desorption (PD), Laser 
Desorption (LD), Matrix-Assisted Desorption Ionization (MALDI), Thermospray, Atmospheric 
Pressure Ionization, Atmospheric Pressure Chemical Ionization, Atmospheric Pressure 
Photoionization, and Atmospheric Pressure Secondary Ion MS which is Direct analysis on real time 
(DART). Each with their own advantages and disadvantages depending on the samples to be 
analysed. The chosen ionization sources must be combined with a mass analyser, of which there are 
also many to choose from each with different capabilities; electric sector, magnetic sector, 
quadrupole, ion trap, time-of-flight, Fourier transformation ion cyclotron resonance, Fourier 
transform orbitrap and hybrids of these different analysers. The final constituent of a MS instrument 
is the detector which can be a: Photographic Plate, Faraday Cup, Electron Multiplier or an Electro-
optical Ion Detector. 
1.1.6.1 – Ionisation  
 EI ionization required the sample to be in gas-phase through which a beam of electrons is 
passed, electrons collide with the neutral analytes to produce a charged ion. The common term 
“collide” and “impact” to describe how electrons impart charge to molecules is a misconception, an 
electron has a certain wavelength and kinetic energy value which are correlated. A 2.7 Å wavelength 
has an energy of 20 eV and 1.4 Å is equal to 70 eV. When this energy corresponds to a transition 
within the molecule it leads to various electronic excitement, where there is enough energy an 
electron can be expelled resulting in a changed analyte (Bentley and Johnstone, 1970). EI is a hard 
ionization technique which induces extensive fragmentation which provides useful information for 
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elucidating the structure of unknown analytes, however the molecular ion is not always observed. 
CI is a softer ionization technique which yields spectra with less fragmentation and molecular ion is 
clearly recognized. Like EI, CI also uses electron “impact”, but it is used to ionize a reagent gas which 
then reacts with the analyte to produce an ion. This is a softer ionization technique that EI which 
was particularly useful for larger molecules and polyfunctional compounds (Munson and Field, 
1966). FAB ionization is like CI and is a relatively low fragmentation technique. It is carried out by 
colliding electrons with slow moving atoms such as Ar, Xe, or Cs to ionize them. These ionized atoms 
are then accelerated to a beam which is directed at a sample which is either solid or within a matrix 
such as glycerol, which in turn ionizes the analyte. FAB is particularly useful for large, non-volatile, 
thermally unstable compounds as samples are not required to be in gas-phase for analysis (Barber 
et al., 1981). FI uses very strong electric fields to produce ions from gas-phase molecules. The energy 
transferred during FI is a fraction of 1 eV, therefore generates ions with an extremely low excess of 
internal energy thus exhibiting no fragmentation. FI is one of the softest ionization methods, 
however it does require the samples to be volatile and thermally stable as breakdown of the analyte 
can occur during the evaporation process (Beckey et al., 1969).  
There are several desorption ionization techniques, the first of which was field desorption. 
Desorption based methods overcomes the need for samples to be in gas phase, allowing non-
volatile samples to be analysed using MS. FD has be mostly replaced by other desorption methods 
yet it remains particularly useful for the analysis of high molecular mass non-polar compounds such 
as polymers (Beckey, 1977). The most widespread and powerful desorption ionization technique is 
MALDI, which is ideal for the analysis large, non-volatile, and thermally liable compounds such as 
proteins, oligonucleotides, synthetic polymers and large inorganic compounds. MALDI involves the 
analyte is dissolved in a matrix. This matrix is a solvent containing small organic molecules which 
have strong absorption at the laser wavelength. The analyte and matrix are dried prior to placing 
under vacuum and then ablated by intense laser pulses over a short duration. Although not fully 
understood, the laser irradiation is believed to induce rapid heating which causes sublimation of the 
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matrix crystals which also removes analyte for the surface. The charged matrix then imparts charge 
to the analyte via proton transfer. MALDI is more sensitive than other laser ionization techniques 
due to the matrix minimizing damage to the analyte from the laser pulse and increasing energy 
transfer to the analyte (Zenobi & Knochenmuss, 1998). MALDI can detect femtomoles of proteins 
with a molar mass up to 300,000 Da (Spengler & Cotter, 1990).  
Although there is are plentiful ions sources available to most relevant for the use of identifying a 
wide range of unknown plant compounds and bacterial metabolites is ESI. The success of ESI is due 
to its versatility, although was originally considered to be an ionization technique for protein 
analysis. ESI its use extended to polymers, biopolymers and small polar molecules. ESI allows very 
high sensitivity to be reached and is easily coupled with HPLC. ESI is based on the generation of gas-
phase ions from a solution flowing through a small outlet, when voltage is applied. Once enough 
voltage is supplied between the solution and MS inlet, the solution is dispersed in fine droplets with 
the aid of a sheath gas which is usually N2 which undergo a succession of solvent evaporation and 
coulombic fission, lastly leading to multi-charged molecular ions with intact analytes (Rohner, Lion 
& Girault, 2004). Electrospray can used with either positive or negative applied voltage leading to 
the formation of cations or anions, respectively. A power supply is connected the solution and a 
counter electrode, when there is no voltage applied the only force acting on the liquid is surface 
tension causing the surface to be hemispherical. Once electrostatic force is applied and is balanced 
with the surface tension, the surface forms a conic shape called the Taylor cone (Taylor, 1964). With 
a slight increase in applied potential, the solution/air interface at the apex of the cone becomes 
unstable dispersing the solution into charged droplets. The droplet evaporates and as the coulombic 
repulsion exceeds the surface tension, each drop explodes to produce further smaller droplets. 
Continuous generation of smaller and smaller droplets leads to the production of gas-phase ions 
(Rosell-Llompart & De La Mora, 1994). The sensitivity of ESI is based on the concentration of the 
analyte rather than the quantity of samples injected into the source, in fact sensitivity is improved 
the lower the flow rate of sample down to tens of nanolitres per minute.  
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ESI along with all other ionization methods suffer from ion suppression, which is a phenomenon 
occurring when there is a high concentration of non-volatile compounds inhibiting droplet 
formation, release into gas phase and ultimately the detector. Highly concentrated samples 
compete for limited charges and space on the droplet.  This results in the molecules with higher 
mass suppressing smaller molecules, and more polar compounds are more susceptible to 
suppression. (Sterner et al., 2000, Bonfiglio et al., 1998, and Annesley, 2003). Ion suppression can 
be affected several variables, system variable, compound variables and method variables. System 
variables are electric field, ES-capillary diameter, ES-capillary voltage, distance to counter electrode, 
heat capillary of ambient gas, solvent saturation level of ambient gas. Compounds variables are 
surface activity, proton affinity, pKa and solvation energy. Method variables are flowrate, electrolyte 
concentration, pH and surface properties such as boiling point and surface tension (King et al., 
2000). The presence of electrolytes is vital to observe a stable spray, however normal solvents 
contain enough electrolytes for this purpose. As the maximum tolerable concentration of 
electrolytes to have good sensitivity is 10-3 M, it is more important to remove electrolytes for the 
samples to obtain good ionization (Hoffmann & Stroobant, 2007). Therefore, ion suppression can 
be reduced by implementing several strategies. Sample matrix, coeluting compounds and crosstalk 
can contribute to ion suppression, therefore sample purification using SPE (or other means of 
purification) and suitable chromatographic separation can reduce this effect. With respect to 
sample matrix impacting on ion suppression TFA is a known to be one of the best liquid 
chromatography modifiers. TFA does not interfere with spectrophotometric detection but it does 
significantly cause problems for mass spectrometric analysis. TFA increases the surface tension of 
the mobile phase which causes the “Taylor cone” to be unstable causing the spray to often break 
down reducing the analyte ion signal, by using a weaker acid such as acetic or formic acid ion 
suppression can be reduced (Hayati et al., 1986).  
ESI ion formation occurs at ambient pressure meaning that there are numerous collisions between 
ions and molecules which are not seen in a vacuum. Proton transfer, producing a cation or anion is 
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the most common ion-molecules reaction at ambient or high pressure. This reaction is based on 
proton affinity, the neutral or anionic acceptor of a proton must have a higher affinity that the 
neutral or cationic donor thus transferring the proton. This reaction also occurs when the molecule 
fragments, the proton can only be present on one of the fragments. An adduct is an ion formed by 
the combination of a neutral molecule and an “ionizing” ion other than a proton. Sodium (M+23)+ 
and ammonium (M+18)+ are common positive adducts and chlorine (M+35)- , (M+37)- and acetate 
(M+59)- are common negative adducts. Commonly acids are added to mobile phases and can for 
adducts such as formic acid forming formate (M+45)- negative ions. Dimers and other aggregates 
can also form (M+M+H)+ (Hoffmann & Stroobant, 2007).  
1.1.6.2 – Mass Analyser 
 Once gas phase ions have been produced, they must be separated based in their masses 
and determined. The physical property which is measured is the mass to charge ratio rather than 
the mass alone, therefore multiply charged ions will be a fraction of the actual mass. There are 5 
main characteristics of mass analysers: mass range limit, analysis speed, transmission, mass 
accuracy and resolution. Mass range is the limit of m/z over which a mass analyser can measure, 
and analysis speed is the rate at which the analyser is able to measure over that range. Transmission 
is a measure of the number of ions lost during mass analysis, it is the ratio between the ions reaching 
the detector and the ions entering the mass analyser. Mass accuracy is a measure of the difference 
between the measured m/z and the theoretical m/z, high mass accuracy has significant applications 
in elemental composition determination. Resolution concerns the ability of an analyser to 
distinguish between two ions with small m/z differences. Mass analysers ability to resolve m/z are 
categorized into low and high; the distinction being less than or greater than 10,000 FWHM 
(Hoffmann & Stroobant, 2007). 
 Quadrupole analysers separate ions based on the stability of their trajectory in oscillating 
electric fields. Quadrupoles are made up of a source, focusing lenses, and four perfectly parallel 
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rods. As the ions enter the focusing lenses, they are passed longitudinally through the centre of 
these charged parallel rods to the detector. Opposite rods are electrically connected with RF and/or 
DC voltages, meaning adjacent rods have opposite charges. The ions will be drawn laterally to the 
opposite charge. If the potential changes sign before it discharges itself on the rod, the ion will 
change direction. If the lateral pull to either charged rod remain stable for the length of the 
quadrupole the ion will be detected, electrical potentials are adjusted so only certain ions with 
specific m/z are selected to pass through the rods to the detector. RF only voltage results in a wide 
range of m/z traversing through the quadrupole, which is usually used for ion-focusing. When both 
DC and RF are applied ions of a specific m/z can be tuned, by increasing the DC and RF voltage and 
keeping the ratio constant the mass range can be scanned to transmit ions of increasing m/z to 
acquire a mass spectrum. In practice the highest detectable m/z of a quadrupole is about 4,000 Th 
and resolution of around 3,000 FWHM making them low resolution instruments. Quadrupoles are 
the cheapest analyser but are also very robust, they do not depend of kinetic energy of the ions, 
robust in terms of pressure changes and have high scan speed therefore are well suited to be 
coupled with chromatographic techniques. Multiple quadrupoles can be applied in tandem to obtain 
fragmentation analysis. If three quadrupoles were lined up a collision gas such as He would be 
introduced into the central quadrupole and then the first and last could either scan of a range of 
ions or select for specific m/z ranges.  
 Ion trap analysers use an oscillating RF quadrupolar electric fields to trap ions in two or three 
dimensions and store them. An ion trap analyser is made up of a circular electrode with two ellipsoid 
caps. They work in similar way to a quadrupole only in a loop instead of a rod. Instead of changing 
the potentials to allow ions through the rods, ions of different masses are stored within the ion trap 
and then expelled according to their masses to obtain a spectrum (Stafford et al., 1984). Ions can be 
produced by injecting electrons in the ion trap. The 3D ion trap also known as Paul ion trap is subject 
to spatial charge effects which effect the stability of the ions within the trap when there are too 
many ions present. This effect is lessened in 2D ion trap known as linear ion traps (LIT), which can 
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accommodate ten-fold more ions than 3D without suffering from poor resolution. Ion traps are 
often combined with other mass analysers in order to improve the efficiency of the MS instrument 
allowing more ions to be analysed (Douglas et al., 2005). 
 Time of flight (TOF) analysers separates ions based on the velocity of the ions within a flight 
tube after being accelerated by an electric field. TOF analysers work well with ion sources which 
produce pluses of ions such as laser-based techniques. The m/z is measured by the time ions takes 
to move from the source to detector. TOF analysers have a high analysis speed, broad m/z ranges 
and no upper limit therefore ideally suited to soft ionisation techniques and work with proteins. 
However, they detect a weak number of ions which is insufficient to produce high precision and 












1.2 - Methods – Natural Products  
1.2.1 – General Reagent 
Table 1: List of all general reagents, suppliers and grades. 
Reagent name Supplier  Grade 
Methanol (MeOH) Fisher Scientific  HPLC grade 99.9 % 
Methanol-d4 Sigma-Aldrich 99.8 atom % D 
Dimethyl Sulfoxide (DMSO) Supelco –  LiChrosolv ≥99.7 % 
Water  Milli-Q 18.2 Ω – Q-pod purifier 




Mueller Hinton agar  Merck For microbiology 
Mueller Hinton broth  Merck For microbiology 
Yeast malt agar Merck For microbiology 
Yeast malt broth Merck For microbiology 
Brucella Agar with 5% Sheep Blood, 
Hemin and Vitamin K  
Millipore  For microbiology 
Dulbecco’s modified eagle media 
(DMEM) 
Gibco Suitable for cell culture 
Hepes Gibco 1 M, Suitable for cell culture 
Foetal Calf Serum  Gibco Suitable for cell culture 
Kanamycin solution Sigma-Aldrich 10 mg/mL in 0.9% NaCl, BioReagent, 
suitable for cell culture 
Amphotericin B solution  Sigma-Aldrich 250 mg/L in deionized water, 
BioReagent, suitable for cell culture 
Defibrinated sheep blood Oxoid NA 
Phosphate buffered saline  Sigma-Aldrich 10x concentrate, suitable for cell culture 
Triton-X 100 Sigma-Aldrich Laboratory grade 
Eagle modified essential media 
(EMEM) 
Gibco Suitable for cell culture 
Basement membrane extract with 
phenol red 
Gibco Suitable for cell culture 
Foetal Bovine Serum (FBS) Gibco Value FBS, suitable for cell culture 
MEM Non-essential amino acid 
solution (100x) 
Gibco Without glutamine, BioReagent, 
suitable for cell culture 
L-Glutamine  Gibco 200mM, suitable for cell culture 
Ampicillin sodium salt Sigma-Aldrich Powder, BioReagent 
Meropenem trihydrate Sigma-Aldrich Powder, BioReagent 
Ciprofloxacin HCl Supelco Pharmaceutical secondary standard 
Lithium Mupirocin  Sigma-Aldrich Powder, >95% 
Levofloxacin  Sigma-Aldrich Powder, >98% 
Chloramphenicol  Sigma-Aldrich Powder, BioReagent 
Rifampicin  Sigma-Aldrich Powder, BioReagent 
Tetracycline  Sigma-Aldrich Powder, 98-102% 
Cefotaxime sodium salt Sigma-Aldrich Powder, BioReagent 
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Nalidixic acid sodium salt Sigma-Aldrich Powder 
Gentamycin sulphate Sigma-Aldrich Powder 
Streptomycin sulphate salt Sigma-Aldrich Powder, BioReagent 
2-hydroxy-1,4-naphthoquinone 
(HNQ or lawsone) 
Sigma-Aldrich 97% 
Urea  Supelco 8 M (after reconstitution with 16 mL 
high purity water) 
DL-Dithiothreitol (DDT) Sigma-Aldrich >98% 
Iodoacetamide Sigma-Aldrich BioUltra 
TRIS Solution Millipore OmniPur, 1.0 M pH 7.5 
Trypsin Promega Mass Spectrometry Grade 
Chloroform Sigma-Aldrich HPLC Plus, ≥99.9% 
 
1.2.2 – Extraction and purification  
 I. glandulifera was collected from a riverbed in Llanfarian, Ceredigion, Wales, UK 
(52.37667°N, -4.07833°W). F. japonica was collected from a riverbed in Penparcau, Aberystwyth, 
Ceredigion, SY23 3TL (52.403472°N, -4.068028°W). Rhododendron ponticum plant material was 
collected from Llanilar, Aberystwyth, Ceredigion, SY23 4SB (52.352833°N, -4.020306°W). Only the 
aerial parts of the plant were collected and stored in a -80 °C freezer within 1 hour of collection.  
 In order to fully extract all compounds contained within each plant all cellular structure 
needed to be disrupted therefore all plant material was ground into a powder using liquid nitrogen, 
pestle and mortar. Powdered plant material was extracted in 75% aqueous methanol stirring at 
room temperature for 24 hours. The plant material was separated from the solvent using a sieve, 
discarding the plant material and drying the solvent under vacuum.  
 Purification and analysis of samples will be carried out using C-18 solid phase, therefore 
samples need to be prepared as such. After conditioning a 10 g LC-18 SPE cartridges (Supelco, UK), 
dry sample extract was added. Water was added to the sample and pulled through the cartridge 
under vacuum. This fraction was collected and will be referred to as “unbound”. This is because 
analytes present within this fraction have not bound to the C-18 solid phase within the SPE cartridge. 
Further purification and analysis of this fraction would require chromatographic techniques which 
are suitable for the most polar of analytes such as HILIC. Due to the benefits and ubiquity of reversed 
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phase chromatography (see 1.1.5 – Liquid Chromatography) it was decided that analytes which are 
suitable for these separation technique would be the main focus. However, the unbound fraction 
was freeze dried under vacuum and stored at -80 ˚C, should we need to return to this sample. The 
cartridge was then washed with methanol and collected separately. This fraction will be referred to 
as the “bound” fraction, as any analytes which are passed through the column can be separated 
using reversed phase chromatography. This fraction was also freeze dried at stored at -80 ˚C. In 
addition to separating the analytes relevant for further purification based on which type of 
chromatography would be most relevant this also cleaned the samples for further purification. Any 
particulate matter or analytes which cannot pass through a C-18 column would be removed 
improving the quality of any further chromatography carried out.  
 Using the bound fraction, further separation was carried out using Isolera 4 (Biotage, 
Sweden) flash purification system into fractions using a gradient of ultrapure 18.2 Ω H2O and 
analytical grade MeOH from 0-100% MeOH (flow rate of 100 mL/min) using a 60 g Biotage SNAP 
Ultra C18 flash cartridge (Biotage, Sweden). This “SNAP Ultra” column allowed the bound fraction 
of sample to be purified quickly and with the highest purification performance offered by the 
Biotage flash purification system. This yielded a range of fractions for each plant which were assayed 
for a range of biological activities. A fraction was exhibiting potent biological activity and further 
purification using C18 semi-preparative HPLC system (Dionex, ThermoFisher Scientific, UK). A 
custom isocratic gradient using ultra-pure 18.2 Ω H2O and analytical grade MeOH were used to 
purify this fraction into two pure compounds only one of which was found to be a potent 
antimicrobial.   
1.2.3 – HPLC-PDA-MS Analysis   
1.2.3.1 – HPLC-PDA- Low resolution MS  
 The instrumentation and method described below was used to analyse crude plant extracts 
and fractions from flash purification. This is run a relatively long gradient to isolate peaks and 
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tentatively identify their structure. The aim was not full structural characterisation but to 
understand the purity and type or compounds present within these samples.  
  The bound and unbound plant extract (100 μL) were inserted into HPLC vials. The analysis 
used a Thermo-Finnigan HPLC/MSn system (Thermo Electron Corporation, USA) which comprised a 
Finnigan surveyor photodiode array (PDA) plus detector and a Finnigan LTQ (linear trap quadrupole) 
with an electron spray ionisation (ESI) source, the system was linked to an analytical workstation. 
The column used was a reversed phase Waters C18 Nova-Pak (4 μm, 3.9 mm × 100 mm). 10 μL of 
sample was injected for each run. The PDA detection wavelengths were set between 240 nm – 600 
nm, with a flow rate of 1 mL min-1. The mobile phase consisted of water-formic acid (solvent A; 
100:0.1, v/v) and HPLC grade methanol-formic acid (solvent B; 100:0.1, v/v). The starting condition 
was 95%A/5%B, with the percentage of solvent B increasing linearly to 100% over 30 minutes. The 
LC-MS interface used N2 as the sheath and auxiliary gas and He was used as the collision gas. For 
ionisation in negative mode, the interface and mass-selective detection parameters were as follows: 
sheath gas, 30 arbitrary units; auxiliary gas, 15 units; spray voltage, -4 kV; capillary temperature 320 
°C; capillary voltage, −1 V; tube lens offset, −68 V. Xcalibur analytical software (Thermo Fisher 
Scientific, USA) was used to process the chromatographic data. Results were compared to various 
online libraries such as KEGG ligand (KEGG, Japan) and Mass bank (Horai et al., 2010) as well as 
scientific journals.  
1.2.3.2 –HPLC-PDA- High resolution MS  
 The instrumentation and method described below was used once pure compounds were 
achieved. A relatively short gradient and run time was utilised as these compounds did not require 
separation. The aim of this method was to be able to aid in the full structural characterisation of 
compounds using the high-resolution MS and running standards for comparison.  
 LC-HRMS analysis was performed on an Orbitrap Fusion Tribrid mass spectrometer (Thermo 
Scientific) that was coupled to an UltiMate 3000 liquid chromatographic system (Dionex, Thermo 
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Scientific). A Hypersil Gold (Thermo Scientific) reversed phase C18 column (2.1 mm x 150 mm; 
particle size 5 µm) was used and maintained at a temperature of 60 °C at a flow rate of 0.6 
mL/minute. 10 µL was injected and eluted using a gradient mobile phase system with eluent A 
containing ultra-pure water (18.2 Ω) with 0.1% formic acid (mass spectrometry grade, Fluka), and 
eluent B MeOH (HPLC grade, Fisher Scientific) with 0.1% formic acid. The initial conditions were sat 
at 95% A with a linear increase to 95% B over 7 minutes. 100% B was held for 3.5 minutes before 
equilibration at initial conditions for a further 2.5 minutes. 
 Ions were generated in a HESI-II source with a source voltage of 3500/2500 V for 
positive/negative mode. The sheath gas was set to 45 psi, aux gas flow set to 13 AU, with a vaporiser 
temperature of 358 °C and an ion transfer temperature of 342 °C. Ions were detected in profile 
mode over 100-2000 m/z in the orbitrap detector at a resolution of 240000 and an injection time of 
100 milliseconds in both positive and negative mode. 
1.2.4 – NMR Analysis 
 1H NMR spectra were recorded on a Bruker DRX500 instrument operating at 500 MHz using 
CD3OD as the solvent and SiMe4 as the internal standard. Chemical shifts (δ) are given in ppm 
relative to SiMe4. Post-acquisition processing was performed on MestReNova (Version 6.0.2) 
Mestrelab Research, Compostela). 1H spectra were processed using automatic peak picking and 
manual integration. Where applicable, coupling constants (J) were calculated using the MestReNova 
manual multiplet analysis function and are expressed in Hz.  
 
1.2.5 – Antimicrobial susceptibility testing – 24-hour growth curve  
   Initial plant extracts and early purified products were subjected to a 24-hour growth 
curve antimicrobial assay. This method allows many samples to be tested on one plate against 4 
different aerobic bacterial species: Bacillus subtilis ATCC 663, Escherichia coli – ATCC 25922, 
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Pseudomonas aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 29213. All samples were 
tested in triplicate with no serial dilution at concentration of 1 mg/mL. 
 Bacterial suspensions were prepared by direct colony suspension in Mueller Hinton broth 
(Merck, Darmstadt) and incubated overnight at 37 °C in a temperature-controlled orbital shaker at 
300 rotations per minute (rpm). The overnight cultures were standardized to a McFarland standard 
value of 0.5 which is equivalent to 1 × 108 cfu/mL. This is done by diluting the suspension to obtain 
an optical density (OD) of 0.1 at 600 nm using a spectrophotometer (Wiegand, Hilpert and Hancock, 
2008; Hecht et al., 2007). A further 1 in 10 dilution of this bacterial suspension was carried out to 
make a standardised bacterial solution of 1 × 107 cfu/mL. Mueller Hinton broth (150 μL) was added 
to each well in the 96-well plate. Into rows A-E was added 40 μL of 5 mg/mL solution of sample was 
added and mixed, one sample per row. Rifampicin (61 μM, control) was added to row F. The wells 
in rows G and H were left untreated. Standardized overnight culture (10 μL; 1 × 107 cfu/mL) was 
added to rows A−G to provide a final in-well concentration of 5 × 105 cfu/mL. Row H left with no 
sample and no bacteria as a blank and a contamination control. Plates were incubated in a Hidex 
Sense Plate Reader (LabLogic, Sheffield UK) at 37 °C within an orbital shaker at 300 rpm for 24 hours. 
The OD was measured at 600 nm every 20 minutes for 24 hours this data was used to produce a 
growth curve. The high concentration is justified as the samples contain a mixture of many 
compounds therefore a high concentration is required to see any activity. By measuring growth over 
24 hours any disturbances in growth can be analysed even if the sample did not affect the total 
amount of bacteria present after 24 hours. A percentage inhibition can be calculated by dividing the 
OD at 24 hours of a sample by the OD at 24 hours of the positive control and multiplying by 100.  
1.2.6 – Antimicrobial susceptibility testing – Minimum inhibitory concentration  
 Calculating the minimum inhibitory concentration (MIC) of a compound was carried out 
once a pure compound has been obtained and involves testing a range of concentrations to show 
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the lowest amount of compound which can prevent the growth of different bacteria over the 
generation tome of the bacteria.  
 Bacterial suspensions were prepared by direct colony suspension in Mueller Hinton broth 
(Merck, Darmstadt) and incubated overnight at 37 °C in a temperature-controlled orbital shaker at 
300 rpm. The overnight cultures were standardized to a McFarland standard value of 0.5 which is 
equivalent to 1 × 108 cfu/mL. This is done by diluting the suspension to obtain an OD of 0.1 at 600 
nm using a spectrophotometer (Wiegand, Hilpert and Hancock, 2008; Hecht et al., 2007). Broth (190 
μL) was added to each well in the 96-well plate. Further broth (160 μL) was added to wells A1− A12, 
followed by test solution (40 μL). The sample was mixed, and aliquots (200 μL each) were taken and 
added to each well through to row E. Rifampicin (61 μM, control) was added to row F. The wells in 
rows G and H were left untreated. Standardized overnight culture (10 μL; 1 × 107 cfu/mL) was added 
to rows A−G to provide a final in-well concentration of 5 × 105 cfu/mL. Plates were incubated in a 
Hidex Sense Plate Reader (LabLogic, Sheffield UK) at 37 °C within an orbital shaker at 300 rpm for 
24 hours (72 hours in the case of B. anthracis). The OD was measured at 600 nm at initial time point 
and after 24 hours, this was used to calculate the percentage growth when compared to bacterial 
growing without the presence of an antimicrobial compound.  
 Samples and bacterial combinations were carried out in triplicate, the lowest concentration 
of MNQ which inhibited the growth of bacteria was deemed to be the MIC. If there is a discrepancy 
between the triplicate analyses an average of the three MIC values were taken.  
 Most of the bacteria used for this test were all aerobic; Bacillus anthracis NCTC 10340 (72-
hour generation time), Bacillus subtilis ATCC 663, Escherichia coli – ATCC 25922, Pseudomonas 
aeruginosa ATCC 27853, Salmonella enteritidis wild type, Staphylococcus aureus ATCC 29213 and 
Staphylococcus aureus MRSA ST8: USA300. 
 Two isolates of Clostridium difficile were also assayed; 291 previously described by Calabi et 
al. 2001, and 630 previously described by Farrow, Lyras and Rood 2000. These are strictly anaerobic 
46 
 
bacteria, meaning they are very sensitive to the presence of oxygen. They were incubated in an 
anaerobic chamber with a gas mix of 5% CO2, 10% H2, 85% N2. Unfortunately, there was no option 
to shake while incubating so they were placed on an orbital shaker at 300 rpm for 10 mins prior to 
taking the initial OD reading then entering the anaerobic chamber. The same was shaking was 
carried out prior to the final reading taken at 72 hours.  
1.2.7 – Antifungal susceptibility testing – 24h growth curve and minimum inhibitory 
concentration  
  Antifungal assays were carried out in the same format as antimicrobial assays only using 
Candida albicans (ATCC 10231) and yeast malt broth (Merck, Darmstadt) as a growth medium. The 
only fungal species used for this assay was Candida albicans NCTC 3255.  
1.2.8 – Schistosoma mansoni schistosomula culture compound screening - Roboworm 
Platform 
  S. mansoni (Puerto Rican Strain, Naval Medical Research Institute- NMRI) cercariae were 
collected from infected Biomphalaria glabrata (NMRI) snails after exposure to 2 hours of light at 
26°C and then mechanically transformed into schistosomula as described (Colley and Wikel, 1974). 
Newly transformed schistosomula were prepared for 72 hours high throughput screening (HTS) in 
384-well black-sided microtiter plates (Perkin Elmer, MA, USA) as described in Nur-E-Alam et al., 
2017, with a final DMSO concentration of 0.625%. The effect of compounds on 72 hours cultured 
schistosomula was deduced by analysing the effect on both motility and phenotype of treated 
schistosomula using the image analysis model described by Paveley et al., 2012.  
1.3 - Results – Natural Products  
 The following summarises the strategy used to isolate anti-microbial compounds. All 
powdered plant material was extracted in 75% methanol, dried under vacuum and bound to C18 
reversed phase silica prior to flash purification using gradient of ultra-pure 18.2 Ω H2O and analytical 
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grade MeOH from 0-100% MeOH (flow rate of 100 mL/min) using a 60 g Biotage SNAP Ultra C18 
flash cartridge. To identify which fractions and compounds were of interest a range of biological 
assays were carried out. Following flash purification 24h bacterial growth assays were carried out at 
1 mg/mL. Further purified fractions and compounds were tested for antimicrobial activity using MIC 
assay and other bioassays. Following flash purification fractions of interest were purified further 
using semi-preparative HPLC. HPLC-PDA-ESI-MS/MS was carried out to identify compounds. For 
compounds of interest which were purified fully NMR was also carried out.  
1.3.1 – Impatiens glandulifera 
1.3.1.1 – Impatiens glandulifera - Isolation of compounds – Flash Purification 
 In order to obtain antimicrobial compounds of interest from the plant extract a bioactivity 
led purification method was employed, this is summarised in Figure 5. The I. glandulifera plant 
extract was prepared for purification by passing through a C18 SPE cartridge firstly eluting with 
water and then methanol. The methanol fraction was purified further using C18 reversed phase 
flash purification. The mobile phases were water and methanol, a gradient from 0-100% methanol 




Figure 5: Summary of the separation pathway of I. glandulifera material 
 
  
Figure 6: Flash purification of I. glandulifera material, which was separated into 5 fractions 
denoted by the vertical black lines. The coloured area of the graph represents the total UV 
absorption of the analytes leaving the column at that time. The red line represents UV absorption 
at 280 nm and black line represents UV absorption at 330 nm. Colour changes indicated that the 
flash purification system has detected a significant change in UV absorption which could indicated 




Flash Purification  






1.3.1.2 – Impatiens glandulifera -Identification of compounds 
 Five fractions of I. glandulifera were obtained using flash purification each was analysed 
using HPLC-PDA-ESI-MS/MS (Appendix 1). Each major peak present in both PDA and negative mode 
mass chromatogram is shown in Error! Reference source not found.. The tentative identifications 
are based upon the use of online mass spectral database MZedDB and based on their fragmentation 
patterns.  





PDA  λ  
max (nm)  
MS1 [M-H]- 
ions (m/z)  
MS2 [M-H]- ions  
(m/z)  
Tentative 
identification   
1  6.25  289, 312  400.62  302.89,  228.80, 
200.80  
Unknown   
9.39 251, 273,  
326 
316.92 229.79,228.77, 200.79, 
184.80  
Myricetin 
2  2.53  261  286.73  240.74  Unknown   
5.20  281  480.87  258.73,  288.70,  
212.72, 200.73  
Unknown   
8.25  272, 355  332.82  272.79,  260.74,  
104.54  
Unknown   
9.35  251, 273,  
326  
316.92  229.79,  228.77,  
200.79, 184.80  
Myricetin   
10.64  285, 379  258.81  258.75,  231.88,  
230.74  
Unknown   
11.17  252, 282,  
338, 379  
634.90 616.82,  482.82,  
472.77, 454.81  
Trigalloyl glucose  
3  8.92  274, 343  550.37  303.11  8-methylsulfinyl-
noctylglucosinolate  
9.39  289, 340,  
379  
584.74  538.69, 376.60  Unknown   
11.22  252282,338, 
379  
634.90 616.82,  482.82,  
472.77, 454.81  
Trigalloyl glucose  
12.63  255, 353  548.62  504.8  Quercetin-3-
Omalonylglucoside  
14.06  265, 345,  
379  
532.50 488.79  Luteolin-7-O-
6malonylglucoside  




12.16  255, 354  608.96  300.73  Rutin  
13.52  265, 347  593.00 286.00, 284.87  Tiliroside  
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5  12.09  249, 278,  
339, 379  





1.3.1.3 – Impatiens glandulifera -Antimicrobial activity of flash purification fractions 
 In order to streamline the purification process, antimicrobial assays were carried out on the 
5 flash purification fractions obtained from I. glandulifera prior to any further purification. A 24-
hour antimicrobial growth curve method was carried out using fractions at 1 mg/mL (see 1.2.5). The 
total percentage inhibition of growth over 24 hours for each fraction was calculated and displayed 
in Table 3. 
Table 3: Summary of all flash purification fractions (1 mg/mL) antimicrobial activity 
expressed as percentage inhibition after 24 hours of growth (n=3) 
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15 0 16 20 
IG 3 
 
3 0 47 19 
IG 4 
 
17 0 53 0 
IG 5 
 
55 0 95 48 
 
 Of the 5 fractions tested, IG5 clearly showed the most significant antimicrobial activity. IG5 
had the highest % inhibition against all the bacterial species tested, although P. aeruginosa 
remained unaffected by all the fractions. IG5 showed the most significant activity against S. aureus, 
allowing only 5% growth over a 24-hour period. 
1.3.1.4 – Impatiens glandulifera – Isolation of compounds – HPLC Purification of IG5 
 Of the five fractions IG5 was chosen for further purification due to its significant 
antimicrobial activity. To obtain pure compounds HPLC purification was carried out using a Nova-
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Pak C18 Prep Column, 60 Å, 6 µm, 7.8 mm X 300 mm on a preparative HPLC system with a PDA 
detector (Dionex, ThermoFisher Scientific, UK). 100 µL of a 10 mg/mL solution was made up in 60% 
MeOH and injected using a custom gradient of 60% Methanol to 80% methanol over 10 minutes 
before washing at 100% and returning to starting conditions over a total of 25 minutes. The PDA 
detector was set to 240 nm and all eluent was collected into tubes. This method was developed to 
obtain two well-resolved peaks along with four small peaks. The two main peaks were named IG5.1 
and 5.2 yielding 2 and 5 mg of dry product respectively, the other smaller peaks were also collected 
but their weights were negligible. The injection volume as increased to 200 µL and the resolution 
between peaks was maintained, and repeated a further 20 times, obtaining around 10 mg of IG5.1 
and over 25 mg of IG5.2.  
1.3.1.5 – Impatiens glandulifera – Antimicrobial activity of IG5.1 and IG5.2  
 Using the material gained from the HPLC purification along with the flash purification 
fractions an MIC assay was carried out against MRSA (Table 4). This clearly demonstrates the result 
of the purification, it has marginally improved the potency of IG5 in the case of IG5.2 by removing 
any inactive impurities, present in IG5.1 and other peak too small to carry out an assay. This 
compound has shown activity 20-fold better than any other fraction against MRSA. 
Table 4: Minimum inhibitory concentration of IG fractions against MRSA ST8: USA300 (n=3) 
Fraction MIC (mg/L) 
IG 1 1420 
IG 2 1660 
IG 3 490 
IG 4 1130 
IG 5 39 
IG 5.1 100 




 The Les Bailie group had a range of interesting pathogens which I was able to also able to 
use. This widened the scope of the anti-bacterial activity of the IG5.1 and 5.2. Their interest was in 
Bacillus anthracis along with a few other bacteria (Table 5). Yet again the IG5.2 fraction showed 
impressive antimicrobial activity against more species of bacteria, C. difficile. Although these results 
are not as impressive as the activity seen against S. aureus.  
Table 5: Minimum inhibitory concentration of IG5.1 and IG5.2 against a further 5 strains 











IG5.1 462 >1000 895 256 >1000 
IG5.2 116 533 329 79.7 290 
 
1.3.1.6 – Impatiens glandulifera –Identification of IG5.2 
 The fraction IG5.2 was identified as 2-methoxy-1,4-naphthoquinone (MNQ) using NMR 
(Figure 7 and Table 6) and HR-MS (Figure 8). 1H NMR revealed that IG5.2 only had 4 distinct proton 
environments, in combination with the HRMS data it was known that this was a small molecule with 
a molecular mass of 188 m/z (189.05472 [M+H]+). Using this information and literature (Yang et al., 
2001; Mitchell et al., 2007) to support this compound being derived from I. glandulifera the 
structure was confirmed to be MNQ. For further proof of this structural elucidation commercially 
available MNQ was obtained (Merck, Darmstadt) and run using the same HR-MS methodologies and 
compared the chromatography obtained from IG5.2 (Figure 9). The retention time matched and the 




Figure 7: 1H NMR spectrum of IG5.2  
 
  









C-3 6.18 s 
C-4 - 
C-5 8.13 dd 
C-6 7.67 dt 
C-7 7.73 dt 
C-8 8.08 dd 
C-9 - 
C-10 - 




Figure 8: HPLC-HR-MS of IG5.2. The top graph is a mass chromatogram over the 7 min run time 
showing the relative abundance of ions being detected at certain retention times. The bottom 
graph is a mass chromatogram taken at the apex of the peak within the mass chromatogram. 
 
  
Figure 9: HPLC-HRMS of commercially available MNQ. The top graph is a mass chromatogram over 
the 7 min run time showing the relative abundance of ions being detected at certain retention 
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T: FTMS {1,1}  + p ESI Full ms [70.00-1400.00]
































419.31583294.11218 460.12408 554.23877 1022.56012860.67706684.22150611.30389 1319.299681128.49951 1223.08569965.74762
E:\PhD\Data\LTQ\Exactive\161028-Dai\MNQ 10/29/16 01:17:54
RT: 0.00 - 22.04


















































































F: FTMS + 
p ESI Full 
ms   MS 
MNQ
MNQ #217 RT: 4.49 AV: 1 NL: 2.23E8
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1.3.2 – Fallopia japonica 
1.3.2.1 – Fallopia japonica - Isolation of compounds  
 The same methodologies used for I. glandulifera were also applied to F. japonicum.  A 
summary of the purification and assays carried out is depicted in Figure 10. The plant extract was 
prepared for purification by passing through a C18 SPE cartridge firstly eluting with water and then 
methanol. The methanol fraction was purified further using C18 reversed phase flash purification. 
The mobile phases were water and methanol, a gradient from 0-100% methanol over 30 mins at a 
flow rate of 10 mL/min was used (Figure 11). 
  




Flash Purification  
 







Figure 11: Flash purification of F. japonica material which was separated into 6 fractions denoted 
by the vertical black lines. The coloured area of the graph represents the total UV absorption of the 
analytes leaving the column at that time. The red line represents UV absorption at 280 nm and 
black line represents UV absorption at 330 nm. Colour changes indicated that the flash purification 
system has detected a significant change in UV absorption which could indicated a different 
analyte being eluted. The blue line represents the increasing gradient of methanol over time. 
 
1.3.2.2 – Fallopia japonica – Identification of compounds  
 Five fractions of F. japonica were obtained using flash purification each was analysed using 
HPLC-PDA-ESI-MS/MS (Appendix 2). Each major peak present in both PDA and negative mode mass 
chromatogram were summarised in Table 7.  
Table 7: Summarised HPLC_PDA_ESI_MS/MS data of the 5 fractions obtained from F. japonica  
Fraction  RT  
(min)  
PDA  λ  
max (nm)  
MS1  [M-
H]-  
ions (m/z)  
MS2  [M-H]-  
ions (m/z)  
Tentative identification   
FJ1  5.5  310  336.89  190.78, 162.76   Trans-5-para-coumaroylquinic 
acid  
6.46  323  366.99  192.80,  
193.85,  
172.81, 133.77  





1.3.2.3 – Fallopia japonica – Biological Assays 
 Antimicrobial assay was carried using the F. japonica fractions in the same way as for I. 
glandulifera for comparison (Error! Reference source not found.). Fractions 3,4 and 5 showed the 
6.65  325  352.94  191.96,  
190.82, 178.82  
3-O-caffeoylquinic acid  
7.96  313  294.76  162.74,  
148.70, 130.59   
Para-coumaroyl-pentose  
 8.88  327  324.86  192.83  Feruloyl tartaric acid  
FJ2  8.29, 
9.29  
311  336.89  190.78, 162.76  Trans-5-para-coumaroylquinic 
acid  
 7.9  279  578.69  301.03,  
288.87, 245  
Naringin  
 10.5  314  308.87  276.81 162.77,  
144.72  
Unknown  
FJ3  9.31  304  434.75  388.74, 227.06  Resveratrol glycoside  
FJ4  10.08  306  435.75  388.74, 227.06  Resveratrol glycoside  
FJ5  12.48  256, 354  609.06  300.86  Unknown  
 13.34  256, 353  478.47  337.22, 460.14  Myricetin-O-hexoside  
 13.6  256, 349  492.48  472.98,  




most significant activity against S. aureus, however this activity was far below that seen in I. 
glandulifera.   
Table 8: Summary of all flash purification fractions (1 mg/mL) antimicrobial activity 
expressed as percentage inhibition after 24 hours of growth (n=3) 








FJ 1 2 0 0 0 
FJ 2 4 0 0 0 
FJ 3 13 0 39 0 
FJ 4 8 0 37 0 
FJ 5 9 0 30 0 
 
 Due to the low level of antimicrobial activity seen in these fractions no further purification 
was carried out and these fractions were not assayed against other bacteria species. However, the 
Hoffmann Research Laboratory offered their services to Life Sciences Research Network Wales 
projects. They have a high-throughput screening platform called Roboworm, which tests the ability 
of compounds to inhibit the viability of a larval schistosomula. As these fractions were plentiful and 
not as important as the IG5.2 fraction, which was critical, these fractions were a good opportunity 
to trial this assay. As these fractions were not active against bacteria, there is no reason they would 
not be a potent inhibitor of Schistosoma mansoni schistosomulae. Figure 12 shows that JK5 manage 
to significantly affect the motility of the schistosomulae but unfortunately did not affect the 




Figure 12: Anti-helminthic activity of F. japonica fractions against S. mansoni. There are two 
parameters measured, motility and phenotype. In order to regarded as an active compound (a hit 
within the green area) the compound must score below -0.15 for phenotype and below -0.3 for 
motility. Auranofin (AUR) and Praziquantel (PZQ) are proven anti-schistosomal drugs. 
 
1.3.3 – Rhododendron ponticum 
1.3.3.1 – Rhododendron ponticum - Isolation of compounds  
 As for the previous two plants a summary of the purification carried out is shown in Figure 
13 and Figure 14 shows the flash purification of R. ponticum which was carried out in the same way 




Figure 13: Summary of the purification of R. ponticum  
 
 
Figure 14: Flash purification of R. ponticum material which was separated into 3 fractions denoted 
by the vertical black lines. The coloured area of the graph represents the total UV absorption of the 
analytes leaving the column at that time. The red line represents UV absorption at 280 nm and 
black line represents UV absorption at 330 nm. Colour changes indicated that the flash purification 
system has detected a significant change in UV absorption which could indicated a different 












1.3.3.2 – Rhododendron ponticum – Identification of compounds  
Three fractions of R. ponticum were obtained using flash purification each was analysed using HPLC-
PDA-ESI-MS/MS (Appendix 3). Each major peak present in both PDA and negative mode mass 
chromatogram were summarised in Table 9. 
Table 9: Summarised HPLC_PDA_ESI_MS/MS data of the 3 fractions obtained from R. 











ions (m/z)  
Tentative identification   




Unknown   
4.57  296,  
323  





5.433  287  370  324.93,  
162.95  
Unknown   
5.88  287,  
298  
337.06  163  2-O-acetyl-trans-coutaric acid   
2  1.96  N/A* 168.99  124.88  Unknown   
3.27  N/A* 593  425  Quercetin 2-glucoronide sulphate   
4.74  N/A* 577.01  424.99  Kaempferol 3-glucoronide-7-
sulphate   
5.03  N/A* 577.01  424.99  Kaempferol 3-glucoronide-7-
sulphate   
5.89  N/A*  337.06  163  2-O-acetyl-trans-coutaric acid   
6.61  N/A* 483.08  207.98  Artonin P  
7.58  N/A* 502.65  456.94  Unknown   
8.12  N/A* 334.86  288.98  Unknown   
10.27  N/A* 373.04  327.04  Ovalitenone   
10.94  N/A* 479.05  315.95,  
316.98  
Myricetin 3-galactoside   




3  9.78  288  243.11,  
259.05  
N/A Unknown   
 10.28  251,  
340  
259.1  N/A Dihydropyrans  
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 10.94  255,  
357  
243.14  N/A Geranyl benzoquinone   
 11.85  256,  
352  
258.97  N/A Caffeic acid-3-sulphate   
 12.38  255,  
354  
259.08  N/A Dhelwagin  
 13.53  256,  
354  
249.06  N/A Lunularin  
 
1.3.3.3 – Rhododendron ponticum – Biological Assays 
 As for the other two plants the same antimicrobial assay was carried out for R. ponticum 
(Table 10).  
Table 10: Summary of all flash purification fractions (1 mg/mL) antimicrobial activity 
expressed as percentage inhibition after 24 hours of growth (n=3) 








RP 1 25 46 20 37 
RP 2 19 58 37 55 
RP 3 8 22 13 11 
 R. ponticum fraction 1 and 3 showed barely any activity against any bacterial species when 
carrying out a 24-hour assay. Although RP2 showed moderate antimicrobial activity across all four 
bacterial species. An MIC assay was carried out using RP2, although the antimicrobial activity was 
not enough to kill the bacteria at a concentration tested. In order to display this data in a meaningful 
way the minimum concentration of RP2 required to limit the growth of the bacteria to 50% and 90%. 
This is referred to as the minimum limiting concentration (MLC) (Table 11). The concentration of 
RP2 required to inhibit the growth of all four bacteria is relatively poor compared to that of I. 
glandulifera. Although activity was relatively poor RP was consistently active against all four species, 
which was not seen in any other plant. The activity seen against P. aeruginosa was particularly good 




Table 11: The minimum concentration of R. ponticum fraction 2 required to limit growth of 
four bacterial species by 50 and 90% over 24 hours (mg/L) (n=3) 
Bacterial Species  MLC50  MLC90  
E. coli  740  1340  
S. aureus  530  950  
P. aeruginosa  470  840  
B. subtilis  450  810  
 To increase the breadth of the biological testing carried out the R. ponticum fractions were 
also assayed for their ability to inhibit the growth of Candida albicans. This opportunistic pathogenic 
yeast is common in human mouths and throughout the gastrointestinal tract. These yeast cells are 
morphologically like bacteria and able to develop the antimicrobial susceptibility testing to be able 




Figure 15: The 24-hour growth curve of C. albicans ATCC 102313 in the presence of three R. 
ponticum fractions (1 mg/L), hygromycin as an antifungal control, with no inhibiting compounds as 
a positive control and no fungi as a negative contamination control. 
 None of the fractions showed significant activity, with RP1 showing the best antifungal 
activity with an MLC50 of 1.4 mg/L, which was calculated based on the linear extrapolation of the 
single concentration tested.  
1.4 - Discussion – Natural Products  
1.4.1 – Impatiens glandulifera   
 I. glandulifera fractions were found to be effective against E. coli, S. aureus and B. subtilis at 
1 mg/mL. Fraction IG5 was by far the most active fraction overall; 55%, 95% and 48% inhibition 
respectively yet it was unable to affect P. aeruginosa (Table 3). Further purification was carried out 
on IG5 which yielded two fractions, IG5.1 and IG5.2. Of these two fractions IG5.2 was found to be 
an extremely potent inhibitor of MRSA, Bacillus anthracis, B. subtilis, Salmonella, and C. difficile 
(Table 4 and Table 5). The best activity was seen against MRSA, with an MIC of 23 mg/L. A range of 
antibiotics can be used to treat MRSA infections each with ranging MIC values depending on the 
strain; clindamycin (0.125-0.5 mg/L), daptomycin (0.063-4 mg/L), Doxycycline (0.25-32 mg/L), 
Erythromycin (0.25-<64 mg/L), Linezolid (2-32 mg/L), trimethoprim-sulfamethoxazole (0.06-20 
mg/L), and vancomycin (1-4 mg/L) (Fowler et al., 2006; Kalil et al., 2014; LaPlante et al., 2008). 
Comparing the MIC of MNQ to currently used antibiotics it is around 10-fold less potent. However, 
activity can be dependent on the strain being used. The above studies did not use USA300 so it 
cannot be directly compared. Further strains will need to be tested to fully understand the potential 
of MNQ. Only IG5.2 has been tested, which is a plant extract, commercially available MNQ has been 
purchased and further screens can be carried out using this. Looking at the mass chromatograms 
Figure 8 and Figure 9, the purchased MNQ has a cleaner chromatogram than the plant extract. This 
increase in purity could improve the potency to rival the efficacy of antibiotics such as vancomycin.  
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 Using a combination of HPLC-PDA-HRMS and NMR (Table 6 and Figure 8) IG5.2 was 
identified as 2-methoxy-1, 4-naphthoquinone (MNQ). This compound has been isolated previously 
from Impatiens balsamina which is a close relative of I. glandulifera, and MNQ was also shown to 
inhibit the growth of bacterial species Staphylococcus aureus, Bacillus cereus, B. megaterium, B. 
subtilis Aeromonas salmonicida, Aquaspirillum serpens and fungal species Candida albicans, 
Fusarium oxysporum, Aspergillus fumigarus, Macrospore gypseum, Trichophyton mentagrophytes 
(Yang et al., 2001). The activity of MNQ against S. aureus in this paper was found to be 16 mg/L 
which is marginally better than this study. This could be due to the strain or the presence of 
impurities as discussed earlier.  
1.4.2 – Fallopia japonica  
  The most active fractions FJ3 & FJ4 isolated from F. japonica showed moderate 
antimicrobial activity against S. aureus (Table 8). The major compounds present in these fractions 
were identified as resveratrol glycoside using HPLC-PDA-ESI-MS/MS (Error! Reference source not 
found.). According to the mass spectrometry data, FJ3 and 4 yielded a base ion of m/z 435 and 
secondary fragmentation ion of 389 [(M-H)-46]- which is consistent was a formate adduct formed 
due to there being formic acid in the mobile phase. Therefore, the molecular ion is 389 [M-H]-. There 
is further fragmentation from m/z 389 to 227 which is a loss of m/z 162 which is consistent with the 
loss of a hexose sugar in literature (Jerkovic et al., 2007; Vukics and Guttman, 2010). FJ3 and 4 have 
different retention times although they share the same mass spectra, resveratrol has two isomers 
in cis and trans conformation and these effects the retention time on C18 column chromatography 
(Lamuela-Raventos et al., 1995).  
  Resveratrol has been identified in over 70 plant genera and has been shown to have many 
beneficial biological activities; antimicrobial activity, anti-inflammatory, anticancer, and antioxidant 
activity (Frémont, 2000; Joe et al., 2002; Pervaiz, 2003). The presence of resveratrol in F. japonica is 
well documented as being considered as a commercially viable source of raw material for resveratrol 
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production as well as other anthraquinones such as emodin and physcion (Chen et al., 2013). Due 
to the fact resveratrol and F. japonica are so well documented no further research was carried out 
on F. japonica.  
1.4.3 – Rhododendron ponticum    
  All three R. ponticum fractions were consistently active against E. coli, P. aeruginosa, S. 
aureus, B. subtilis and the fungi C. albicans. Although the level of activity was relatively low 
compared to other fractions, R. ponticum was the only plant which was able to inhibit the growth 
of P. aeruginosa. Although level of activity was not significant, to see any activity against the gram-
negative bacterium P. aeruginosa is interesting as this suggests the compounds within this fraction 
of R. ponticum are showing a different pattern of antimicrobial activity to that found in the other 
plant extracts.  
  The compounds tentatively identified in RP2 using HPLC-PDA-ESI-MS/MS were mainly 
flavonoid, flavonoid glycosides and related compounds, because there was characteristic mass 
fragmentation which matches that see in the literature (Vukics and Guttman, 2010) (Table 9). 
Flavonoids and their glycosides have been previously reported and were shown to have anti-
inflammatory, antinociceptive (Erdemoglu et al., 2008), antiapoptotic (Zhang et al., 2010). The 
antibacterial and antifungal activity of Rhododendron species have been previously studied (Ertürk 
et al., 2009). The activity seen previously was tested using plate diffusion assays and the activity 
seen in our study exceeds that seen by Ertürk et al. This difference could be accounted due to 
different methods. However, the increased activity in the UK variety could be due to the UK variety 
being invasive. As an invasive species this plant is not exposed to its natural predators and pests 
which would be present in Turkey. The predator-prey relationship would have evolved over time to 
keep both species in check, once the predator is removed by moving the plant to the UK this plant 
is able to grow faster and be more aggressive. Without the stress of the predator the UK variety may 
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be able to produce different bioactive, or in different quantities which cause a more antimicrobial 
extract. This could be an example of the ERH in action.   
 Unfortunately, the flash purification of R. ponticum did not yield as many fractions as the 
other two plants. Fortunately, in the case of the other two plants a relatively pure, biologically active 
fraction was yielded, identified and assayed. The issue with carrying out bioactivity led purification 
when all fractions show relatively low activity it is difficult to choose which fraction to purify further. 
Ideally a better first round of purification should have been carried undertaken, this could have been 
done by either utilising a longer, slowed gradient which would have separated peaks better or a 
customised step gradient. A step gradient approach would involve running a series of isocratic 
elutions only increasing the percentage of organic solvent when it looks like there are no more 
analytes being eluted. This could have easily been applied to purification using the Biotage flash 
purification systems PDA detector.  
1.5 – Conclusion   
 The focus of this project is to discover novel drug candidates for the treatment of MRSA. 
The aim of this chapter is to screen a range of problematic invasive weed species for molecules 
which show antimicrobial activity. Antibiotic resistance is a particularly big issue facing society and 
MRSA is the most high-profile pathogen of all. If a compound can be found which is able to treat 
this infection, then this will be the highest priority of all.   
 The main candidate compound found in F. japonica was tentatively identified as a 
Resveratrol glycoside. This compound is well documented and has a broad range of bioactivities. 
However, the activity against S. aureus isn’t particularly impressive and does not have any potential 




 R. ponticum showed a low level of activity against all bacteria and fungi. This is interesting 
as no other compounds had any impact on the growth of P. aeruginosa. The quality of the 
purification of the R. ponticum was not as effective as the other plants. No single compounds were 
isolated or identified. The low level of activity could be due to active compounds being diluted by 
the presence of other non-active compounds being present in the fractions.  This plant has the 
potential to produce an active inhibitor of gram-negative bacterial growth. However, this is not the 
focus of this project and R. ponticum did not show significant activity against S. aureus.  
 A potential drug has been found within I. glandulifera, in the form of MNQ. This exciting 
molecule has been shown to have antimicrobial activity far beyond any other found within this 
project. It was found to have a broad range of activity against a range of pathogenic bacteria but 
showed particularly potency against S. aureus and MRSA. This molecule will be the focus of this 
project going forward. 
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Chapter 2 Lead Compound MNQ bioactivity and Drug 
suitability 
 
2.1 Introduction – MNQ Bioactivity  
2.1.1 – Chapter Aims   
 The major outcome of the first chapter was the isolation of MNQ from I. glandulifera which 
was shown to have potent antimicrobial activity, especially against MRSA which was comparable to 
that of current antibiotics. The known bioactivity of naphthoquinones will be discussed to 
understand the potential of this molecule as a future antibiotic. MNQ has been tested against a 
relatively small range of bacteria. To comprehensively understand the antibacterial profile, a broad 
range of clinically relevant bacterial species and strains must be tested. Although MRSA is the focus 
of this project it is important to understand the full bioactive ability of this molecule. Schistosoma 
mansoni is a pathogenic parasite which needs new treatment options, therefore MNQ will be tested 
against three stages of the S. mansoni life cycle. Cytotoxicity is vital factor for any potential drug, 
MNQ must show selective toxicity against bacteria so a range of tests must be carried out to assay 
the toxicity of MNQ. 
2.1.2 Bioactivity of Naphthoquinones   
 Naphthoquinones (NQ) are a class of organic compounds derived from naphthalene, the 
simplest polycyclic aromatic hydrocarbon, with the addition of two ketones. These carbonyls can be 




Figure 16: Chemical structure of 1,2-naphthoquinone (A) and 1,4 naphthoquinone (B)  
 
2.1.2.1 - 1, 2-Naphthoquionines  
  A range of 1, 2-NQ derivatives have been found to show potent anti-diabetic activity based 
on their ability to inhibit protein tyrosine phosphate 1B (PTP1B). PTP1B pays a role in the negative 
regulation of insulin signalling and is involved in the insulin resistance associated with Type-2 
diabetes (Kennedy and Ramachandran, 2000). 1, 2-NQ itself with no alteration was considered a hit 
with an IC50 of 1.64 µM. Thirty-one 1, 2-NQ derivatives were synthesised by Ahn et al. with 
alteration made to the 4 position (to increase stability by preventing Michael type nucleophilic 
addition) and subsequently evaluated for their in vitro inhibitory activity against recombinant 
human PTP1B. 5 of the 31 derivatives were completely inactive, 10 showed improved activity verses 
the original NQ and 17 were still active but no improvement on the original 1, 2-NQ core. The 
addition of aryl groups significantly improved antidiabetic activity of 1, 2-NQ derivatives and the 
addition of fluorine or hydroxide groups to the aryl further improved potency. Addition of a 
cyclohexyl group, proved to be the most potent (IC50 of 0.32 µM) but other alkyl substitutions only 
decreased activity (Table 12) (Ahn et al., 2002).   
 
 
A  B  
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Table 12: Inhibitory activity of 1,2-naphthoquinone 
derivatives against PTP1B (Ahn et al.,2002) 













3-Indole-5-carboxylic acid 3 
(CH2)5CH3 3.3 
Cyclopentyl 4.2 

















 1,2-NQs are also known to disrupt the effects of other Protein Tyrosine Phosphatases (PTP) 
which are involved in a wide range of biological functions. The presence of two neighbouring 
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carbonyls which is seen in all 1,2-NQs is essential for PTP inhibition which (Urbanek et al., 2001). For 
example, CD45 is involved in cellular growth, differentiation, mitotic cycle and oncogenic 
transformations, and is critical for T-cell receptor mediated T-cell activation. Derivatives of 1, 2-NQ 
with aryl alterations at the position 4 were found to be potent inhibitors of CD45 and T-cell 
proliferation in vitro. It is suggested that the 1, 2 NQs carbonyl of the dione attaches to the active 
site cysteine851 of CD45 rendering the enzyme catalytically inactive. However, removal of the 
vicinal carbonyl groups (replaced with Fluorine) yielded no activity and 1,4-NQs showed poor activity 
implicating additional mechanisms of action. Nocardione A (1,2-NQ with a hydroxyl group at 
position 7 and a pentose attached directly onto positions 3 and 4) inhibit three different type of 
PTPs; CDC25B (involved in cell proliferation), PTP1B (T-cell activation), and FAP-1 (linked to cell 
death and apoptosis) (Otani et al., 2000).  
 1,2-NQ have been shown to have anti-tumour activity. 1,2-NQ with thiosemicarbazone (TSC) 
group in the 2-position showed significant inhibitory activity against MCF-7 human breast cancer 
cells. Unaltered 1,2-NQ had an IC50 of 13.37 µM, the addition of TSC significantly improved the 
activity with an IC50 of 3.14 µM. Further improvement can be made by forming a NQ-TS Ni2+ 
complex which has an IC50 of 2.25 µM. Other metal complexes were formed with Cu and Pd, but 
these marginally decreased the activity (Chen et al., 2004).   
2.1.2.2 - 1, 4-Naphthoquionines  
  1,4-Naphthoquinones have a wide variety of biological activities including antibacterial and 
anticancer. For example, shikonin is a major component of Lithospermum erythrorhizon which is a 
Chinese herbal medicine with various biological activities, one of which is the inhibition of human 
immunodeficiency virus (HIV) type 1-induced cytopathology (Chen et al., 2003).  Four 1 ,4-NQ 
derivatives have been assessed for anti-fungal activity based around shikonin (5,8-dihydroxy-6-(1-
hydroxy-4-methyl-3-pentenyl)-1,4-naphthalenedione). These derivatives at position 6; include the 
additions of either an acetyl group, a hydroxy-iso-valeryl group or removal of the hydroxy group. 
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Each derivative showed decreased potency against a range of fungal species, compared to shikonin 
which showed similar levels of activity to fluconazole, a first generation triazole (Sasaki, Abe and 
Yoshizaki, 2002). This illustrates that natural selection can produce the most bioactive derivative so 
any synthetic changes have the potential to reduce potency.  
 Several 1, 4-naphthoquinoe derivatives have also been tested for anti-cancer activity 
against Walker 256 carcinosarcoma implanted into rats. Two active derivatives were 
2,3bis(phenylsulfanyl)-1,4-naphthoquinone and 5,8-dihydroxy-2-methyl-1,4-naphthoquinone 
(Tandon et al., 2004). While another 1,4-naphthoquine derivative, S-(1,4-naphthoquinone-2-yl)-
mercaptoalkanoic acid amide, was active against Lymphoid leukaemia P 388 in rats (Tandon, Singh 
and Yadav, 2004).  
 For anti-viral activity two 1,4-NQs; S-(1,4-NQ-2-yl)-5,8-dihydroxymercaptoalkanoic acid with 
an additional hydroxyl group and 5,8-dihydroxy-2-arylthio-1,4-NQ showed in vitro anti-viral activity 
against influenza-A virus and Herpes simplex virus. (Tandon, Singh and Yadav, 2004).   
 NQs have been shown to be useful in areas other than biology; 1,4-NQ has been shown to 
inhibit the corrosion of aerated and de-aerated aluminium in sodium chloride solutions. Showing 
that the presence of this naphthoquinone reduced pitting potentials, decreased anodic currents, 
and surface polarisation resistances are increased. The most effective concentration of 
naphthoquinone was found to be 1x10-3 M (Sherif and Park, 2006). Combining the broad 
antibacterial activity and the anti-corrosion activity of 1,4-NQs means this molecule could have 
potential as a cleaning solution for medical devices. 
2.1.3 Biosynthesis of naphthoquinones  
 NQs are a diverse group of natural products naturally occurring in many plant species, fungi 
and even bacteria. If MNQ is to be considered as potential antibiotic it is important to understand 
how this molecule is produced by plants and what purpose it serves. 
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 The o-succinylbenzoate (OSB) pathway which begins with chorismate and after 9 reactions 
results in MNQ (Figure 17). The OBS pathway was first discovered in the 1960s when [14C]-shikimate 
fed to E. coli (Cox & Gibson, 1964) and maize shoots (Whistance, Threlfall & Goodwin, 1966) to 
investigate the biosynthesis of vitamin-K. Tracer studies carried out using I. balsamina and [U-14C]-
α-ketoglutarate showed that this was incorporated into lawsone (Grotzinger & Campbell, 1972). 
Although this pathway has been studied for many years many reactions are not fully understood. 
 
Figure 17: The o-succinylbenzoate (OSB) biosynthetic pathway producing 2-methoxy-1,4-
naphthoquinione (MNQ) from shikimate via 10 reactions. The first 6 steps convert shikimate into 
chorismate, then isochorismate, then 2,2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexane-2-
carboxylate (SEPHCHC), then 3, 2-succinyl-6-hydroxy-2,4-cyclohexadiene-2-carboxylate (SHCHC), 
and finally OBS into OBS-coenzyme A (CoA). These steps have genetic evidence to support these 
reactions. The reaction which converts OBS-CoA to dihydroxynaphthoyl (DHNA)-CoA has a lack of 
supporting genetic evidence to be sure this is the correct reaction. All further reactions from DHNA 
into other naphthoquinones have little supporting genetic information and the enzymes 
responsible for these reactions are unknown. 
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 The pathway begins with chorismate which is derived from shikimate, an important 
metabolite for the biosynthesis of aromatic amino acids (Herrmann & Weaver, 1999). The first 
reaction is the isomerisation of chorismate to isochorismate by isochorismate synthase (Garcion et 
al., 2008). Followed by the addition of α-ketoglutarate which is catalysed along with the next two 
reactions by the trifunctional enzyme PHYLLO; containing 2-succinyl-5-enolpyruvyl6-hydroxy-3-
cyclohexene-2-carboxylate (SEPHCHC) synthase, 2-succunyl-6-hydroxy-2,4-cyclohexadiene-2-
carboxylate (SHCHC) synthase, and OBS synthase domains (Gross et al., 2006). This addition of α-
ketoglutarate results in SEPHCHC (Grotzinger & Campbell, 1972), followed by the 2,5-elimination of 
pyruvyl side chains to form SHCHC (Jiang et al., 2008), and dehydration to form OSB (Meganathan 
& Bentley, 1983). The ring (now aromatic) will form one of the rings of the naphthalene. OSB-
Coenzyme A (CoA) ligase attaches a CoA group to the succinyl side chain of OSB which is then 
cyclised by dihydroxynaphthoic acid (DHNA)-CoA synthase to form the second ring of the 
naphthalene core in DHNA-CoA (Kwon, Bhattacharyya & Meganathan, 1996). The removal of CoA 
by hydrolysis catalysed by thioesterases results in DHNA (Meganathan, 2001). At this point there is 
a significant fork in the pathway, where DHNA can be converted into phylloquinones (Lohmann et 
al.,2006), anthraquinones (Eichinger et al., 1999), juglone (Leistner & Zenk, 1968), and most 
importantly for this project lawsone which is a precursor of MNQ (Zenk & Leistner, 1967). Lawsone 
is formed into MNQ via an S-adenosylmethionine-dependent O-methyltransferase (Liscombe, Louie 
& Noel, 2012). 
 There are two other NQ producing metabolic pathways stemming from chorismate, the 
homogentisate (HGA)/mevalonic acid (MVA) pathway which produces chimaphillin (Bolkart & Zenk, 
1969) and the 4-hydroxybenzoic acid/MVA pathway yields deoxyshikonin, shikonin, alkannin and 
other derivatives (Schmid & Zenk, 1971). One other metabolic pathway, the acetate-polymalonate 
pathway, can produce NQs. These are plumbagin, droserone, 5-O-methyldroserone and 7-
methyljuglone although the reactions and enzymes responsible for these NQs are unknown (Durand 
& Zenk, 1971). 
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 NQs are synthesized by organisms throughout all kingdoms of life involved in a range of 
metabolic processes. For example, within plants and algae 1,4-NQs are involved in photosynthesis 
although this is not linked to their bioactivity which is not relevant to this project (Brettel, Sétif & 
Mathis, 1986). NQs produced by certain plants have an allelopathic effect on the plants around 
them, an example of this would be the phytotoxic effect of juglone from Juglans nigra. By excreting 
this NQ into the surrounding area to prevent growth of other plants (Soderquist, 1973). This 
allelopathic activity has also been observed in I. glandulifera and the compounds responsible is 
thought to be MNQ, this is likely a contributing factor to this plant’s successful invasion of most of 
the norther hemisphere (Ruckli et al., 2014). NQs produced by plants also interact with bacteria and 
fungi to the benefit on the plant. As has been clearly shown MNQ has significant antimicrobial 
activity and this will protect I. glandulifera from any bacterial of fungal infections. MNQ has been 
shown to be an effective inhibitor of Ecdysone 20-Monooxygenase, which is the insect cytochrome 
P450-dependent hydroxylase which plays a pivotal role in insect reproduction and development 
(Mitchell et al., 2007). Many species of fungi produce a wide range of different NQ which cause 
pigmentation of fruiting bodies for sexual reproduction as well as protection from UV light and 
insects (Studt et al., 2012). They are also produced in reaction to unfavourable factors in the 
environment, combining this with their broad range of biological activity it can assumed these 
compounds play a protective role (Medentsev & Akimenko, 1998; Darvill & Albersheim, 1984). 
Within the bacteria Actinomycetes numerous 1,4-NQs are produced which have a range of 
bioactivity seen previously but these are also used as precursors to produce polyketides which also 
have a broad range of bioactivities with protective properties (Moore & Hopke, 2001).  
 The natural purpose of NQs are for protections from other organisms, whether that be plant 
versus plant in the case of allelopathy see in I. glandulifera, or plant versus pest in the case of MNQ 
inhibiting insect development enzymes, or fungi producing NQs for a selective advantage over 
competitors in unfavourable environments. Many antibiotics, most famously penicillin, are 
produced by fungi in order to harm surrounding competitors to gain a selective advantage (Losada 
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et al., 2009). Antibiotic compounds such as penicillin are isolated and utilised by humans to destroy 
infectious pathogens. NQs seemingly serve the same protective purpose within plants, fungi and 
bacteria; therefore, it can be assumed these molecules can also be utilised to treat infections. 
2.1.4 Bacterial Cell Membranes   
 Bacteria can be grouped generally into three groups based on their membranes; gram-
negative, gram-positive and mycobacteria. Each offer different challenges for antibiotic compounds 
which need to be overcome to prevent the growth of bacteria. These structures can influence the 
efficacy of drugs with many antibiotics being selective for gram-positive, gram-negative, 
mycobacteria or in some cases broad spectrum covering a wide variety of bacteria. These factors 
are important to consider when determining the antimicrobial profile of MNQ.  
  A wide range of bacterial species and strains will be tested in this chapter tested for 
susceptibility against MNQ to evaluate its potential as an antimicrobial chemotherapeutic agent. 
Two factors which are important when selecting which bacteria to screen is variation in cell wall 
composition and possible resistance mechanisms. These can provide information on the suitability 
of the potential drug to a therapeutic use and any known resistance mechanism which can thwart 
its activity. Although MRSA is the focus of this project the bioactivity of MNQ is considerable, so to 
fully understand its potential a broad range of bacteria will be tested with different barriers to 
overcome. 
 Gram negative cell envelopes are made up of three principle layers; the outer membrane 
(OM), the peptidoglycan cell wall, and the inner membrane (IM). Between these two concentric 
membranes are areas called periplasmic spaces. The OM is a lipid bilayer composed of phospholipids 
on the inner leaflet with the outer composed of glycolipids, principally, lipopolysaccharides (LPS) 
(Kamio and Nikaido, 1976). The OM is crucial for the survival of E. coli and other gram-negative 
bacteria, yet its only known function is to serve as a protective barrier. It is known to contain 
enzymes such as phospholipase, protease, and enzymes which modify LPS, but these are not 
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essential as mutants lacking these shown no striking phenotype (Silhavy, Kahne and Walker, 2010). 
There are two classes of protein embedded within the OM; lipoproteins and β-barrel proteins which 
are involved in bacterial growth (Wu et al., 2006). There are about 100 lipoproteins encoded by in 
E. coli and the function of most are unknown (Miyadai et al., 2004). Most of the integral 
transmembrane proteins are assumed to be β-barrel proteins, they are formed of β-sheets wrapped 
into cylinders which cross the OM. These are also referred to as porins and they allow passive 
diffusion of small molecules, such as monosaccharides, disaccharides, and amino acids (Cowan et 
al., 1992). LPS play a crucial role in the barrier function of the OM and represent an effective barrier 
against hydrophobic molecules. Within this OM there is also a rigid peptidoglycan exoskeleton which 
determines bacterial cell shape.  Peptidoglycan is made from disaccharide N-acetyl glucosamine-N-
acetyl muramic acid repeating units crosslinked by pentapeptide chains. The peptidoglycan in gram 
negative bacteria is smaller than in gram positive bacteria but it still plays a significant role, 
interacting with proteins in the cell envelope and providing stability (Godlewska et al,. 2009). 
Between the OM and the IM is the periplasmic space, which is an aqueous compartment filled with 
proteins, that are more viscous than cytoplasm (Mullineaux et al., 2006). This compartment allows 
bacterial to sequester potentially harmful degradative enzymes but also beneficial proteins which 
serve a range of functions. Which include periplasmic binding proteins, involved in sugar and amino 
acid transport and chemotaxis as well as chaperone-like molecules are involved in envelope 
biosynthesis (Ehrmann, 2007).   
 Eukaryotic cells contain several membranous organelles such as mitochondria for energy 
production, smooth endoplasmic reticulum (ER) for lipid synthesis, rough ER for protein secretion, 
and cytoplasmic membrane sense the environment and transporting molecules. Bacteria do not 
have these organelles therefore these membrane-associated functions are performed by the IM 
which is a phospholipid bilayer. There are several structures embedded into this envelope such as 
flagella, secretion systems, and efflux pumps. Efflux pumps play important roles in pathogenicity 
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and antibiotic resistance, they export xenometabolites such as antibiotics from the cell across the 
envelope and into the surrounding media (Eswaran et al., 2004).   
 The gram-positive cell envelope differs in several ways, the major difference being the lack 
of an OM. As discussed earlier this outer membrane provides protection from toxic molecules and 
structural rigidity along with the peptidoglycan and periplasmic space. Gram-positive bacteria often 
live in harsh environments just like their negative counterparts yet are less protected and as a result, 
the peptidoglycan layer in gram positive bacteria is far thicker (30-100 nm versus a few nm in gram-
negative) In addition to the increased thickness, there are teichoic acids (TA) threading though gram 
positive peptidoglycan. These are linear anionic polymers consisting of repeating units of ribitol and 
glycerol linked by phosphodiesters, covalently bonded to the peptidoglycan giving the wall and net 
negative charge. TA can form larger structures such as wall teichoic acids (WTA), by coupling to 
peptidoglycan, and lipoteichoic acids (LTA), anchored to the cell membrane. WTAs are mostly 
composed of disaccharide linkages of polyribitol phosphate (polyRboP) or polyglycerol phosphate 
(polyGroP) with as many as 60 repeating units. These extend perpendicularly through the 
peptidoglycan mesh to form a “fluffy” layer beyond the cell envelope (Neuhaus and Baddiley, 2003). 
While LTAs are composed of polyGroP polymers, often with D-alanine or a sugar moiety, and their 
glycerolphosphate repeating units have the opposite chirality to those in WTAs. They also typically 
contain fewer repeating units and are shorter resulting in the molecules extending from the cell 
membrane into the peptidoglycan, rather than through and beyond. These TA are not essential for 
viability, but biosynthetic mutants show morphological and growth defects demonstrating a 
structural importance (Morath, von Aulock and Hartung, 2005). TAs also have roles in cation 
homeostasis (Marquis, Mayzel and Carstensen, 1976), influencing the rigidity and porosity of the 
cell wall and its susceptibility to antibiotics (Peschel et al., 2000). Several functionally important 
proteins are also bound to the peptidoglycan surface of the cell, some analogous to those found in 
the periplasm of gram-negative bacteria (Lambert, 2002; Dramsi et al., 2008). The structure of 
peptidoglycan in gram positive bacteria also differs from gram negative with peptides cross-linking 
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between the glycan strands a connected through pentaglycine branches extended (instead of 
pentapeptide side chains) from the third amino acid of the stem peptide (Vollmer, 2008). These 
branches are assembled by nonribosomal peptidyl transferases which are crucial for the survival of 
the bacteria. The branched stem peptide plays a variety of roles; they serve as attachment sites for 
covalently associated proteins and implicated in β-lactam resistance (Rohrer and Berger-Bächi, 
2003). Proteins present on the surface of the peptidoglycan layer play many pivotal roles; adhesins, 
fibronectin, fibrinogen and elastin are vital for colonisation of the host, modifications of the cell 
envelope for immune system evasion, internalisation, phage binding are carried out by sortases 
(Silhavy, Kahne and Walker, 2010).  
 Mycobacterial cell walls are more complex than those of typical gram-positive bacteria and 
this increased complexity contributes to their virulence. They possess a standard IM attached to a 
peptidoglycan layer, but this contains arabinogalactan which is covalently attached to long chain (up 
to C90) mycolic acids.  In addition, modified peptidoglycan mycobacteria have a symmetrical OM 
which is dependent on mycolic acids, but their organisation is unclear (Hoffmann et al., 2008). This 
cryptic barrier provides an extremely permeable barrier to noxious compounds resulting the in the 
high intrinsic resistance of mycobacteria to many drugs (Brennan & Nikaido, 1995). 
2.1.5 – Schistosomiasis   
 The levels of potency seen within MNQ and the breadth of its activity within the literature 
is such that it could be considered as a potential treatment for parasitic infections as well as 
bacterial. There is a clear need to fight antibiotic resistance, yet parasitic diseases are also 
devastating and are in desperate need to new treatments. In collaboration with Hoffmann Research 
Laboratory at Aberystwyth University a range of Schistosomal screens would be carried out using 
MNQ.  
 Schistosomiasis is the most devastating parasitic disease in humans behind malaria. It is an 
infection with blood fluke from the genus Schistosoma with 200 million people infected and a 
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further 800 million people at risk (Steinmann et al., 2006). There are 5 species of Schistosoma 
parasites in humans; S. mansoni, S. haematobium, S. japonicum, S. intercalatum and S. mekongi. S. 
mansoni which is the widest geographically distributed of all species is transmitted by Biomphalaria 
snails and causes intestinal and hepatic schistosomiasis in Africa, the Arab peninsula, and South 
America, Adult Schistosomes are white/greyish worms 7-20 mm in length with cylindrical bodies, 
two terminal suckers, a complex tegument, a blind digestive tract, and reproductive organs. Other 
trematodes have separate sexes which live independently and must meet for reproduction to take 
place. Both male and female S. mansoni worms exist together, the male body forming a groove in 
which the longer thinner female is held, the permanently embraced couples live within the 
mesenteric venous plexus feeding on blood and globulins. The females produce hundreds to 
thousands of eggs daily which migrate to the hosts intestine for excretion and can remaining viable 
for up to 7 days. Once out of the primary human host it begins the search for an intermediate host 
such as a freshwater snail, it does this by releasing a miracidium on contact with water guided by 
light and chemical stimuli. Once within the intermediate host asexual multiplication occurs 
producing multicellular sporocysts and later into cercarial larvae with embryonic suckers and 
characteristic bifurcated tail. After 4-6 weeks in the snail infectious cercariae are released to return 
to a human/mammalian host by penetrating the skin. This maturing larval form of the parasite is 
called the schistosomula and requires 5-7 weeks to become an egg producing adult worm, with the 
adult surviving 3-10 years on average (Colley et al., 2014). An adult worm pair can produce and 
disseminating thousands of eggs daily propagating the disease further. Evidence suggest that 
schistosome eggs are the cause of morbidity rather than the adult worm. Many eggs are not 
excreted and become permanently lodged in the intestines or liver. Trapped eggs cause an 
aggressive response from the host immune system along with many pathologies; anaemia, growth 
stunting, impaired cognition, decreased fitness, periportal fibrosis, portal hypertension, urogenital 
inflammation and scarring, hepatosplenism and other organ-specific effects (Burke et al., 2009). 
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 Praziquantel (PZQ) in the current drug of choice for schistosomiasis, effective against all 
Schistosoma species but the mechanism of action is not fully understood. PZQ is also ineffective 
against certain stage of the life cycle of S. mansoni. Multiple people within a population are likely to 
be infected at once, however, not all will be showing symptoms and therefore do not take PZQ. This 
leads to the propagation of the disease within communities and makes it difficult to treat 
comprehensively (Pica-Mattoccia and Cioli, 2004). This leads to massive repeated use on large 
number of individuals accelerating the development of resistance. PZQ is currently a broad-
spectrum anthelminthic yet certain parasites such as Fasciola hepatica and F. giganica are refractory 
and S. mansoni and S. japonicum are becoming resistance (Chai, 2013). It can be argued that new 
treatments for parasitic infections are needed as badly as bacterial infections. Due to this great need 
for anthelminthic drugs MNQ will also be assayed for its ability to inhibit the growth of S. mansoni 
at multiple stages of its life cycle to ensure it does not have the same issues as PZQ.  
2.2 Methods – MNQ Bioactivity   
2.2.1 - Antimicrobial susceptibility testing – All aerobic bacterial strains   
  This method is described in section 1.2.6 – Antimicrobial susceptibility testing – Minimum 
inhibitory concentration were carried out by the Specialist Antimicrobial Chemotherapy Unit at 
Public Health Wales which offer this antimicrobial evaluation service through the Life Sciences 
Research Network Wales who fund this PhD. A list of all bacteria used can be seen in Appendix 4 – 
All bacterial strains. 
2.2.2 - Antimicrobial susceptibility testing – Clostridium difficile and Bacteroides fragilis   
  The Clinical and Laboratory Standards Institute (CLSI) agar dilution procedure was 
undertaken to assess the susceptibility of a range of C. difficile and B. fragilis strains. Brucella agar 
supplemented with lysed sheep blood, haemin and vitamin K (Hecht et al., 2012). These assays were 
carried out by the Specialist Antimicrobial Chemotherapy Unit at Public Health Wales which offer 
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this antimicrobial evaluation service through the Life Sciences Research Network Wales who fund 
this PhD. 
2.2.3 - Antimicrobial synergistic assay  
  The antimicrobial synergistic checkerboard assay was performed as previously described by 
Orhan et al (2005) using MNQ in combination with a range of known antibiotic compounds and 2-
hydroxy-1,4-naphthoquinone against MRSA ST8:USA300. As a measure of the synergistic activity the 
fractional inhibitory concentration (FIC) index (ΣFIC) (Equation 4):  
𝛴𝐹𝐼𝐶 = 𝐹𝐼𝐶 𝐴 + 𝐹𝐼𝐶 𝐵  
𝑀𝐼𝐶 𝑀𝑁𝑄 𝑖𝑛 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 
𝐹𝐼𝐶 𝐴 =    
𝑀𝐼𝐶 𝑀𝑁𝑄 𝑎𝑙𝑜𝑛𝑒 
𝑀𝐼𝐶 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑖𝑛 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ 𝑀𝑁𝑄 
𝐹𝐼𝐶 𝐵 =   
𝑀𝐼𝐶 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑎𝑙𝑜𝑛𝑒 
Equation 4: Fractional inhibitory concentration (FIC) index (ΣFIC) 
 
 The combination of antimicrobial agents which result in an ΣFIC or ≤0.5 is considered 
synergistic, a value >0.5 and <2 is indifferent and ≥2 is antagonistic (Orhan et al., 2005) although the 
due to low reproducibility in other research the level for antagonism has also been set to ΣFIC>4 in 
other literature (Odds, 2003).  Both values will be considered. 
2.2.4 - Schistosoma mansoni schistosomula culture compound screening - Roboworm 
  This method was used in chapter 1 for F. japonica fractions to find some novel bioactivity 
within this plant extract, however none of the fractions met the “hit” criteria. The most bioactive 
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compound in the form of MNQ has been identified and will be assayed for its anthelmintic activity 
in the same way, see 1.2.8 – Schistosoma mansoni schistosomula culture compound screening - 
Roboworm Platform.  
2.2.5 - Schistosoma mansoni adult worm culture and compound screening  
  MF-1 mice (Harlan, UK) were infected by percutaneous exposure to 200 cercariae. Mature 
adult parasites were recovered from hepatic portal veins by perfusion seven weeks post infection 
as described by Smithers and Terry. Three adult male and three adult female worms (i.e. three worm 
pairs) were cultured per well in a 48-well tissue culture plate (Fisher Scientific, Loughborough, UK) 
containing 1 mL of Dulbecco’s modified eagle media (DMEM) (Gibco, Paisley, UK) media (containing 
10% v/v Hepes (Sigma-Aldrich, Gillingham, UK), 10% v/v Foetal Calf Serum (Gibco, Paisley, UK), 0.7% 
v/v 200 mL-Gluta-mine (Gibco, Paisley, UK), 1% v/v Kanamycin/Amphotericin B (Gibco, Paisley, UK)). 
6 worm pairs per treatment were incubated for 1 hour at 37°C in a humidified atmosphere 
containing 5% CO2 before being dosed with test compounds obtaining final concentrations of 50, 
25, 12.5 and 6.25 mM (0.3% DMSO final concentration). While all worms were scored manually after 
24, 48 and 72 hours using microscopic methods described in the literature (Ramirez et al., 2007), 
only motility metrics at 72 hours are reported. At 72 hours, eggs were also collected and counted 
from each well.   
2.2.6 - Erythrocyte Lysis  
 To this point the toxicity of MNQ has been tested against a variety of bacteria which has 
produced positive results. All these positive antibacterial results can be undone if MNQ is found to 
be as toxic against humans. An antibiotic must show selective toxicity against bacteria. Toxic 
phenolic compounds have been shown to have detrimental effects on human erythrocytes, 
including haemolysis (Bukowska & Kowalska, 2004). Haemolysis is a relatively simple assay to carry 




  Defibrinated sheep blood (Oxoid Ltd Hampshire UK) was used to determine the ability of 
the isolated compounds to cause erythrocyte lysis. 1 mL of defibrinated sheep blood (RBC) was 
added to six sterile microcentrifuge tubes and centrifuged for 5 minutes at 1,000 x g (Heraeus 
Biofuge Pico). The supernatant was discarded, and pellet washed three times in phosphate buffered 
saline (PBS) with centrifugation at 1,000 x g between each wash. The RBC were diluted in PBS 50% 
v/v. A 180 µL volume, of PBS was added to wells A1-A12 in sterile, transparent, flat bottomed 96 
well plate and 100 µL to all wells except row G to which 90 µL was added. A total of 20 µL of each 
sample being screened was added to row A in triplicate (four per plate) and serial diluted down the 
plate from A to F. 10 µL of 2% triton-X 100 (Sigma-Aldrich, Gillingham, UK) was added to wells G1-
12 as a RBC lysis control. To each well was added 100 µL of the 50% v/v RBC solution. Plates were 
then covered and left at 37°C for 1 hour. The plates were then centrifuged at 1,000 x g (Heraeus 
Multifuge 3 S-R). The 100 µL of supernatant from each well was transferred to a new transparent, 
flat bottomed 96 well plate. The optical density (OD) of the supernatant was measured at 450 nm 
using a Hidex Sense Plate Reader expressed as percentage haemolysis compared to 0.1% triton-X 
(Blazyk et at, 2001; Oyama et al., 2017).  
2.2.7 - HepG2 cell culture and MTT assay  
  Cells were grown to 80% confluency in culture media (basement membrane extract with 
phenol red for HepG2 cells, 10% v/v Foetal Bovine Serum, 1% v/v EMEM non-essential amino acid 
solution, 1% v/v 200 mM L-Glutamine, 1% v/v gentamycin/amphotericin B). Confluent cells were 
prepared for cytotoxicity assays in the same manner as stated by Nur-E-Alam et al., 2017. Briefly, 
2.5 × 104 were seeded in a black walled 96-well microtiter plate (Fisher Scientific, Loughborough, 
UK) and incubated for 24 h at 37 °C in a humid atmosphere containing 5% CO2. Test compounds in 
triplicate were then added at final concentrations of 100, 75, 50, 25, 10, 1, 0.1, 0.01 μM (1.25 final 
% DMSO) in parallel to negative (DMSO; 1.25%) and positive (1% v/v Triton X-100) (Dayeh et al., 
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2004) controls. Following a further incubation for 24 h, the MTT assay was performed as previously 
described Nur-E-Alam et al., 2017.  
2.2.8 - Galleria mellonella cytotoxicity screen and infection model  
  Galleria mellonella (Live Foods, UK) were purchased and injected within one week of arrival. 
Only individuals between 225 and 275 mg were selected with an assumed average of 250 mg. 
Samples were diluted to working concentrations with a maximum of 10% DMSO and bacteria (MRSA 
USA300) were grown at 37°C overnight in Mueller-Hinton (MH) broth. 500 µL of overnight culture 
was used to inoculate 4.5 mL of MH broth which was incubated at 37 °C, 180 rpm for 3 hours. Cells 
were harvested and via centrifugation and resuspended to obtain an OD600 of 0.1. Larvae were 
inoculated with 10 μL in the front right proleg using 10 μL Hamilton syringe. Bacterial injection was 
used as a negative control showing survival rates when infected with bacteria versus compounds 
and for an infection model as previously described by Desbois and Coote, 2011.   
2.3 – Results – MNQ Bioactivity  
2.3.1 – Antimicrobial susceptibility testing – Aerobic bacteria 
2.3.1.1 – Antimicrobial activity against Staphylococcal Species  
  After identifying that MNQ was the most active compound within the plants tested further 
antimicrobial assays were undertaken to assess the potential of MNQ as an antibacterial agent. As 
this project is aimed at discovering a compound which can counter the challenges of MRSA a broad 
range of Staphylococcal species and strains were tested. Initially, S. aureus ATCC 29213 was used to 
assess anti-staphylococcal activity of plant extracts, but in order to counter the challenges of MRSA 
multi resistant strains must be assayed (Table 13). MNQ was effective against all staphylococcal 




Table 13: Antimicrobial activity of 2-methoxy-1,4-naphthoquinone against a range of 
staphylococcal strains (n=3) 
Bacterial strain   MIC (mg/L)  
S. aureus- ATCC 29213 (MSSA)  19  
S. aureus-ATCC 33591 (MRSA)  11  
S. aureus-H-EMRSA-15 (MRSA)  13  
S. aureus-ST8-USA300 (MRSA)  13  
S. epidermis- NCTC 11047  4  
S. saprophyticus- Wild strain  31  
 MNQ was shown to be active against the highly virulent strains of MRSA however to screen 
a larger number of strains further testing was undertaken at the Specialist Antimicrobial 
Chemotherapy Unit (SACU), University Hospital of Wales (Table 14). The same standard S. aureus 
strain was used by SACU, but the methods used by this laboratory suggested that MNQ had better 
antimicrobial activity than we described previously. Three different stock strains of MRSA were 
tested with either resistance to flucloxacillin (conferred by mecA), erythromycin/clindamycin 
(conferred by macrolidelincosamide-streptogramin B (MLSB) resistance), and vancomycin 
heteroresistance Mu3 strain. In addition to these three strains, S. aureus (11051), a tetracycline 
resistant clinical isolate from a patient in Cardiff hospital, was also tested. The exact mechanism of 
tetracycline resistance in 11051 is unknow. 
Table 14: Antimicrobial activity of 2-Methoxy-1,4-naphthoquininone (MNQ) against a 
range of staphylococcal bacteria by the Specialist Antimicrobial Chemotherapy Unit at 
University Hospital of Wales (n=3) 
Strain No.   Organism   Resistance   
MIC (mg/L)  
Ampicillin  MNQ 
ATCC 29213  S. aureus  -  4  8  
NCTC 12493  S. aureus  Flucloxacillin  >128  8  
ATCC BAA-977  S. aureus  Erythromycin/Clindamycin  64  8  
ATCC 700698  S. aureus  Vancomycin  >128  8  
11051  S. aureus  Tetracycline  >128  8  
25760  S. epidermidis  -  64  4  
25495  S. epidermidis  -  8  4  
194073  S. saprophyticus  -  4  8  
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2.3.1.2 – Antimicrobial activity against other clinically relevant Gram-positive bacteria  
  MNQ was assessed for broad spectrum efficacy against a range of clinically relevant gram-
positive bacteria (Table 15). MNQ was able to consistently inhibit the growth of all gram-positive 
bacteria tested., However, E. faecalis which does not possess any antibiotic resistant mechanisms 
showed the highest level of resistance against MNQ with an MIC of 64 mg/L which is regarded as 
very poor activity. The best activity was seen against M. smegmatis, where MNQ far outperformed 
the antibiotic ampicillin with an MIC of 1 mg/L compared to 16 mg/L. A range of S. pneumoniae were 
tested with three antibiotic resistant strains, MNQ performed consistently against all with an MIC 
of 16 mg/L. 
Table 15: Antimicrobial activity of 2-methoxy-1,4-naphthoquininone (MNQ) against a 
range of gram-positive bacterial species (n=3) 
Strain No. Organism Resistance 
MIC (mg/L) 
Ampicillin MNQ 
ATCC 29212  Enterococcus faecalis  -  2  64  
NCTC 12201  E. faecalis  Vancomycin  4  4  
ATCC 51299  E. faecalis  Vancomycin  8  4  
NCTC 333  Mycobacterium 
smegmatis   
-  16  1  
20456  Streptococcus bovis  -  1  32  
21816  S. bovis  -  1  32  
21818  S. bovis  -  1  32  
22358  S. Group A  -  0.06  16  
22362  S. Group G  -  0.25  16  
ATCC 49619  S. pneumoniae  -  0.25  16  
18778  S. pneumoniae  Erythromycin / Tetracycline  0.25  16  
21394  S. pneumoniae  Penicillin  32  16  
21395  S. pneumoniae  Erythromycin / Clindamycin  0.5  16  
13121  S. pneumoniae  -  0.25  16  
13122  S. pneumoniae  -  0.25  16  
 
2.3.1.3 –Antimicrobial activity against clinically relevant Gram-Negative bacteria  
  MNQ has been shown to inhibit the growth of a wide range of gram-positive bacterial 
species, however, gram-negative cells possess a more complex barrier (outer membrane)that can 
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have a major effect on the potency of antimicrobial compounds (Table 16). Other than A. baumannii 
and B. cepacia with poor MIC of 32 and 64 mg/L respectively MNQ was unable to affect the growth 
of gram-negative bacteria (≥128 mg/L) 
Table 16: Antimicrobial activity of 2-methoxy-1,4-naphthoquininone (MNQ) against a range 
of gram-negative bacterial species (n=3) 
Strain No.   Organism  Resistance   
MIC (mg/L)  
Ampicillin  MNQ 
572  
Acinetobacter 
baumannii  -  128  32  
NCTC 10661  Burkholderia cepacia  -  >128  64  
ATCC 25922  Escherichia coli  -  8  128  
ATCC 35218  Escherichia coli  Ampicillin  >128  128  
NCTC 13353  Escherichia coli  3rd gen cephalosporins  >128  128  
353  Escherichia coli  Nitrofurantoin/ trimethoprim  >128  >128  
21856  Klebsiella pneumoniae  -  >128  >128  
Controls  Klebsiella pneumoniae  Carbapenems  >128  128  
ATCC 700603  Klebsiella pneumoniae  4th gen cephalosporins  >128  >128  
NCTC 13442  Klebsiella pneumoniae  Carbapenems  >128  128  
NCTC 10975  Proteus mirabilis  -  >128  128  
ATCC 27853  
Pseudomonas 
aeruginosa  -  >128  >128  
8204  Salmonella enteritidis  -  4  128  
 
2.3.2 - Testing antimicrobial activity against anaerobic bacteria  
  Two other bacteria Bacteroides fragilis and Clostridium difficile were also assayed for 
susceptibility to MNQ. These clinically relevant species are obligate anaerobes and required a 
different susceptibility testing methodology to aerobic species (Table 17). MNQ showed very 
consistent activity against all C. difficile strains, on par with the antibiotic in most cases (MIC 1-4 
mg/L). The ability of MNQ to inhibit the growth of B. fragilis ranged from 2 to >128 mg/L. However, 
the >128 mg/L result was due to metronidazole resistance within one strain. This could indicate that 
MNQ has a similar mechanism of action to metronidazole. 
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Table 17: Antimicrobial activity of 2-methoxy-1,4-naphthoquininone (MNQ) 
against a range of Bacteroides fragilis and Clostridium difficile (N=3) 
Strain No.   Organism  Ribotype  
MIC (mg/L)  
Meropenem  MNQ  
ATCC 25285  Bacteroides fragilis  -  0.06  2  
13350  Bacteroides fragilis  Metronidazole 
resistance  
0.03  >128  
1579  Bacteroides fragilis  -  0.125  16  
1580  Bacteroides fragilis  -  0.125  16  
1581  Bacteroides fragilis  -  0.5  16  
1582  Bacteroides fragilis  -  0.125  16  
1583  Bacteroides fragilis  -  0.25  8  
1584  Bacteroides fragilis  -  4  8  
1585  Bacteroides fragilis  -  1  8  
1591  Bacteroides fragilis  -  128  16  
1592  Bacteroides fragilis  -  1  16  
1593  Bacteroides fragilis  -  1  16  
1594  Bacteroides fragilis  -  4  16  
1595  Bacteroides fragilis  -  32  4  
1596  Bacteroides fragilis  -  0.5  8  
1597  Bacteroides fragilis  -  1  16  
1598  Bacteroides fragilis  -  2  16  
1599  Bacteroides fragilis  -  1  16  
1600  Bacteroides fragilis  -  0.125  32  
1601  Bacteroides fragilis  -  0.25  32  
1602  Bacteroides fragilis  -  0.25  16  
R43812  Clostridium difficile  Ribotype 001  1  2  
R43875  Clostridium difficile  Ribotype 001  1  4  
R43935  Clostridium difficile  Ribotype 001  1  1  
R43943  Clostridium difficile  Ribotype 001  1  1  
R43968  Clostridium difficile  Ribotype 001  1  1  
R43883  Clostridium difficile  Ribotype 014  1  2  
R44000  Clostridium difficile  Ribotype 014  1  1  
R44002  Clostridium difficile  Ribotype 014  0.5  1  
R44003  Clostridium difficile  Ribotype 014  0.5  1  
R44015  Clostridium difficile  Ribotype 014  1  2  
R43874  Clostridium difficile  Ribotype 027  2  1  
R43942  Clostridium difficile  Ribotype 078  1  1  
R43997  Clostridium difficile  Ribotype 078  1  1  
R43998  Clostridium difficile  Ribotype 078  1  1  
R44004  Clostridium difficile  Ribotype 078  1  1  
R44007  Clostridium difficile  Ribotype 078  1  2  
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2.3.3 - Synergistic assessment of MNQ interactions with other antimicrobials   
  Antimicrobial drugs as they are often used in combination to treat bacterial infections. 
Therefore, to understand how MNQ works in conjunction with other antibiotics is useful information 
for its development as a potential antimicrobial chemotherapy agent. MRSA USA300 was used as 
the test bacterial strain a model for this assay as MNQ has a good MIC against MRSA. MNQ was 
combined with 11 antibiotics to establish to test for augmented activity against MRSA (Table 18). 
MNQ was found to be synergistic with ciprofloxacin and rifampicin which shows these have 
complementary modes of action. MNQ shows poorer activity when combined with gentamycin, 
streptomycin and lawsone. However, some literature suggests this methodology has poor 
reproducibility and only ƩFIC values of ≥4 should be considered as true antagonism, therefore only 
lawsone showed antagonism with MNQ.  
Table 18: Synergistic activity of 2-methoxy-1,4-naphthoquinone (MNQ) with other antibiotics 
against Staphylococcus aureus MRSA USA 300 (n=3). * - high level of significance 
  MIC (mg/L) MIC MNQ (mg/L) FIC A FIC B  ƩFIC  Activity  
Ciprofloxacin  5  12.5  0.125  0.125  0.25  Synergistic  
Mupirocin  1.25  12.5  0.25  0.5  0.75  Indifferent  
Levofloxacin  1.25  12.5  1  1  2  Indifferent  
Chloramphenicol  3.125  12.5  0.25  0.5  0.75  Indifferent  
Rifampicin  0.07  12.5  0.125  0.0313  0.15  Synergistic  
Tetracycline  6.25  12.5  0.5  0.5  1  Indifferent  
Cefotaxime  25  12.5  1  1  2  Indifferent  
Nalidixic acid  12.5  12.5  0.25  0.5  0.75  Indifferent  
Gentamycin  3.125  12.5  2  1  3  Antagonistic 
Streptomycin  50  12.5  1  2  3  Antagonistic 
Ampicillin  100  12.5  1  1  2  Indifferent  
Lawsone 100  12.5  2  2  4  Antagonistic*  
 
2.3.4 – Schistosoma mansoni schistosomula compound screening - Roboworm Platform 
  MNQ was assessed for its ability to effect general health and viability of both S. mansoni 
adult worms and schistosomula. The effect of MNQ on the schistosomula stage of the life of S. 
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mansoni was assessed using the Roboworm platform. The Roboworm platform is an automated 
high-throughput, imaging analysis platform measures both phenotype and motility of treated 
larvae. To be considered a positive result on this screen the phenotype and motility score of the 
compound must fall below -0.15 and -0.35, respectively, in ≥70% of the larvae assayed. A positive 
control is present in the form of auranofin which is a potent inhibitor of S. mansoni at the 
schistosomula stage of the life cycle. A negative control is also run in the form of DMSO (0.625%) 
which is used to solubilise the samples. MNQ was tested at a concentration of 1.88 mg/L (10 µM) 
with an average phenotype score of -0.614 and average motility score of -0.945. These values are 
far below the activity threshold suggesting that MNQ was an effective anti-schistosomal agent 
(Figure 18).  
  
Figure 18: Anthelminthic activity of 2-methoxy-1, 4-naphthoquinone (MNQ), Auranofin (positive 
control) and dimethyl sulfoxide (DMSO) (negative control) against Schistosoma mansoni 
schistosomula based on mobility and phenotypic impact (n=2) 
2.3.5 – Schistosoma mansoni adult worm compound screening 
 Further tests were carried out using the adult S. mansoni worm, measuring the effect of 
MNQ on the motility in both male and female worms and the total viable egg production. MNQ had 







inhibited motility at 4.7 mg/L (25 µM) with an IC50 of 4 mg/L (21.71 µM) (Figure 19). MNQ showed 
a preference against female worms with an IC50 3.69 mg/L (19.61 µM) and IC50 4.73 mg/L (25.11 
µM) against male worms, with there being a significant difference between male and female motility 
at 50 µ (Figure 20). This contrasted with PZQ which is more active against male worms.   
 
  
Figure 19: Anthelminthic activity of 2-methoxy-1, 4-naphthoquinone tested at 4 concentrations 
compared to a positive control auranofin (AUR) and negative control dimethyl sulfoxide (DMSO) in 
adult S. mansoni measured using motility score (bar) and counting the total number of viable eggs 































Figure 20: Anthelminthic activity of 2-methoxy-1, 4-naphthoquinone naphthoquinone tested at 4 
concentrations compared to a positive control auranofin (AUR) and negative control dimethyl 
sulfoxide (DMSO) in adult male and female S. mansoni measured using motility score (n=6). 
 
2.3.6 – Erythrocyte lysis   
  To consider MNQ as a potential chemotherapeutic agent, its human toxicity must be 
established. This was undertaken using a range of assays including; erythrocyte lysis, HepG2 cell 
lines, Galleria mellonella model organism toxicity assay.  
 A simple assay was carried out to determine the concentration of MNQ required to lyse RBC 
(Table 19).  RBC lysis of > 10% was only seen at ≥ 50 mg/L which was considerably greater than most 




















Table 19: Percentage haemolysis of erythrocytes in the presence of 2-methoxy-1, 4-
naphthoquinone (n=3) 
Concentration (mg/L)  Percentage haemolysis   
100  33.519  
50  13.676  
25  3.741  
12.5  0.830  
6.25  2.702  
 
2.3.7 – HepG2 Cytotoxicity  
  HepG2 human liver hepatocellular carcinoma cells are routinely used as a reproducible cell 
line for the screening liver toxicity of compounds. MNQ was found to have an EC50 of 0.269 mg/L 
(1.431 µM). This was lower than the concentration needed to kill even the most susceptible bacteria 
(Figure 21). At log values below 0 (concentrations below 1 µM) the normalised absorbance values 
are around 100 indicating health cells, however at log 0 there is a large error bar this is because at 
this concentration the cells begin to die and there is a large amount of variability at this point. 
Beyond log 0 the normalised absorbance drops to around 0 because the cells have dies and all 
replicates agree with small error bars.  
 
Figure 21: Line graph of log concentration against normalised absorbance, showing cytotoxicity of 
2-methoxy-1, 4naphthoquinone against HepG2 cells 
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2.3.8 – Galleria mellonella toxicity  
 G. mellonella has been shown to be a simple and inexpensive in vivo infection model which can 
provide information based on the likely cytotoxicity and antibacterial efficacy (Desbois and Coote, 
2011). This wax moth model has been shown to respond similarly to mice in bacterial infection 
models (Jander, Rahme and Ausubel, 2000) and has the added advantage of being less expensive 
and time consuming. This assay tests both the cytotoxicity of MNQ against a live organism and the 
ability to fight an infection within a living system.  
  The tolerance of G. mellonella to MNQ alone needed to be established prior to carrying out 
an infection model experiment to ensure MNQ was not toxic to G. mellonella. A range of MNQ 
concentrations were injected into healthy wax moth larvae and observed over 72 hours monitoring 
the survival rate (Figure 22). MNQ has an MIC of 8 mg/L and 10x and 100x MIC was tested to see if 
any toxicity was observed in the wax moth larvae. Of the 20 replicate larvae in each group, only one 
individual larva died over all MNQ treatment after 72 hours. There was no statistically significant 
difference between the highest MNQ concentration and no treatment (Log-rank (Mantel-Cox) test 
p=0.3173). Showing that MNQ has limited toxicity on wax moth larvae even at 800 mg/L.  
 
Figure 22: Line graph showing he number of  G. mellonella surviving after 72 hours of treatment 
with 2-methoxy-1,4-naphthoquinone (MNQ) at a range of concentrations, vancomycin (VAN), 
dimethyl sulfoxide (DMSO) and untreated.  
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2.3.9 – Galleria mellonella infection model   
  Given the limited toxicity of MNQ it was possible to infect the larvae with MRSA and assess 
if MNQ could reduce infection development of MRSA. A lethal dose of MRSA was injected into the 
100 larvae and separated into 6 groups of 20 for different treatments. Three MNQ treatments were 
applied to the infected larvae at x1 (8 mg/L), x10 (80 mg/L) and x100 (800 mg/L) MIC. Vancomycin 
is a proven treatment for MRSA and one group was injected with 40 mg/L of vancomycin as an 
antibiotic comparison. 20 other larvae were treated using the 10% DMSO solution used to solubilise 
the samples as a negative control. A further 20 larvae obtained from the same batch as the others 
were not infected and not treated as a positive control. This test will show the antimicrobial activity 
of MNQ within a living organism compared to a well-established antibiotic in the form of 
vancomycin. 
 MNQ seemed to show some protective activity at the highest concentration of 800 mg/L 
with 7 larvae surviving after 48 hours and 3 at 72 hours (Figure 23 and Table 20). This was more than 
DMSO alone, however the difference was not found to be significant (Table 21). Even with the 
vancomycin not all the larvae survived but after 72 hours 14 were surviving, significantly more than 





Figure 23: Line graph showing the number of surviving G. mellonella infected with MRSA treated 
with 2-methoxy-1,4-naphthoquinone (MNQ), vancomycin (VAN), dimethyl sulfoxide (DMSO) and 
untreated over 72 hours. 
Table 20: The number of larvae surviving after each time point after injection of a 
lethal dose of MRSA and treatment with antibiotics (n=20) 
Treatment  Alive 0h  Alive 24h  Alive 48h  Alive 72h  
Control  20  20  20  20  
DMSO  20  6  3  2  
MNQ (8 mg/L)  20  5  3  1  
MNQ (80 mg/L)  20  4  4  2  
MNQ (800 mg/L)  20  7  7  3  








Table 21: Statistical Comparison of Survival curves for 2-methoxy1, 4-
naphthoquinone (800 mg/L) vs Untreated infection model  
Log-rank (Mantel-Cox) Test 
Chi square  0.7554  
df  1  
P value  0.3848  
P value summary  ns  
Are the survival curves sig different?  No  
Gehan-Breslow-Wilcoxon Test 
Chi square  0.3444  
df  1  
P value  0.5573  
P value summary  Ns  
Are the survival curves sig different?  No  
Median survival 
Treatment A  24.00  
Treatment B  24.00  
Ratio  1.000  
95% CI of ratio  0.4846 to 1.515  
Hazard Ratio 
Ratio  0.6265  
95% CI of ratio  0.2182 to 1.798  
 
2.4 – Discussion – MNQ Bioactivity  
  MNQ, which showed promising activity against S. aureus was isolated from I. glandulifera 
and subjected to a broad range of biological assays.   
2.4.1 – Staphylococcal species   
2.4.1.1 – Staphylococcus aureus and MRSA 
  Of the staphylococcal species tested (Table 13 and Table 14) MNQ was most effective 
against S. epidermis NCTC 11047 with an MIC of 4 mg/L. S. epidermis is of clinical interest as it is an 
opportunistic pathogen able to cause a range of diseases (Otto, 2009). The MRSA strains of most 
clinical relevance are ATCC 33591, EMRSA and USA300. These have different resistance profiles to 
antibiotics where ATCC 33591 possesses a type III staphylococcal cassette chromosome (SCC) mec 
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which conveys methicillin resistance. This mobile genetic element is widely disseminated through 
staphylococci and contains four commonly shared features (IWG-SCC, 2009):   
 They carry a mec gene complex:  
 mecA (can be A, B, C, D or E depending on type, A in this case because it is type III) – this is 
a gene encoding penicillin binding protein (PBP) 2A which has lower affinity for β-lactams than the 
usual PBP1,2,3 and 4. This provides an alternative PBP that is not affected by the presence of β-
lactam antibiotics meaning transpeptidase remain active allowing cell wall synthesis to continue 
uninhibited.  
 Two regulatory genes. mecI gene produces a repressor protein (MecI), when bound to mecA 
transcription is repressed. mecR1 a signal transducer protein, when bound to β-lactam antibiotics, 
MecR1 releases a polypeptide with proteolytic activity to degrade MecI increasing transcription of 
mecA, and insertion sequence IS431.  
 They carry a ccr gene complex:  
 Composed of two site specific recombinase genes responsible for the motility of SCCmec, 
this makes the mec gene complex a mobile genetic element allowing this virulent complex to be 
transferred to other bacteria. ccrA3 and ccrB3 (number dependent on SCC type – in this case III) 
catalysing the precise excision, site- and orientation- specific integration of SSCmec elements.  
 They have characteristic directly repeated nucleotide sequences and inverted 
complementary sequences at both ends.   
 They can be accepted into integration site sequence for SSCmec (ISS), situated at the 3’ end 
of orfX.   
 The presence of SCCmec type III in ATCC 33951 provides resistance only to β-lactams. As 
MNQ does not possess a 4 membered lactam ring it is unlikely to have the same mechanism of 
action as β-lactams. The protection which SCCmec type III offers is ineffective as MNQ does not bind 
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to PBP therefore it is unsurprising that MNQ can effectively inhibit the growth of this strain of MRSA 
at the same concentration as MSSA.  
 The other two strains, EMRSA and USA300, are clinical isolates from hospitals and are 
considered the two most successful MRSA strain to disseminate globally and these both have 
SCCmec type IV (Sabirova et al., 2014). The first epidemic of MRSA, designated EMRSA-1 was 
recognised in 1981 and followed by many other outbreaks over the years with EMRSA-15 emerging 
in 1991, rapidly displacing most other EMRSA strains (O’neill et al., 2001). EMRSA-15 accounts for 
>95% of MRSA bacteraemia in UK hospitals (Moore and Lindsay, 2002). This strain has become the 
dominant strain in the UK and has also been identified in Australia, New Zealand, Germany, Sweden, 
and Finland. This strain is characterised by weak lysis with phage 75, production of staphylococcal 
enterotoxin-C (SE-C) and nonproduction of urease. The production of enterotoxins contributes to 
the pathogenicity of staphylococcal infections such as food poisoning and toxic shock syndrome 
(TSS). SE-C is one of the least common and is usually isolated form animals (Marr et al., 1993).  SEs 
are classified as superantigens, which can be defined as a toxin of foreign substance which can 
stimulate large populations of T-cells leading to the production of a cytokines which are usually 
produced by pathogenic bacteria as a mechanism of defence against immune response. SEs bind 
Major Histocompatibility Complex (MHC) class two molecules on antigen presenting cells (APC), 
crosslinking APCs with T-cells eliciting the release of cytokines (Pinchuk, Beswick and Reyes, 2010).   
 USA300 was first reported in 2003, one of eight USA MRSA strains (USA100-800) (McDougal 
et al., 2003) but actually came to the attention of the CDC in 2000 during multiple community MRSA 
infection outbreaks in a Mississippi prison (CDC, 2001) and football players in Colorado, Indiana, 
Pennsylvania and Los Angeles (CDC, 2003). It was remarkable at the time that all these individuals 
were infected with not only the same strain, but these young, healthy individuals are not 
traditionally considered to be at risk of MRSA infection. Over time USA300 became the most isolated 
MRSA strain (other than USA100) and particularly in a community setting amongst otherwise 
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healthy individuals (Tenover and Goering, 2009). USA300 diverged form ST8-MSSA acquiring 
SCCmec type IV leading to strains such as EMRSA 2, 5 and USA500, and diverged further with the 
acquisition of genes encoding Panton-Valentine leukocidin (PVL), arginine catabolic mobile element 
(ACME), and msr(A) erythromycin resistance gene, therefore becoming far more virulent. PVL is a 
β-pore forming cytotoxin (leukotoxin, leukocidin, or more broadly invasin) which causes increased 
virulence of S. aureus infections and the specific production of PVL is preferentially linked to 
furuncles, cutaneous abscesses, and severe necrotic skin infections (Cribier et al., 1992; Couppie et 
al., 1994). Leukotoxins in general (others being γ-haemolysin, leukotoxins ED, and AB/HG) have two 
protein subunits classified ‘S’ and ‘F’, referring to slow and fast based on elution speed. The current 
understanding is that the S subunit serves as a homing component which binds specifically to host 
receptor, and then recruits the F subunit. Once localised on the cell surface, subunits assemble into 
an octameric prepore with four of each subunit alternating. The stem domains of the assembled 
subunits unfold and insert into the cell membrane to form β-barrel pores (Kaneko and Kamio, 2004). 
As the name suggests leucocidins form these pores and therefore lyse cells of the leukocytic lineage, 
yet different leukotoxins target different leukocytes and can be more effective against different host 
species. PVL mostly effects human neutrophils (no effect on RBCs unlike haemolysin) yet mouse and 
monkey cells are resistant to lysis by PVL (Löffler et al., 2010). Although this PVL is strongly 
associated with community acquired MRSA strains (~85%) the contribution of this leukotoxin to the 
pathogenesis of MRSA remains inconclusive (Yoong and Torres, 2013). ACME includes two main 
gene clusters; arc (arcA, B, C, D) and oligopeptide permease operon opp (opp-3A, B, C, D, E). The 4 
arc genes encode a complete arginine deiminase pathway which converts L-arginine to CO2, 
adenosine triphosphate (ATP) and ammonia; the production of which is thought to enhance ability 
to grow and survive within a host. The opp genes encode ABC transporter systems. The current 
understanding is that ACME does not directly enhance virulence but improves general fitness and 
ability to colonise the host (Diep et al., 2008; Shore et al., 2011).   
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 The three known strains tested in SACU had resistance to Flucloxacillin (conferred by mecA), 
Erythromycin/Clindamycin (conferred by macrolide-lincosamide-streptogramin B (MLSB) 
resistance), and vancomycin heteroresistance Mu3 strain. MLSB resistance is due to the ermC genes 
which encode a 23S rRNA methyltransferase, facilitating methylation of 23S rRNA at adenine. 
Rendering the ribosomes incapable of binding the MLS antibiotics becoming resistant (Jenssen et 
al., 1987). The first MRSA strain with heterogeneous intermediate resistance to vancomycin (hVISA) 
was reported in 1997 in Japan (Hiramatsu et al., 1997). The heterogeneous resistance to vancomycin 
indicates there are subpopulations of vancomycin-intermediate daughter cells that are susceptible 
to vancomycin. hVISA strains of S. aureus quickly gain resistance to vancomycin when exposed to 
the antibiotic with MIC ranging from 8- 24 mg/L (Saito et al., 2014). This strain is very closely related 
to a fully VISA strain Mu50 (Liu and Chambers, 2003). These resistance mechanisms had major 
effects on the efficacy of ampicillin yet no observable impact on MNQ’s ability to inhibit the growth 
of these bacteria. The MICs for MNQ against all S. aureus strains were 8 mg/L. The breadth of this 
activity across so many resistant strains exceeds all current antibiotics. This suggests that MNQ does 
not work in the same way as many of the antibiotics currently used today, an antibiotic with a new 
mode of action is what is needed to counter the challenge of MRSA.  
2.4.1.2 – Staphylococcus epidermis and S. saprophyticus 
 S. epidermis is a common skin coloniser and usually has a benign relationship with its host. 
However, it can become an opportunistic pathogen causing a range of infections. S. epidermis 
belongs to a group of bacteria called coagulase-negative staphylococci (CoNS), which distinguishes 
it from S. aureus which is coagulase-positive. CoNS bacteria commonly cause infections linked to 
medical devices such as catheters, prosthetics, pacemakers, shunts as well as grafts (Rogers, Fey & 
Rupp, 2009).  S. saprophyticus is the second most frequent cause of urinary tract infections, it can 
also cause kidney infections, septicaemia and endocarditis (Hedman & Ringertz, 1991). Growth of 
the three other clinical isolates of S. epidermis and S. saprophyticus with unknown resistance 
mechanisms were also inhibited by MNQ with MICs of 4-8 mg/L, despite one of the S. epidermis 
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strains showing some resistance to ampicillin. MNQ has outperformed the antibiotic against other 
Staphylococcal species. Antibiotics are usually prescribed in advance of identifying the bacteria 
causing the infection, therefore it is important that MNQ can inhibit the growth of many bacterial 
species especially closely related species such as these.  
2.4.2 - Testing antimicrobial activity against clinically relevant Gram-positive bacteria  
2.4.2.1 – Enterococcus faecalis 
  MNQ was assayed for antimicrobial activity against a range of gram-positive bacteria (Table 
15). Enterococcus faecalis is an opportunistic pathogenic commensal bacterium which inhabits the 
GI tract of humans and other mammals yet can cause diseases such as endocarditis, septicaemia, 
UTIs, meningitis etc (Murray, 1990). Three strains have been used; a standard susceptibility testing 
strain, and two strains which are resistant to vancomycin through two different mechanisms, vanA 
and vanB. Glycopeptide antibiotics (vancomycin, teicoplanin etc.) are often used to treat 
Enterococcus and Staphylococcus infections. These antibiotics bind the peptidyl-D-alanine-D-
alanine termini of peptidoglycan precursors blocking their incorporation into the cell wall (Reynolds, 
1989).   
  VanA resistance is characterised by high level resistance to vancomycin (MIC ≥64 mg/L) and 
teicoplanin (MIC ≥16 mg/L). This is mediated by Tn1546 type transposon containing vanA genes 
encoding a D-alanine-D-alanine ligase with results in a peptidoglycan precursor with reduced affinity 
for glycopeptide antibiotics (Bugg et al., 1991; Lester et al., 2006). VanB resistance results in lower 
level vancomycin resistance (MIC 8-64 mg/L), remaining susceptible to teicoplanin, with the vanB 
locus encoded by a conjugative transposon of the TN1549-/Tn5382-subtype (Bjørkeng et al., 2011). 
These plasmid mediated resistances are worrying as it can be spread quickly not only in Enterococci, 
but other species such as Staphylococcus aureus leading to VRSA. MNQ was relatively ineffective 
against the ATCC 29212 strain of E. faecalis with an MIC of 64 mg/L. This strain is considered as a 
control strain in food testing, susceptibility testing, quality control and does not possess any specific 
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resistance mechanisms. However, MNQ was found to be a particularly potent against vanA and vanB 
encoding strains of E. faecalis with an MIC of 4 mg/L. An MIC of 64 mg/L would be considered a very 
poor result for an antibiotic, however its very impressive MIC of 4 mg/L against vancomycin resistant 
strains is interesting. As vancomycin resistance is very common within E. faecalis finding a 
compound which can treat these resistant strains is extremely valuable (Murray, 2000). This is 
especially valuable as it has been found that vancomycin resistance within E. faecalis can transferred 
to S. aureus (Noble, Virani & Cree, 1992).  
 It is odd that the presence of one transposable element in the form of vanA and vanB would 
reduce the ability of E. faecalis to resist the antimicrobial activity of MNQ which seeming has an 
entirely different mechanism of action. However, the acquisition of resistance to an antibiotic does 
come at a fitness cost, these can be measured indirectly by the relative growth rate, survival and 
competition performance in vitro. In most investigations, a chromosomal mutation which yielded 
resistance did incur a fitness cost (Andersson and Levin, 1999). In the specific case of the vanA 
operon within S. aureus, the expression of resistance is costly to the host especially when challenged 
with vancomycin (to ensure the operon is induced) with minimal fitness cost without vancomycin 
(Foucault, Courvalin and Grillot-Courvalin, 2009). The results in Table 15  is a clear representation of 
this fitness cost, represented by the different MICs of MNQ versus vancomycin resistant and 
susceptible strains of E. faecalis. 
 Further to this point, PBP 2 is not capable of cross-linking peptidoglycan which has been 
modified due to van genes (Severin et al., 2004). This means that the van operon which is 
responsible for alteration of peptidoglycan resulting in vancomycin resistance in not compatible 
with mecA which is produces a modified PBP which renders β-lactam antibiotics ineffective. As these 
two mechanisms are conflicting and the fitness cost associated will be very high and there have 
been instances where there has been a deletion of mecA in the presence of vancomycin to 
compensate for this issue (Adhikari et al., 2004; Noto, Fox and Archer, 2008). The incompatibility of 
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different resistance mechanisms is very promising for the use of combination drug therapies, having 
two antibiotics with different modes of action can theoretically slow the onset of resistance 
(Mouton, 1999). Using combination therapy to treat tuberculosis (Chaisson, 2003) and P. aeruginosa 
(Lister & Wolter, 2005) has been found to be successful for slowing the occurrence of resistance. 
However, there are conflicting accounts in the literature which state that combination therapy has 
little to no impact on the development speed of resistance (Sanders Jr & Sanders, 1988l; Carmeli et 
al., 1999). 
2.4.2.2 – Mycobacterium smegmatis  
  Tuberculosis (TB) remains a major global threat caused by the bacterium Mycobacterium 
tuberculosis. It typically affects the lungs but can also affect other such as the skin, lymph nodes, 
urinary tract, skeletal system, central nervous system and many other sites (Dye et al., 1999). 
Overall, only 5-15% of the 2-3 billion people infected with M. tuberculosis will develop TB disease 
during their lifetime, yet one developed without treatment the death rate is high. There were 
estimated to be 1.8 million TB deaths and 10.4 million new cases in 2015 (WHO, 2016). M. 
smegmatis was used as a fast-growing that is widely used as a surrogate for TB. This is the case, 
although M. smegmatis tends to be more robust and can miss active compounds which can 
effectively inhibit the growth of M. tuberculosis (Altaf et al., 2010). MNQ can effectively inhibit the 
growth of M. smegmatis with an MIC of 1 mg/L. This level of activity exceeds its MICs against 
Staphylococcal species suggesting MNQ could prove to be an antitubercular lead compound.  
2.4.2.3 – Streptococcus pneumoniae  
  The Streptococcus genus contains over 50 species that are associated with a wide range of 
infections. Streptococcus pneumoniae typically colonises the respiratory tract and can be carried 
asymptomatically, however in individuals with weaker immune systems cause pneumonia, 
meningitis, sepsis and other diseases (Krzyściak et al., 2013).  A wide range of clinical isolates with 
erythromycin and tetracycline, penicillin, and erythromycin and clindamycin with a non-resistant 
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reference strains were tested. All strains of S. pneumoniae tested were equally susceptible to MNQ 
with an MIC of 16 mg/L. MNQ had the same MIC against S. pyogenes, also known as group A 
Streptococcus (GAS) and S. dysgalactiae also known as group G Streptococcus (GGS). GAS causes 
mild human infections such as pharyngitis, impetigo, and more serious infections such as necrotizing 
fasciitis and streptococcal toxic shock syndrome. GGS typically causes chronic skin conditions among 
other infections. Penicillins are the recommended treatment for GAS and GGS infections and these 
bacteria have remained susceptible with no development of penicillin resistance anywhere in the 
world (Walker et al., 2014).  S. bovis is commonly found as part of the bowel flora of humans and 
animals, responsible for such diseases as bacteraemia, endocarditis, neonatal infection, and 
meningitis. S. bovis was less susceptible to MNQ treatment than other Streptococcus species with 
an MIC of 32 mg/L. MNQ having again such consistent activity against another range clinically 
relevant species is a promising sign that MNQ has real potential as a broad-spectrum antibiotic. 
2.4.3 – Testing Antimicrobial activity against clinically relevant Gram-Negative bacteria  
2.4.3.1 – Acinetobacter baumannii  
  Acinetobacter baumannii has become increasingly significant as a pathogen over the past 
20 years due to its ability to upregulate or acquire resistance determinants and survive for prolonged 
periods in hospital environments threatening the efficacy of antibiotics. There is a wide array of 
antimicrobial resistance mechanisms described in A. baumannii and a global emergence of β-lactam 
resistance A. baumannii (Peleg, Seifert and Paterson, 2008). Therefore, the traditional treatment of 
β-lactam antibiotics are ineffective and other drugs must be used such as colistin, however, this can 
cause a range of side effects and is only used as a last resort (Abbo et al., 2005).  MNQ was shown 
to inhibit A. baumannii growth with an MIC of 32 mg/L. The strain used is a clinical isolate which is 
resistant to ampicillin which has an unknown resistance mechanism against β-lactam. As MNQ has 
been proven to be unaffected by the presence of β-lactam resistance mechanisms within all strains 
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of bacteria tested so far, this indicates that MNQ could hold a potential solution to the global 
emergence of β-lactam resistance.  
2.4.3.2 – Burkholderia cepacia 
  Burkholderia cepacia, an opportunistic human pathogen typically colonizing the airways 
leading to the exacerbations of pulmonary infections. B. cepacia plays a role in cystic fibrosis 
patients’ respiratory failure and can generally cause lung infections. Treatment for this pathogen is 
difficult as it is resistant to most antimicrobial agents (Coenye et al., 2001). Unfortunately, the MIC 
of MNQ for B. cepacia was MIC of 64 mg/L, which is not considered to be particularly good. However, 
this is better than ampicillin which has an MIC >128 mg/L. 
2.4.3.3 – Escherichia coli 
  E. coli which is usually a commensal bacterium of humans and animals and is the most 
common cause of gram negative nosocomial and community-acquired infections causing diseases 
such as gastroenteritis, UTI, meningitis, peritonitis, and septicaemia (Kaper, Nataro & Mobley, 
2004). In addition to causing a range of diseases, drug resistant E. coli has been reported worldwide 
and the occurrence of resistance in increasing (Von Baum and Marre, 2005).  Four strains of E. coli 
were therefore tested for their susceptibility to MNQ, three of which had resistance mechanisms. 
MNQ had an MIC of 128 mg/L against E. coli with no resistance mechanism, ampicillin and 
cephalosporin resistant E. coli. MNQ has an MIC >128 mg/L against nitrofurantoin/trimethoprim 
resistant E. coli. These are very poor activity profiles against E. coli, likely due to the structure of the 
bacterial membranes of gram negative.  
2.4.3.4 – Klebsiella pneumoniae 
 Klebsiella pneumoniae naturally occurs in the soil and the normal flora of the mouth, skin 
and intestines. Again, this bacterium is an opportunistic pathogen causing pneumonia and other 
infections usually in immunocompromised patients (Podschun and Ullmann, 1998). Four strains 
were tested for susceptibility to MNQ. Two strains resistant to carbapenems were susceptible to 
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MNQ at the highest concentration tested, 128 mg/L. MNQ was not able to inhibit the growth of the 
other two strains, one being non-resistance and the other resistant to cephalosporins. These results 
reflect that seen in E. coli further adding to the hypothesis that MNQ is ineffective against gram-
negative bacteria. Also, that the presence of carbapenem resistance is reducing the fitness of K. 
pneumoniae resulting in higher susceptibility to MNQ. 
2.4.3.5 – Proteus mirabilis 
  Proteus mirabilis is widely distributed in the environment, including polluted water, soil, and 
manure where it plays a role in decomposition. These bacteria are the causative agent of a variety 
of opportunistic nosocomial infections in the respiratory tract, eye, ear, nose, skin, burns, throat, 
wounds, also causing gastroenteritis and UTI (Jacobsen et al., 2008). Growth of P. mirabilis was not 
affected by MNQ in any major way, with a high MIC of 128 mg/L, although MNQ is more effective 
than ampicillin. This is promising as MNQ is consistently showing activity even if it is at a high 
concentration suggesting the killing mechanism of MNQ is difficult to resist. 
2.4.3.6 – Pseudomonas aeruginosa 
  Pseudomonas aeruginosa is a versatile bacterium able to grow in soil, marches, habitats as 
well as plant and animal tissue. P. aeruginosa is proficient in the formation of biofilms which is a key 
factor in the cause of disease and resistance to antibiotics (Hardalo and Edberg, 1997; Costerton, 
Stewart and Greenberg, 1999).  P. aeruginosa is one of the top three causes of opportunistic human 
infections which is resistant to antibiotics and disinfectants (Bodey et al., 1983) and MNQ was 
unable to inhibit the growth of P. aeruginosa at the highest concentration tested, 128 mg/L.  
2.4.3.7 – Salmonella enteritidis 
  Salmonella enteritidis is a major pathogen associated with the consumption of eggs and the 
major cause of nontyphoidal salmonellosis (Rabsch, Tschäpe and Bäumler, 2001). MNQ again only 
inhibited the growth of this gram-negative pathogen at 128 mg/L.   
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  The average MIC of MNQ against gram-positive bacteria is 15 mg/L and the MIC against 
gram-negative bacteria is 155 mg/L (assuming MNQ would be able to inhibit MNQ-resistant strains 
at 256 mg/L). This ten-fold reduction in efficacy suggests the presence of an outer membrane has 
had a significant effect on the ability of MNQ to inhibit the growth of bacteria. This extra barrier of 
protection plays a key role in preventing the mechanism of action of MNQ, either by limiting the 
internalisation of MNQ or preventing access to the membrane if this is the site at which MNQ effect 
the bacteria.  
2.4.4 - Testing antimicrobial activity against anaerobic bacteria  
2.4.4.1 – Bacteroides fragilis 
  Bacteroides species comprise nearly half of the faecal flora community with some critical to 
the host nutrition.  B. fragilis account for <1-2% of cultured faecal flora but play a role in the host 
mucosal and systematic immunity. B. fragilis is also an opportunistic pathogen and a leading 
anaerobic isolate in clinical specimens, bloodstream infections, and abdominal abscesses (Sears, 
2009). B. fragilis is inherently resistant to a range of antibiotics due to resistance being conveyed via 
a plasmid which can be quickly passed throughout bacterial population. This plasmid can resist the 
antibiotics clindamycin, erythromycin, streptogramins and tetracycline (Privitera, Dublanchet & 
Sebald, 1979). Therefore Metronidazole (Met) or a complex mix of antibiotics are used to treat 
infections (Wexler, 2007). MNQ exhibited an MIC against B. fragilis between 2-32 mg/L. However, 
there was one Met resistant strain of B. fragilis which was entirely resistant to MNQ with an MIC 
>128 mg/L. 
 Met is administered as a prodrug which is inactive and requires activation by the partial 
reduction of its nitro group, the active form is a toxic nitroso- radical which binds DNA causing 
double strand DNA breakage. Met resistance in B. fragilis can be caused by the nim genes which is 
carried on a novel conjugative transposon (Husain et al., 2013). This gene is thought to code a 
nitroimidazole reductase which reduces the nitro group of 4- or 5-nitroimidazole to an amino group 
111 
 
to make the inactive compound, 5-aminoinidazole preventing the toxic effects of nitroso radicals 
key for the antibacterial activity of Met (Müller, 1983; Carlier et al., 1997). The antibacterial activity 
of MNQ is dependent on the presence of the methoxy group as seen in the different MIC of MNQ 
and HMQ. If nitroimidazole reductase can reduce MNQ it will lose the methoxy group therefore lose 
its potency. However, Met resistance can persist within nim-negative strains due to increased efflux 
gene transcription levels, alterations in DNA repair systems, metabolic changes and lack of 
activation of the Met molecule. Similarly, naphthoquinones can produce adducts and reactive 
oxygen species (ROS) which can cause alkylation or oxidation of DNA and proteins (Bolton et al., 
2000). Thus, resistance to Met could explain its poor efficacy of MNQ in this strain. However, as this 
is a clinical isolate it is unknown whether Met resistance is mediated through nim genes, yet we can 
tentatively deduce that the presence of nim genes within bacteria could confer resistance against 
MNQ. This is worrying as nim homologues are found in both gram-negative and positive genera or 
both aerobic and anaerobic bacteria and archaea, suggesting that the nim gene family is ancient and 
widespread (Husain et al., 2013). Although MNQ does not contain a nitro group which requires 
reduction for activation therefore it would not make sense for resistance to be conveyed through 
the presence of a nitroimidazole reductase, unless there are other factors at play as this mechanism 
of resistance is not fully understood.  
2.4.4.2 – Clostridium difficile 
  C. difficile is a spore forming bacterium, which causes symptoms such as diarrhoea, fever, 
nausea and abdominal pain. It is involved in just under half of all infections occurring within hospital 
(CDC, 2012). C. difficile infection (CDI) is a major cause of morbidity and mortality from healthcare-
associated infections in economically developed countries. MNQ was tested against 16 clinical 
isolates of C. difficile including 4 different ribotypes (RT). Certain RT have been linked to severe 
outbreaks. RT 78 has been described as “hypervirulent” which tends to affect a younger population 
and is more frequently community associated when compared to type 027 which is also responsible 
for severe CDI outbreaks and is said to be have increased virulence (Goorhuis, Bakker, et al., 2008). 
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RT 014 is a highly successful among the most common RTs causing CDI, predominantly in paediatric 
populations (Knight et al., 2017). RT 78 is most commonly isolated from swine and calves in the US, 
and associated with human community onset infection (Goorhuis, Debast, et al., 2008). RT 001 has 
been associated with increasing prevalence of CDI in human along with a range of antibiotic 
resistance in Germany (Borgmann et al., 2008).  
 Although RT is linked to virulence and severity of the infection this does not necessarily 
increase resistance to drugs although certain RT do tent to pick up resistance mechanisms more 
readily and are thought to cause epidemics. However, even the link between RT and severity of 
infection has been disputed; RT was found to be not significant as a predictor of severity of CDI. 
Other factors such as white blood cell count and albumin count are more clinically relevant factors 
which effect the severity of CDI (Walk et al., 2012). The MIC of MNQ against C. difficile ranged 
between 1-4 mg/L and did not correlate with RT, this is lowest MIC of MNQ seen against any 
bacteria. The level of activity seen in MNQ was as good as meropenem in most cases which is 
impressive activity increasing the range of bacteria MNQ is known to be effective against. This 
activity against all RT of C. difficile is an indication MNQ possesses the level of potency required to 
be a future treatment for C. difficile infections.  
2.4.5 - Synergistic assessment of MNQ interactions with other antimicrobials   
  With 7 of the 11 antibiotics the presence of MNQ had no effect (“indifferent”). With 
gentamycin and streptomycin their ability to inhibit the growth of MRSA was antagonised by the 
presence of MNQ. Both gentamycin and streptomycin are aminoglycosides which irreversibly bind 
the 30S subunit proteins and 16S rRNA preventing protein synthesis, which presumably for MNQ 
was affecting via an unknown mechanism.  MNQ showed synergistic activity when combined with 
ciprofloxacin and rifampicin. Ciprofloxacin is a fluoroquinolone which inhibits enzymes 
topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA 
replication, transcription, repair, strand supercoiling and recombination (Drlica and Zhao, 1997). 
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Rifampicin specifically inhibits bacterial DNA-dependent RNA polymerase leading to suppression of 
RNA synthesis and cell death (Campbell et al., 2001). Although these two antibiotics have different 
mechanisms of actions, they both have a quinones at their core. This could be a contributing factor 
to their synergistic relationship with MNQ which is also has a quinone core. Ciprofloxacin has been 
shown to stimulate the production of reactive oxygen species (ROS) which have a toxic effect, it has 
been suggested this generation of ROS contributes to the antimicrobial activity of ciprofloxacin 
(Goswami, Mangoli & Jawali, 2006). If a quinolone core is responsible for the generation then MNQ 
is likely also able to form ROS. The presence of two agents generating these toxic molecules will 
have a synergistic affect, therefore explaining these results. However, levofloxacin like ciprofloxacin 
is a second-generation fluoroquinolone and would therefore expect synergism, but it has an ƩFIC 
value of 2 which is perfect indifference.   
  In addition to the 11 antibiotics tested for synergistic activity with MNQ, 2-hydroxy-
1,4naphthoquinone (HNQ) also known as lawsone was also assayed for its activity against MRSA and 
in combination with MNQ. HNQ showed 100-fold higher MIC compared to MNQ, therefore, the 
methoxy group of MNQ is required for the highly potent antimicrobial activity against MRSA. HNQ 
was also found to be the most antagonistic of all the tested compounds. HNQ has been shown to 
inhibit the formation of ROS (Saeed et al., 2013), which was found to be the cause of the synergism 
seen in other antibiotics combined with MNQ. This would explain the significant antagonism seen 
when MNQ and HNQ are combined. 
2.4.6 – Screening for anthelminthic activity  
  The current treatment for S. mansoni infection is praziquantel (PZQ) which is ineffective 
against schistosomula. Its mechanism of action is thought to target the schistosome calcium ion 
channels, causing rapid calcium ion uptake along with vacuolation a blebbing near the surface. In 
addition, PZQ is also thought to increase the exposure of antigens on the worm’s surface increasing 
susceptibility to host antibodies (Doenhoff, Cioli and Utzinger, 2008). PZQ has an IC50 5.44 mg/L 
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(17.4 µM) against the adult worm (Kasinathan, et al., 2010), although the efficacy is dependent on 
the age of the infection, the sex of the worm and whether they are paired or unpaired. Immature 
28-day schistosomes are 30 times more resistant to PZQ than the 7-week-old adults. Being female 
and unpaired also decreased the efficacy of PZQ. The inconsistency against different forms of the 
same organism is a problem for the clinical use of PZQ (Pica-Mattoccia and Cioli, 2004), therefore it 
is pivotal to develop new anti-schistosomiasis drugs which are effective against all stages of the 
parasite. MNQ was tested in four ways to show its full activity against the S. mansoni parasite; 
inhibitory activity against the larval schistosomula (Figure 18), adult male, adult female and egg 
production (Figure 19 and Figure 20). Each of these factors are important to have a comprehensively 
active anthelminthic agent, the current drug praziquantel is lacking efficacy against the 
schistosomula and female unpaired worms. MNQ showed exceptional activity against the 
schistosomula with and IC50 of <1.88 mg/L (10 µM) but was less effective against the adult worms 
showing a slight preference for the female worm with an IC50 3.69 mg/L (19.61 µM) and IC50 4.73 
mg/L (25.11 µM) against male worms. The efficacy of MNQ matches that of PZQ against adult worm 
and exceeds against the larval stage of the parasite, making MNQ a potential treatment for S. 
mansoni in the future. 
2.4.7 – Cytotoxicity  
  For a potential drug to be a viable treatment option it must be safe to administer to humans, 
ideally with minimal side effects. Conflicting cytotoxicity results were obtained, firstly MNQ was 
found cause minimal lysis of red blood cells (RBC) indicating that MNQ is relatively non-toxic. 
Considering that naphthalene which is at the core of MNQ is known to damage human red blood 
cells which can lead to haemolytic anaemia, it is a sign that MNQ is less toxic as it was unable to lyse 
RBC easily. Exposure to large amounts of naphthalene can cause a range of negative effects such as 
confusion, nausea, vomiting, diarrhoea, blood in the urine, and jaundice (Sanctucci and Shah, 2000). 
The presence of naphthalene in the body is understood to be metabolised by cytochrome P450 and 
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its structure is altered in three ways resulting in either mercapturic acids, 1,2naphthoquinone, 1,4-
naphthoquinone (Waidyanatha et al., 2002) or 1-naphthol. The cytotoxicity of these metabolites 
against mononuclear leucocytes were assayed; where 1,2-NQ, 1,4-NQ and 1naphthol were all found 
to be significant more cytotoxic than naphthalene (Table 22). Previous studies have shown that 
naphthoquinones are toxic to rat hepatocytes which is related to the disturbance of intracellular 
glutathione (Ollinger and Brunmark, 1991). Although the RBC lysis results were initially promising 
due to the high concentration required to lyse RBC, the fact that naphthalene metabolites are all 
highly toxic means that MNQ also toxic.   
Table 22: The effect of naphthalene and its metabolites on mononuclear leucocytes 
(Wilson et al., 1996).  
Metabolite  Percentage cell death of mononuclear leucocytes  ±  
naphthalene   19  10.00  
1-naphthol   49.8  13.90  
1,2- 
naphthoquinone   
51.4  6.60  
1,4- 
naphthoquinone   
49.1  3.40  
 
 It was found that MNQ was an extremely potent inhibitor of HepG2 cells indicating 
cytotoxicity. Other studies have found that MNQ is a potent inhibitor of cancerous cell lines and has 
been investigated as a potential anticancer agent (Mori et al., 2011; Wang and Lin, 2012; Liew et al., 
2014). HepG2 is a cancerous cell line with increased rate of metabolism, and other changes which 
are typical of cancerous cells this could have made HepG2 more susceptible to MNQ. Further in vivo 
studies were carried out using wax moth larvae which are thought to be a good indicator of 
compound toxicity in humans (Desbois and Coote, 2011). MNQ was found to be non-toxic >800 mg/L 
and an infection model experiment was carried out to determine the ability of MNQ to prevent an 
MRSA infection in the larvae. MNQ was unable to significantly prevent death by bacterial infection 
over 72 hours. These results indicated that in vivo MNQ would likely be very toxic and unable to 
successfully treat a bacterial infection.  
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2.5 – Conclusion   
  In conclusion MNQ was found to be a consistently potent antimicrobial all gram-positive 
bacterial tested but was ineffective against most of the gram-negatives bacteria. Synergistic assays 
also suggested the formation of ROS could play a crucial role in the way MNQ kills bacteria, due to 
its synergism with ciprofloxacin and antagonism with HNQ. MNQ was shown to be a potent inhibitor 
of the parasite S. mansoni with similar level of activity to praziquantel and exceeded the current 
drug of choice because MNQ was also a potent inhibitor of the larval schistosomula which 
praziquantel is ineffective against. There were mixed results with the cytotoxicity data and poor 
performance in the infection model. 
 MNQ has been shown to have antibacterial and anthelmintic activity equal to current drugs 
and seems to have a novel mode of action. Unfortunately, there is also a high probability that MNQ 
is toxic and cannot be used as a drug, although the cytotoxicity assays carried out are not exhaustive. 
The most valuable discovery in the fight against resistance would be the novel mechanism of action 
of MNQ. Therefore, further work will be carried out to understand why MNQ is such a potent 
inhibitor of antibiotics resistant S. aureus. 
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Chapter 3 Mode of action studies: Proteomics and 
Metabolomics   
     
3.1 Introduction – Mode of action  
3.1.1 - Chapter aims  
 As a potent antimicrobial compound has been identified from I. glandulifera, the 
mechanism by which it acts upon bacteria needs to be understood. Novel metabolomics and 
proteomics approaches will be used to further understand the mode of action (MoA) of MNQ 
against MRSA. In this chapter, comparisons will be drawn between MNQ and known antibiotics to 
cluster its activity with already understood MoA. In-depth metabolic pathway analysis will be carried 
out to uncover fine detail of the effect MNQ has on MRSA.   
3.1.2 – ‘Omics’ and the central dogma of molecular biology  
  Over the past two decades since the beginning of the twenty-first century there has been 
rapid growth and advances made in the areas of analytical and informatic technologies driving the 
progress in ‘omic’ technologies, which involves the study of huge data sets. The term ‘omics’ is a 
suffix used to suggest the complete study of a particular area; for example, the genome refers to 
the complete genetic material of an organism whereas genomics is the study of genomes. There is 
a broad range of ‘omics’; genomics, transcriptomics, proteomics, metabolomics and lipidomics. 
These are, respectively, the complete study of genes, transcription, proteins, metabolites, and lipids 
within a living system. When used collectively, these omics platforms are termed as systems biology 
(Hasin, Seldin & Lusis, 2017). At the time of writing, there have been 3941 eukaryotic species 
genomes sequenced and made publicly available via the National Centre for Biotechnology 
Information (NCBI) genome database. This revolutionised the field of biology, where instead of 
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studying one gene, protein or metabolite at a time it is now possible to study the effects of any 
physiological or pathological changes on the expression of all genes, proteins or metabolites.   
  To give metabolomics context it is worth considering its benefits and drawbacks in 
comparison to the other ‘omics’ and where it sits in the central dogma (CD) of molecular biology. 
This dogma states that the flow of genetic information begins with DNA passing through RNA into 
proteins and was first proposed by Francis Crick in 1958 (Crick, 1958). Simply put the theory suggests 
that each level had its own alphabet and that information was transferred residue-by-residue. For 
DNA, this alphabet consists of four base pairs adenine with thymine and cytosine with guanine, RNA 
shares three of the same letters as DNA but substituting thymine for uracil and proteins with their 
20 naturally occurring amino acids. The CD states that there are three types of transfer; general, 
special and unknown transfers. General being the well-established transfer between DNA->DNA, 
DNA->RNA and RNA->Protein. Special transfers only occur in certain circumstances which are the 
transfer between RNA->DNA, RNA->RNA and DNA->Protein (Figure 24) (Crick, 1970). Crick realised 
that reverse transcription was essentially the interconversion of nucleic acids which relies on the 
universal rules of base complementarity therefore the conversion is relatively easy. The conversion 
of nucleic acids to amino acids is more complex than breaking down amino acids into nucleic acids 
but this conversion has been biologically beneficial and therefore has been selected for by 
evolutionary processes. The reverse, which in principle is theoretically possible, is hampered by the 
design of the translation system. Reverse translation would require an elaborate sequence of 
reactions that are not known to exist. Two fundamental steps being; i) recognition of nucleotide 
triplets (tRNA anticodons) by amino acid residues within a polypeptide chain, ii) joining of these 
triplets into an RNA molecule. Furthermore, given the degeneracy of genetic code, reverse 
translation would result in major loss of information (Koonin, 2012).   
  The CD where DNA drives all living systems appears comprehensive but fails to consider the 
impact of metabolism. This is surprising, as so many proteins are enzymes whose specific role is to 
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transform chemicals into metabolites some of which are the building blocks of living systems. The 
catalytic abilities of these metabolically important proteins are encoded in their amino acid 
sequence, therefore derived from the RNA sequence and ultimately from the DNA which rules living 
systems according to the CD. However, the residue-by-residue transfer of information does not 
apply in the metabolic context because chemical structures of metabolites or their fluxes cannot be 
predicted from the genetic code (de Lorenzo, 2014). Therefore, DNA is not driving the living system 
but reacting to its current metabolic environment. 
 
Figure 24: Growing expansion of the central dogma. i) All possible interaction between DNA RNA 
and protein ii) exclusions made by the development of the central dogma iii) CD considering the 
role of metabolism (adapted from de Lorenzo, 2014)  
  Metabolism is discounted from the CD because it does not have a direct impact on the 
sequences of DNA, RNA and proteins. But metabolism does have a massive effect on the regulation 
of genes therefore effecting RNA and proteins. There are many regulatory mechanisms which are 
genetically controlled in response to metabolites, usually mediated through regulatory proteins 
(Struhl, 1999), but interacting directly with mRNA (Nahvi et al., 2002). Therefore, it could be said 
that metabolism both drives and responds to genetics in terms of regulation if not in terms of 
sequence (Figure 24).    
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3.1.3 – Genomics   
  Genomics is the study of the entire DNA sequence of organisms and can focus on its 
function, structure or evolution. DNA sequencing technologies took off in the 1970s with two major 
publications describing different approaches to improve the speed at which sequencing can be 
carried out (Sanger and Coulson, 1975; Maxam and Gilbert, 1977). In particular, the development 
of the Sanger chain-termination method yielded the most used DNA sequencing technique to date 
(Sanger, Nicklen and Coulson, 1977). This method was used to sequence the human genome, which 
deepened our understanding of human evolution, causation of disease and the interplay between 
environment and heredity (Venter et al., 2001). Further, comparative genomics is a versatile tool 
able to highlight large scale similarities and differences between entire organisms (Rubin et al., 
2000) and the small differ between genomes of the same species (Fournier et al., 2006; Feng et al., 
2007; Rasko et al., 2008). Genomics can also be used for understanding the molecular mechanism 
of bacterial pathogenicity (Schoolnik, 2002; Zhang et al., 2012).   
 The emergence of “next-generation” (NGS) technologies has dramatically increased 
sequence throughput albeit at the expense of read length. NGS has also allowed targeted 
resequencing, discovery of transcription factor binding sites, and noncoding RNA expression 
profiling (Morozova and Marra, 2008). It is routinely being used on human genomes to understand 
genetic mutations associated with disabilities and diseases (Link et al., 2011; Sanders et al., 2012; 
Kan et al., 2013) and can be utilised in a similar way, by inducing genetic mutations which result in  




Figure 25:  Genomic approach to MoA studies – Genes of interest can be identified by inducing 
resistance to the drug and comparing to the DNA sequence of a resistant and non-resistant 
bacteria. The genes which have changed convey a protective characteristic against the drug and 
can be used to infer the MoA. 
3.1.4 – Proteomics  
  Proteomics is the large-scale analysis of proteins within organisms to gain important insights 
into many biological processes. Investigation of living systems at the protein level opened new 
horizons in many areas of life science. DNA microarrays and transcriptomics can provide data about 
gene function however proteins are the real mediators of physiological function. Changes in 
biological events such as disease, drug effects, or physiological activity will be reflected in the 
abundancy or processing of proteins. 
122 
 
 Proteomics usually involves several processes; the extraction of the proteins followed by 
purification, fractionation, digestion into peptides which are separated and analysed by liquid 
chromatography mass spectrometry (LC-MS) to identify the proteins. Polyacrylamide gel 
electrophoresis (PAGE) is a technique commonly used to separate protein extracts. This provides a 
visual representation of all proteins present within samples and their relative quantities allowing 
the selection interesting proteins for further analysis (Ünlü, Morgan and Minden, 1997). Gel based 
proteomics can be challenging; 2D-PAGE typically visualising 30-50% of proteins tending to neglect 
membrane-associated proteins, or proteins whose isoelectric point, hydrophobicity, and/or 
molecular weight fall beyond the parameters of the separation method employed (Baggerman et 
al., 2005). LC-MS fundamentally changed the way in which proteins are identified and measured, 
due to its ability to measure thousands of proteins in parallel allowing the investigation of 
increasingly complex biological matrices. MS is now the de facto standard for quantitative 
measurements in proteomics (Bantscheff et al., 2012). With the advances in LC-MS and the inherent 
issues with gel-based proteomics gel-free methodologies were improved by using multidimensional 
capillary LC-MS/MS.   
 Even though MS has become the de facto method for proteomic analysis there are a range 
of different technologies available; metabolic labelling, chemical labelling or label free. The most 
popular metabolic labelling method is stable isotopic labelling with amino acids in cell culture 
(SILAC). Unlabelled and labelled protein populations can be mixed directly after harvesting and mass 
spectrometric identification is straight forward due to the isotopically amino acids in the treatments. 
This method requires limited sample manipulation, and with virtually 100% incorporation of the 
label and quantification is relatively easy (Ong et al., 2002).  An alternative approach involves 
chemical labelling of peptides and proteins. For example, isobaric tags for absolute and relative 
quantification (iTRAQ) is a popular method which targets primary amines for the attachment of tags, 
which have identical masses but can be distinguished and accurately quantified according to MS/MS 
spectra (Wiese et al., 2007). Other techniques do not require labels (Bantscheff et al., 2012). 
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Shotgun proteome digestion approaches yield a complex mixture of peptide which have been 
digested using specific enzymes, so fragmentation can be predicted, and original protein structure 
elucidated from MS/MS data. This technique requires separation and nanoscale ion paring reversed 
phase LC-ESI-MS/MS is commonly used but there have recently been new technologies in this area, 
most notably the use of microfluidic chip-based technology has been emerging. These chips can aid 
in sample clean up, digestion separation, and throughput due to their ability to handle small 
quantities (Lee, Soper and Murray, 2009).    
3.1.5 – Metabolomics  
  Metabolites are small molecules that are chemically transformed during metabolism which 
can be used to interpret the cellular state of an organism. Unlike genes and proteins discussed 
previously, whose functions are subject to epigenetic regulation and post translational modification, 
metabolites serve as direct signatures of biochemical activity. The study of the metabolome, defined 
as the collection of all small metabolites produced by cells, has become widely adopted in clinical 
diagnosis of cancer (Spratlin, Serkova and Eckhardt, 2009), diabetes (Griffin and Nicholls, 2006), 
cardiovascular diseases (Lewis, Asnani and Gerszten, 2008), asthma (Carraro et al., 2007), 
neurological diseases (Dunckley, Coon and Stephan, 2005), and many other diseases (Madsen, 
Lundstedt and Trygg, 2010). Metabolomics is not only an invaluable diagnostic tool it can also 
provide insight into the mechanism by which drugs act on a biological system, for example the effect 
of an antibiotic on bacteria. Metabolomics is an imperfect method due to the fact that databases 
used to identify metabolites are incomplete (Kind, Scholz and Fiehn, 2009), however metabolomics 
has made remarkable progress and has become the apogee of the omics trilogy (Patti, Yanes and 
Siuzdak, 2012).  
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Figure 26: Proteomic and metabolomic approaches: the proteomic and metabolomic profile of a 
bacterium require treatment with the compound of interest along with known antibiotics for 
comparison. This is followed by the extraction of proteins and metabolites and then analysis using 
MS. The proteomic and metabolomic profiles are compared with known MoA, potentially leading 
to target identification. Further information can be obtained by looking at specific regulation of 
certain proteins/metabolites to ascertain MoA.  
3.1.6 – ‘Omics’ for Antimicrobial Mechanism of Action Studies  
  Each of the three ‘omics’ discussed can be used to investigate the Mechanism of action 
(MoA) of antimicrobial compounds. Unlike genomics, proteomics and metabolomics can provide 
real-time information of the MoA of MNQ. By their nature proteins and metabolites are more 
reactive to changes in environment, such as the presence of a drug, therefore resistance will not 
need to be induced. The mere presence of the drug will have significant effects on protein 
expression and metabolite regulation. (Santos et al., 2016) 
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3.1.7 – Antibiotic modes of action  
3.1.7.1 – DNA targeting antibiotics  
 4-quinolones such as nalidixic acid, ciprofloxacin and levofloxacin (Figure 27) are agents 
which target two essential bacterial enzymes, topoisomerase II (DNA gyrase) and IV. Nalidixic acid 
is a first generation naphthyridone quinolone predominantly used for urinary tract infections (Drlica 
& Zhao, 1997). Whereas ciprofloxacin and levofloxacin are second generation fluoroquinolone 
which have enhanced activity, broader spectrum, and able to treat a wide range of bacterial 
infections (Wolfson & Hooper, 1989). 
  
Figure 27: Chemical structure of nalidixic acid (A), ciprofloxacin (B), and levofloxacin (C). 
  These enzymes alter the topological state of DNA which determines the function of DNA in 
cells. Generally, type I topoisomerases cleave one strand of double helical DNA to relax supercoiled 
DNA, whereas type II use energy from the hydrolysis of ATP to cleave both strands and pass an intact 
DNA strand through this “gate” to introduce supercoils. DNA gyrase and topoisomerase IV are both 
type II involved in the supercoiling of DNA. In prokaryotes supercoiling of DNA results in torsion 
strain, and the DNA can be considered in an energetically active state which is crucial for DNA 
replication, transcription and genetic recombination (Gellert, 1981). DNA gyrase binds directly to 
DNA as a tetramer with two gyrA and two gyrB subunits. The B proteins have ATPase activity to 
obtain energy for the A subunits to cleave both DNA strand and increasing or decreasing the linking 
number by two, either increasing torsion leading to positive super coiling or decreasing torsion 
leading to negative supercoiling (Reece and Maxwell, 1991). Gyrase can also relax negative 
A  B  C  
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supercoiling in the absence of ATP therefore the balance between the levels of ATP versus ADP is a 
key aspect of the supercoiling relaxation relationship, making  gyrase and supercoiling sensitive to 
intracellular energetics, and many aspects of the extracellular environment (Drlica and Zhao, 1997). 
DNA gyrase interacts with DNA in multiple ways and there are many ways quinolones can interrupt 
this activity, summarised in Table 23.  
Table 23: Summary of reactions DNA gyrase is capable which subunits are involved, 
whether ATP is required, and which reactions quinolones can interrupt (Reece and 
Maxwell, 1991)  






Supercoiling  A, B  Yes  Yes  
Relaxation  
Negative supercoils  A, B  No  Yes  
Positive supercoils  A, B  Yes  Yes  
Catenation  A, B  Yes  Yes  
Decatenation  A, B  Yes  Yes  
Unknotting  A, B  Yes  Yes  
DNA cleavage  A, B  No  No  
ATPase  B  Yes  No  
 
   For example, quinolones can prevent 6 of the 8 functions of DNA gyrase by forming a 
quinolone-enzyme-DNA complex at the point where the double strand break occurs. There are two 
quinolone binding pockets between GyrA and GyrB (Heddle and Maxwell, 2002), when filled with a 
quinolone the complex is trapped in this open gate position, if gyrase is trapped in this form ahead 
of the fork blocking any further movement along the replication fork along the DNA inhibiting DNA 
synthesis (Kreuzer and Cozzarelli, 1979). The formation and dissociation of this complex leads to cell 




3.1.7.2 – RNA/protein targeting antibiotics  
  Aminoglycosides, such as gentamycin and streptomycin (Figure 28) target the bacterial 
ribosome disrupting protein synthesis. Streptomycin was the first aminoglycoside discovered, 
isolated from Streptomyces griseus. Gentamycin is a 4, 6-disubstituted 2-deoxystreptamine class of 
aminoglycoside, there’s also a 4,5-distrubyted 2-deoxystreptamines class although streptomycin is 
not classified in the same way (Ristuccia and Cunha, 1982). Aminoglycosides have a polycationic 
structure which have an affinity for negatively charged residues such as those in the outer 
membrane of gram-negative bacteria. This affinity allows the drug to electrostatically bind to the 
membrane of bacteria and access the periplasmic space through porin channels (Hancock et al., 
1991). The antibiotic is then transported across the cytoplasmic membrane utilising the electron 
transport chain in an energy and oxygen dependant process. This is the rate limiting step and means 
that these antibiotics are less effecting in anaerobic conditions. Once in the cytosol the antibiotics 
bind 30S subunit, not preventing the formation of the of the initiation complex but perturbing the 
elongation of the nascent chain by impairing the proofreading processes controlling translation 
accuracy. These proteins may be inserted into the membrane leading to altered permeability and 




Figure 28: Aminoglycoside antibiotics streptomycin (A) and gentamycin (B). Chloramphenicol (C), 
Mupirocin (D) and Rifampicin (E)  
  Chloramphenicol (Figure 28c) was first isolated from Streptomyces venezuelae in 1947 and 
was later synthesised in 1949, making it the first antibiotics to be synthesised rather than extracted 
from microorganism. Unlike most antibiotics’ chloramphenicol does not belong to a family of other 
similar drugs and is classed as “other”. Chloramphenicol, like aminoglycosides, inhibit protein 
synthesis but in a different way, it is bacteriostatic, binding the L16 subunit of the 50S ribosomal 
protein. This protein binds directly to the 23S ribosomal RNA located at the peptidyl transferase 
centre which plays an essential role in subunit assembly (Murray et al., 1995). It directly interferes 
with substrate binding, whereas macrolides, a family of antibiotics which work in a similar way 




 Mupirocin does not belong to a class of antibiotics with a unique mechanism of action. It 
was discovered in 1971 when it was isolated from Pseudomonas florescens (Fuller et al., 1971). 
Mupirocin binds to isoleucine-tRNA ligase, which catalyses the attachment of isoleucine to tRNA, 
although this is a unique MoA this in effect inhibits protein synthesis (Hurdle, O’neill and Chopra, 
2004). Although this mainly effects protein synthesis this also negatively impacts DNA activity and 
cell wall formation (Hughes and Mellows, 1978).   
 Rifampicin is a polyketide with a naphthalene at the core (Figure 28e) belonging to a class 
of chemicals called ansamycins, it is a semisynthetic antibiotic derived from rifamycin antibiotics 
which are naturally produced by Nocardia mediterranei. Rifampicin was discovered in 1965 (Sensi, 
1983). Rifampicin’s bactericidal activity is due to its strong binding affinity to and the inhibition of 
bacterial DNA-dependant RNA polymerase, which catalyses the transcription of DNA into RNA using 
the four ribonucleoside triphosphate as substrates (Hartmann, 1967).  
3.1.7.3 – Cell wall targeting antibiotics  
  Vancomycin (Figure 29) is a branched tricyclic glycosylated nonribosomal peptide first 
isolated from Amycolatopsis orientalis in 1953 (Griffith, 1981). Due to the large hydrophilic structure 
of vancomycin it prevents proper cell wall synthesis in gram positive bacteria it forms hydrogens 
bond interactions with D-Ala-D-Ala moiety of N-acetylmuramic acid (NAM) and N-acetylglucosamine 
(NAG) peptide subunits of peptidoglycan. Without these bonds the peptidoglycan layer cannot 
remain intact and fall away leaving the bacteria without a protective barrier eventually causing the 




Figure 29: Chemical structure of Vancomycin  
 
3.2 – Methods – Mode of action  
3.2.1 – Bacterial strains and growth conditions   
 All experiments carried out in a biosafety containment level 2 using ST8:USA300 MRSA 
grown in Brain heart infusion (BHI) media incubated over night at 37 °C while shaking at 250 rpm 
(Vitko and Richardson, 2013). Optical density (OD) at 600 nm was used to determine bacteria 
concentrations as described in 1.2.5 – Antimicrobial susceptibility testing – 24-hour growth curve. 
This strain was chosen due to the clinical relevance of MRSA and MNQ has been shown to be 
particularly effective against S. aureus. The required inhibitory concentrations of all antibiotics used 
in this section was determined using this strain at these growth conditions.  
3.2.2 – Standardisation of antibiotic treatment   
  All antimicrobial agents; chloramphenicol (CHL), ciprofloxacin (CIP), gentamycin (GEN), 
levofloxacin (LEV), mupirocin (MUP), nalidixic acid (NAL), rifampicin (RIF), streptomycin (STR), 
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vancomycin (VAN), and 2-methoxy-1,4-naphthoquinone (MNQ) were obtained from Sigma-Aldrich, 
Gillingham, UK. For both proteomics and metabolomics antibiotic treatments need to be 
standardised so each antibiotic is having an equal effect on the bacteria over 6 hours. In order to 
obtain enough material to accurately detect and quantify proteins and metabolites a higher 
concentration of bacteria was required. MIC susceptibility testing is standardised to 5 × 105 cfu/mL 
but for metabolomics it was found that 1x108 cfu/mL was required. Therefore, susceptibility tests 
were carried out against the higher concentration and over 6 hours. To investigate the MoA of these 
antibiotics the bacteria cannot be killed outright, this would not reveal how the drugs work 
therefore the amount of antibiotic required to reduce growth by half over 6 hours was used in the 
proteomic and metabolomic experiments (Table 24). This would allow the bacteria to react to the 
challenge of the antibiotics without dying. This also standardises the effect of each antibiotic so they 
should all have the same proteomic and metabolic impact on the bacteria. 
Table 24: Concentration of antibiotic required to inhibit growth of USA300 MRSA by 50% over 6 
hours at a bacterial concentration of 1x108 cfu/mL and their mode of action.  
Antibiotic  Concentration 
(mg/L)  
Mode of action   
CHL  250  RNA - Binds 50S subunit (L16) or rRNA inhibiting protein synthesis.  
CIP  15.625  DNA – 4-quinolone - Inhibition of the enzyme topoisomerase II 
(DNA gyrase) & IV preventing DNA replication and transcription 
(Drlica and Zhao, 1997).  
GEN  250  RNA – aminoglycoside - Binds 30S subunit (S12) of rRNA misreading 
mRNA and incorrect amino acid insertion.  
LEV  10.625  DNA - 4-quinolone - Inhibition of the enzyme topoisomerase II (DNA 
gyrase) & IV preventing DNA replication and transcription (Drlica 
and Zhao, 1997).  
MNQ  250  Unknown  
MUP  5.313  RNA - Binds isoleucyl-tRNA synthetase inhibiting bacterial protein 
and RNA synthesis.   
NAL  250  DNA - 4-quinolone - Inhibition of the enzyme topoisomerase II (DNA 
gyrase) & IV preventing DNA replication and transcription (Drlica 
and Zhao, 1997).  
RIF  0.122  RNA - Inhibit DNA-dependent RNA polymerase supressing RNA 
synthesis.  
STR  250  RNA - Binds 30S subunit (S12) of rRNA misreading mRNA and 
incorrect amino acid insertion.  
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VAN  10.625  Cell Wall - Prevents incorporation of N-acetylmuramic acid (NAM) 
and N-acetylglucosamine (NAG) peptide subunits from being 
incorporated into the peptidoglycan matrix. In addition, altering 
bacterial-cell membrane permeability and RNA synthesis.  
 
3.2.3 – Proteomics – Bacteria treatment and standardisation  
  A 1 L culture of MRSA was grown overnight (section 3.2.1) and bacterial concentration 
standardised to 1x108 cfu/mL using a spectrophotometer OD600 (Hidex Sense Plate Reader 
LabLogic, Sheffield UK) by adding sterile growth media. This culture was aliquoted into twelve 50 
mL sterile centrifuge tubes. Three antibiotic treatments were chosen; MNQ, Vancomycin (current 
treatment for MRSA), Levofloxacin (Table 24), and a no treatment control with three biological 
replicates. Following addition of antibiotics, the 50 mL cultures were mixed and incubated at 37°C 
shaking at 250 rpm. Two time points were sampled for proteomics, 0 hours (which is roughly 1 min 
after adding the antibiotic) and 6 hours after the addition. Upon sampling 14 mL was transferred 
into a new centrifuge tube, frozen in liquid nitrogen and stored in a -80°C freezer overnight. Samples 
were thawed and centrifuged (4°C, 4500 rpm) with the resulting pellet washed in 10 mL of cold 
saline solution (0.85% NaCl) and centrifuged again (4°C, 4500 rpm). All samples were adjusted to an 
OD600 of 1 in 200 µL of water (18.2 Ω) prior to protein extraction.   
3.2.4 – Proteomics – Protein extraction and quantification   
  To the 200 µL samples was added 200 µL of 20% trichloroacetic acid in acetone and 
subjected to 50 cycles of sonication (1 minute), rapid freezing liquid nitrogen, thawing and vortex (1 
minute). A 1 hour incubation at -20°C to precipitate proteins followed. Sample were centrifuged 
(4°C, 13,000 rpm), washed twice in acetone followed by further centrifugation, supernatant was 
removed, and samples left to dry at -20°C for 15-20 minutes. Protein concentration of all samples 
were calculated using the Braford method for protein quantification (Kruger, 2002). The lowest 
concentration of protein yielded in any sample was 514.844 µg, therefore all samples were made to 
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a concentration of 500 µg in 100 µL of 6 M urea buffer (2.0 g of urea, 1.25mLof 0.4 M Tris solution 
and 5mLwith Milli-Q H20).   
3.2.5 – Proteomics – Protein Trypsin Digestion   
  To the 100 µL extracted and standardised protein solution in urea buffer (Supelco), was 
added 5 µL of the reducing agent dithiothreitol (DTT) (Sigma-Aldrich) (0.031 g of DTT in 750 µL of 
MilliQ-H2O, and 250 µL 0.4 M Tris solution(Millipore)), followed by vortex and 60 minutes 
incubation at room temperature. 20 µL of alkylating agent (0.037 g iodoacetamide (Sigma-Aldrich) 
in 750 µL of MilliQ-H2O, and 250 µL 0.4 M Tris solution (Millipore)) was added followed by vortex 
and 60 minutes incubation at room temperature. A further 20 µL of the reducing agent was again 
added then vortexed and incubated for 60 minutes at room temperature. Samples were diluted 
using 775 µL MilliQ-H2O and vortexed. Trypsin (Promega, Gold Mass Spectrometry Grade) was 
added at 1:50 ratio to the amount of protein, mixed and the digestion was carried out at 37°C 
overnight.  
3.2.6 – Proteomics –Data analysis   
  Proteomics data was analysed using Spectrum Mill (Agilent, Santa Clara) and Swissprot 
(Swiss Institute of Bioinformatics, Lausanne). 261 proteins were identified using the proteome data 
available from Swissprot (STAPHUSA300TCH1516). Univariate and multivariate analyses were 
performed with MetaboAnalyst 3.0 (Xia Lab, McGill University). Differences in the proteomic profiles 
of samples were analysed with unsupervised principal component analysis (PCA) and supervised 
partial least-squares discriminant analysis (sPLS-DA). The significance of the cross-validated P-
values, based on volcano plot comparisons between control and treatment at individual time points 
(P<0.1).    
3.2.7 – Metabolomics – Bacterial treatment and standardisation  
  A 2 L culture of MRSA was grown overnight (section 3.2.1) and bacterial concentration 
standardised to 1x108 cfu/mL using a spectrophotometer OD600 using sterile growth media. This 
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was roughly a ½ dilution which provided around 4 litres of bacterial culture and 2.75 L were required 
in total. This culture was aliquoted into 55, 50 mL sterile centrifuge tubes. All antibiotic treatments 
were used at concentrations stated in Table 24, and a no treatment control using 5 biological 
replicates. Antibiotics were added to 50 mL cultures and mixed. Throughout the experiment the 
bacteria were incubated at 37°C shaking at 250 rpm. As the antibiotic was added (0 hour), after 2, 
4, and 6 hours; 10 mL was transferred into a new 15 mL centrifuge tube and frozen in liquid nitrogen 
and stored in a -80°C freezer overnight. Samples were thawed and centrifuged (4°C, 4500 rpm) with 
the resulting pellet washed in 10 mL of cold saline solution (0.85% NaCl) followed by further 
centrifugation (4°C, 4500 rpm). All samples were adjusted to an OD600 of 1 in 200 µL of water prior 
to metabolite extraction.   
3.2.8 – Metabolomics – Metabolite extraction and quantification   
  Aliquots of 200 µL of chloroform/methanol/water (1:3:1) solution were added to 200 µL 
samples. All samples were subjected to 5 freeze thaw cycles with periodic vortexing to extract all 
metabolites. Samples were then centrifuged at 4500 rpm to remove any particulate matter and 200 
µL of supernatant was transferred to a new microcentrifuge tube. A second extraction was carried 
out by adding a further 100 µL of chloroform/methanol/water (1:3:1) to the pellet with further 
vortexing. After centrifugation, 150 µL of the supernatant was combined with supernatant from the 
first extraction. From these 350 µL metabolite extracts 50 µL was transferred to glass vials containing 
0.2 mL flat bottomed micro insert for flow injection electrospray high-resolution mass spectrometry 
(FIE-HRMS) analysis. Master mixture samples were made up of all 5 biological replicates at all time 
points creating a total of 264 samples. These samples were randomised with methanol blanks 
equally distributed throughout the run.   
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3.2.9 – Metabolomics – Metabolite fingerprinting by flow injection electrospray high-
resolution mass spectrometry   
 A high-throughput, non-targeting metabolite fingerprinting method which does not 
incorporate chromatography was used to analyse the metabolomes of MRSA treated with MNQ and 
other antibiotics (Beckmann et al., 2008). Flow injection electrospray high-resolution mass 
spectrometry (FIE-HRMS) was performed using an Exactive HCD mass analyser equipped with an 
Accela UHPLC system (Thermo Scientific) generating metabolite fingerprints in both positive and 
negative ionisation modes in a single run.  Of the 50 µL samples, 20 µL was injected into a flow of 
100 µL/min methanol/water (70:30, v/v). Ion intensities were acquired between m/z 50 and 1000 
for 3.5 minutes at a resolution setting of 100,000 (at m/z 200) resulting in 3 (± 1) ppm mass accuracy. 
ESI source parameters were set according to Thermo Scientific recommendations. Raw files were 
exported to CDF-files, mass aligned and centroided in MATLAB (V8.2.0, The MathWorks) 
maintaining highest mass accuracy. Mass spectra around the apex of the infusion peak were 
combined in a single intensity matrix (runs x m/z) for each ion mode. Data from intensity matrix was 
log-transformed before further statistical analysis.  
3.2.10 – Metabolomics –Data Analysis   
  Univariate and multivariate analyses were performed with MetaboAnalyst 3.0. Differences 
in the metabolomics profiles of samples were analysed with unsupervised principal component 
analysis (PCA) and supervised partial least-squares discriminant analysis (sPLS-DA). The significance 
of the cross-validated P-values, based on one-way analysis of variance (ANOVA), was set to P < 0.05. 
Multiple comparison and post hoc analysis used Tukey’s Honestly Significant Difference (Tukey’s 
HSD). Both ANOVA and Tukey’s HSD allowed the identification of significant metabolite changes 
between groups (control or antibiotics). Metabolites that did not show significant differences 
between treatment and control were not further analysed. For each mass-ion (m/z) the annotation 
was made using a 3 ppm tolerance on their accurate mass. Metabolomic annotation was made using 
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MZedDB (Draper et al., 2009) (http://maltese.dbs.aber.ac.uk:8888/hrmet/index.html), the E. coli 
Metabolome Database (ECMDB, http://ecmdb.ca/) and LipidMaps (http://www.lipidmaps.org/) 
databases, considering the following possible adducts: [M + H]+ , [2M + H]+ , [M + 2H]2+ , [M + 3H]+ 
, [M + Na]+ , [M + Na + 2H]+ , [2M + Na]+ , [M + 2Na−H]+ , [M + 2Na + H]+ , [M + Na + H]2+ , [M + 
2Na]+ , [M + 3Na]3+ , [M + K]+ , [M + K + H]2+ , [M + 2K + H]+ , [M−FA + H]+ , [M−H2O + H]+ , [2M + 
3H2O + 2 H]2+ , [M + NH4]+ , [M + NH4 + H]+ , [M + NH4 + H]2+ , [2 M + NH4]+ , [M + ACN + H]+ , 
[M + ACN + Na]+ , [2M + ACN + H]+ , [M + ACN + 2H]+ , [M + 2ACN]2+ , [M + 2ACN + H]+ , [M + 2ACN 
+ 2H]+ , [M + 3ACN + 2H]+ , [M + ACN + Na]+ , [M + CH3OH + H]+ ; [M−H]−, [2M−H]−, [3M−H]−, 
[M−2H]−, [M−3H]−, [M−H2O−H]−, [M + Cl]−, [M + FA−H]−, [2M + FA−H]−, [M + Hac−H]−, [M + 
Na−2H]−, [2M + Na−2H]−, [M + K−2H]−, [M + TFA−H]−. This was carried out using R statistical 
software package (R-project, version 3.6.1). A script was written to feed a csv file into the selected 
databases to output the most likely metabolite identification for each m/z value which was found 
to be significant (Appendix 5 – R-statistical package script). The targeted metabolites were mapped 
on to Kyoto Encyclopaedia of Genes and Genomes (KEGG) for pathway analysis 
(http://www.genome.jp/KEGG/pathway.html).  
3.2.11 – Transmission Electron Microscopy  
  Overnight cultures of MRSA USA300 were adjusted to 1x108 cfu/mL and treated with 
standardised concentration of MNQ for 6 hours. 1 mL samples were taken at 0, 2, 4 and 6 hours, 
then centrifuged at 10,000 rpm for 5 minutes. The supernatant was removed, 1 mL of fixative (2.5% 
glutaraldehyde in 0.1M sodium cacodylate at pH 7.2) was added to the bacterial pellet, resuspended 
and stored at 2-8 °C. After 30 minutes fixation, the samples were centrifuged, and the supernatant 
discarded. The pellets were re-suspended in another 1 mL of fresh fixative and a further 30 minutes, 
samples were centrifuged, supernatant discarded and re-suspended in 1 mL 0.1 M sodium 
cacodylate wash buffer pH at 7.2. The samples were centrifuged, and the supernatant discarded. 
They were resuspended in 1 mL of a secondary fixative consisting of 1% osmium tetroxide (Agar 
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Scientific Ltd) made up in 0.1M sodium cacodylate buffer pH at 7.2 and after 30 minutes fixation, 
the samples were centrifuged, the supernatant carefully discarded and it was replaced with a quick 
rinse in 1 mL of wash buffer. After 5 minutes rinse, the samples were centrifuged, and the 
supernatant discarded. The pellets were re-suspended in another 1mL of wash buffer. The samples 
were centrifuged, and the supernatant discarded. The samples were re-suspended in 100 µl agarose 
solution at 25⁰C and placed in a refrigerator to gel at 4⁰C. After gelling overnight, the agarose 
containing the bacteria was cut from the Eppendorf tubes and transferred into 1 mL wash buffer in 
a capped 5 mL glass vials at 4⁰C. After 30 minutes the gelled agarose pellets were placed in fresh 
wash buffer. Samples were then progressed through an alcohol series of 30%, 50%, 70%, 95% and 
three changes of 100% for at least an hour. The samples were transferred to a 1:2 mixture of ethanol 
to LR White hard grade resin (London Resin Company) then a 2:1 mixture of ethanol to resin and 
finally 100% resin overnight at 4⁰C. The next morning, the resin was removed and replaced with 
fresh resin and later that day the samples were then placed in size 4 gelatine moulds (Agar 
Scientific), filled up with fresh resin and polymerised overnight in an oven at 60⁰C. 2 µm thick 
sections containing the bacteria were cut and dried down on drops of 10% ethanol on glass 
microscope slides. They were stained with AMB stain (Merck, Darmstadt) and photographed using 
a Leica DM6000B microscope (Leica Biosystems, Wetzlar). Ultrathin 60–80 nm sections were then 
cut on a Reichert-Jung Ultracut E Ultramicrotome with a Diatome Ultra 45 diamond knife and 
collected on Gilder GS2X0.5 3.05 mm diameter nickel slot grids (Gilder Grids, Grantham, UK) float-
coated with Butvar B98 polymer (Agar Scientific) films. All sections were double stained with uranyl 
acetate (Agar Scientific) and Reynold's lead citrate (TAAB Laboratories Equipment Ltd, Aldermaston, 
UK) and observed using a JEOL JEM1010 transmission electron microscope (TEM) (JEOL Ltd, Tokyo, 
Japan) at 80 kV. The resulting images were photographed using Carestream 4489 electron 
microscope film (Agar Scientific, UK) developed in Kodak D-19 developer for 4 minutes at 20 °C, 
fixed, washed and dried according to the manufacturer's instructions.  
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 To visualise the presence of hydrogen peroxide (H2O2) produced by MRSA bacterial samples 
untreated and treated with MNQ and HNQ were placed in cerium chloride prior to fixation. Cerium 
chloride reacts with H2O2 resulting in the presence of cerium perhydroxide which shows up as black 
needle-like crystals under TEM (Bestwick et al., 1997).   
3.2.12 – Antimicrobial Assay with antioxidants  
  This assay was repeated as discussed in 1.2.6 – Antimicrobial susceptibility testing – 
Minimum inhibitory concentration, MNQ was combined with catalase and ascorbate (100 mg/L).   
3.3 – Results – Mode of action  
3.3.1 – Proteomics  
  Label free proteomic methodologies were used to further understand how MNQ effects the 
growth of MRSA after immediate exposure and 6 hours. In addition, two antibiotics were also used 




Figure 30: A – Principle component analysis showing the separation of all proteomic antibiotic 
treatments and time points based on the different quantities of proteins identified. B - Dendrogram 






 When analysing all proteome data at once Vancomycin has had the most significant effect 
on the proteome of MRSA over 6 hours, showing clear separation in a principle component analysis 
and the dendrogram (Figure 30).  
 
 
Table 25: Statistical analysis of all treatments and the total number of significantly affected proteins 
(n=3).  
Treatment   MNQ  LEV  VAN  
Time Point (hours)  0  6  0  6  0  6  
Volcano Plot (p<0.1)  3  4  16  52  3  128  
Fold change (threshold 2)  94  51  134  111  71  228  
ANOVA (p<0.05)  4 4 17 17 91 91 
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Figure 31: Box plots showing significantly (p<0.1) changed proteins when MRSA in exposed to MNQ 
at 0 and 6 hours. 
 Of the three antibiotics tested vancomycin had the largest number of significantly different 
proteins in all statistical tests, followed by Levofloxacin and MNQ had by far the fewest protein 
differences (Table 25). This indicates that vancomycin had the largest impact on the proteome of 
MRSA which is unsurprising given that it is the drug of choice for treating MRSA. MNQ however, had 
so few significantly perturbed proteins that it is difficult to suggest any MoA based on the proteomic 
data. The small number of proteins affected could indicate that the MoA of MNQ does not involve 
protein synthesis. The proteins identified using the volcano plot are shown in a box plot format in 
Figure 31.   
3.3.2 – Metabolomics  
3.3.2.1 – Metabolomics – Overview of the data  
  High throughput streamlined metabolomic methodologies were employed to compare the 
response of MRSA to MNQ and a wide range of antibiotics at four time points; 0, 2, 4, and 6 hours.   
 










CHL CIP GEN LEV MNQ MUP NAL RIF STR VAN 
Antibiotics at time points 
0 h 2 h h 4 6 h 
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Figure 32: Bar chart representing the total number of negatively ionised detected which were 
found to be significantly different from the control across all time points.   
 
 
Figure 33: Bar chart representing the total number of positively ionised detected which were found 
to be significantly different from the control across all time points.   
  Figure 32 and Figure 33result from an ANOVA (P<0.05) carried out between the antibiotic 
and the control. Each bar represents the total number of metabolites which have been significantly 
perturbed from normal growing conditions. This allows the identification of the most crucial time 
point for each antibiotic suggestion how quickly each antibiotic is acting upon the bacteria. I would 
be expected that as time progresses the number of significantly altered metabolites would increase. 
This is true for gentamycin (-), rifampicin (+/-), vancomycin (+/-) and streptomycin (+/-), however in 
most cases the antibiotics are not having this effect. MNQ has the same time profile in both positive 
and negative ionisation, this highest number of perturbed metabolites at 0h, followed by 4h, then 
2h and finally 6h. This could indicate that MNQ works very quickly. 
 These figures could also suggest how much impact each antibiotic has upon the 
metabolome of MRSA over time. Both rifampicin and gentamycin which are both protein targeting 
antibiotics seem to be having the largest impact on the metabolome. MNQ is having the 6th largest 
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3.3.2.2 – Metabolomics – Statistical analysis   
 Figure 35, Figure 36, Figure 37, Figure 38, Figure 39, Figure 40, Figure 41 and Figure 42 show 
principal component analyses (PCA) of the metabolite profiles obtained with each antibiotic 
treatment at each time point. MNQ datapoints were significantly separated from the control at all 
time points along with many of the other antibiotics. However, each antibiotic seems to show a 
specific clustering pattern showing that each has had different effects on the metabolome of MRSA. 
As MNQ has not clustered closely to any other antibiotic at any time or in either charged form. This 
suggests that MNQ has a novel MoA.  
 The antibiotics used fall into three general targeting categories; DNA (ciprofloxacin, 
levofloxacin and nalidixic acid), RNA/Protein (chloramphenicol, gentamycin, mupirocin, rifampicin 
and streptomycin) and Cell wall (vancomycin). These were combined into groups and analysed again 
along with MNQ and the control (Figure 43). By combining all the antibiotics into their broad groups, 
it was hoped that MNQ would fall into one of the three categories. MNQ distinctly clusters away 
from these three groups as it did when all antibiotics were separate both in positive and negative 
mode. This clearly indicates that MNQ does not target DNA, RNA, proteins or the cell wall in the 






Figure 34: PCA combination of the three principal components of all antibiotics at 0 hours. A - PC1 
vs 2 (neg). B – PC1 vs 3 (neg). C – PC2 vs 3 (neg). D - Three dimensional PCA with PC1, 2 and 3 
(neg).  





Figure 35: PCA combination of the three principal components of all antibiotics at 0 hours. A - PC1 
vs 2 (pos). B – PC1 vs 3 (pos). C – PC2 vs 3 (pos). D - Three dimensional PCA with PC1, 2 and 3 (pos).   
A  






Figure 36: PCA combination of the three principal components of all antibiotics at 2 hours. A - PC1 
vs 2 (neg). B – PC1 vs 3 (neg). C – PC2 vs 3 (neg). D - Three dimensional PCA with PC1, 2 and 3 
(neg).  
A  B  





Figure 37: PCA combination of the three principal components of all antibiotics at 2 hours. A - PC1 
vs 2 (pos). B – PC1 vs 3 (pos). C – PC2 vs 3 (pos). D - Three dimensional PCA with PC1, 2 and 3 (pos).  
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Figure 38: PCA combination of the three principal components of all antibiotics at 4 hours. A - PC1 
vs 2 (neg). B – PC1 vs 3 (neg). C – PC2 vs 3 (neg). D - Three dimensional PCA with PC1, 2 and 3 
(neg).  
  
A  B  





Figure 39: PCA combination of the three principal components of all antibiotics at 4 hours. A - PC1 
vs 2 (pos). B – PC1 vs 3 (pos). C – PC2 vs 3 (pos). D - Three dimensional PCA with PC1, 2 and 3 (pos).  
  
A  B  





Figure 40: PCA combination of the three principal components of all antibiotics at 6 hours. A - PC1 
vs 2 (neg). B – PC1 vs 3 (neg). C – PC2 vs 3 (neg). D - Three dimensional PCA with PC1, 2 and 3 
(neg).  
A  B  





Figure 41: PCA combination of the three principal components of all antibiotics at 6 hours. A - PC1 
vs 2 (pos). B – PC1 vs 3 (pos). C – PC2 vs 3 (pos). D - Three dimensional PCA with PC1, 2 and 3 (pos).  
A  B  




Figure 42: PCA combining all antibiotics into their general MoA; DNA (ciprofloxacin, levofloxacin 
and nalidixic acid) RNA/Protein (chloramphenicol, gentamycin, mupirocin, rifampicin and 
streptomycin) and Cell wall (vancomycin) and 2-methoxy-1,4-naphthoquinone (MNQ). A - Negative 
ionisation. B - Positive ionisation.   
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  Table 26 shows the number of metabolites whose regulation has been perturbed 
significantly by each antibiotic and matched a KEGG metabolic pathway of S. aureus subsp. aureus 
USA300_TCH1516.  
  In terms of structural similarity and proportional effect on metabolic pathways of MRSA 
MNQ is most like that of DNA targeting antibiotics; with high numbers of disturbed carbohydrate 
metabolites and relatively low proportion of amino acids affected. Therefore, MNQ and the DNA 
gyrase targeting antibiotics were docked to the using mcule 1-click docking 
(https://mcule.com/apps/1-click-docking/). This online platform calculates how well MNQ fits into 
the active site of S. aureus DNA gyrase subunit B (UniProt: GYRB_STAAU) compared to the other 
antibiotics (Table 27 and Figure 43). Based on the structural similarities MNQ has similar docking 
cores to all the DNA targeting antibiotics, possibly revealing the MoA of MNQ.  
Table 27: Top 4 docking scores of MNQ and quinolone 
antibiotics when bound to DNA gyrase subunit B    
 Docking position  MNQ  NAL  CIP  LEV  
1  -6  -6.4  -7.3  -7  
2  -6  -5.9  -7.1  -6.1  
3  -5.7  -5.4  -7  -5.9  




Figure 43: mcule 1-click docking. #1 docking orientation of 2-methoxy-1,4-naphthoquinone (A), 
nalidixic acid (B), ciprofloxacin (C), and levofloxacin (D)  
 
3.3.2.4 – Metabolomics – Specific Pathway mapping – TCA Cycle 
 Using the significantly perturbed metabolite identities which are linked to KEGG pathway it 
is possible to see in detail how certain pathways are being affected by MNQ. Several highly 
significant metabolites were identified which were involved in the TCA cycle. Not only were they 
significantly different from the control but also the other antibiotics in most cases, indicating this a 
specific to the MoA of MNQ.  
A  





Figure 44: Left: Box plots indicating the regulation of specific metabolites involved in the TCA cycle 
across all time points between MNQ and no treatment control. Right: Box plots indicating the 





Figure 45: Left: Box plots indicatingthe regulation of nicotinamide adenine dinucleotide (NADH) 
across all time points between MNQ and no treatment control. Right: Box plots indicating the 
regulation of NADH across all antibiotics at 0h time point. 
 
Figure 44 and Figure 45 show the unique effect which MNQ has upon the TCA cycle of MRSA. MNQ 
causes MRSA to upregulate all TCA cycle metabolites when compared to the control and most other 
antibiotics. NADH, a metabolite which is closely related to the TCA cycle, was also included as it 
shows a significantly decreased regulation. Multiple m/z have matched with adducts of the same 
metabolite which increases the confidence in these results.  
3.3.2.5 – Metabolomics – Specific Pathway mapping – Sugar metabolism 
 As well as the TCA cycle sugar metabolism stood out as another metabolic pathway which 
was specifically and significantly affected by MNQ.   




Figure 46: Left: Box plots indicating the regulation of specific metabolites involved in the sugar 
metabolism across all time points between MNQ and no treatment control. Right: Box plots 
indicating the regulation of specific metabolites involved in the sugar metabolism across all 




Figure 47: Left: Box plots indicating the regulation of specific metabolites involved in further sugar 
metabolism across all time points between MNQ and no treatment control. Right: Box plots 
indicating the regulation of specific metabolites involved in further sugar metabolism across all 
antibiotics at 0h time point. 
 The ability to metabolise sugars is crucial for the survival of organisms (Figure 46 and Figure 
47), MNQ was found to have a significant effect on many metabolites which were found to be either 
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sugars or linked to sugar metabolism. These were also found to be unique to MNQ treatment and 
their differential regulation was not seen in any of the other antibiotics tested.   
3.3.2.6 – Metabolomics – Specific pathway mapping – Lipid metabolism  
 In addition to the TCA cycle and sugar metabolism, MNQ also had a significant effect on lipid 
metabolism. MNQ was shown to influence most lipid types, especially the fatty acids (Table 28). 
Table 28: The regulation of all lipid families identified as significantly different from the control 
Lipid family LipidMaps 
classification 
Up Down Total 
Fatty acid conjugates FA01 84 21 105 
Octadecanoids FA02 1 0 1 
Eicosanoids FA03 3 0 3 
Fatty aldehydes FA06 2 0 2 
Fatty esters FA07 2 2 4 
Fatty amides FA08 5 0 5 
Monoradylglycerols GL01 2 0 2 
Diradylglycerols GL02 19 3 22 
Triradylglycerols GL03 2 0 2 
Glycerophosphocholines GP01 2 2 4 
Glycerophosphoethanolamines GP02 1 2 3 
Glycerophosphoserines GP03 2 0 2 
Glycerophosphoglycerols GP04 0 2 2 
Glycerophosphates GP10 2 1 3 
Glyceropyrophosphates GP11 0 1 1 
Macrolides and lactone polyketides PK04 1 0 1 
Aflatoxins and related substances PK10 1 0 1 
Flavonoids PK12 2 0 2 
Aromatic polyketides PK13 5 1 6 
Acylaminosugars SL01 2 0 2 
Sphingoid bases SP01 1 0 1 
Phosphosphingolipids SP03 1 0 1 
Neutral glycosphingolipids SP05 2 0 2 
Sterols ST01 2 0 2 
Steroids ST02 4 0 4 
Secosteroids ST03 11 5 16 
Bile acids and derivatives ST04 1 0 1 
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3.3.3 – Transmission Electron Microscopy   
 To visually inspect the impact MNQ is having upon MRSA transmission electron microscopy 
(TEM) was carried out. Figure 48 shows TEM of MRSA treated at a standardised concentration of 
MNQ at 2, 4, 6 and 24 hours. Although MNQ has been shown to impact the metabolome of MRSA, 
these changes are not visible when using TEM alone. However, at 24 hours (D) cell debris can be 
seen, cells are lighter grey and are not actively dividing, this is a clear sign of cell death. Although 
the metabolomics suggested that MNQ works quickly, this is not supported by the TEM images.  
 
Figure 48: Transmission electron microscopy of MRSA; treated with a standardised concentration 
of MNQ at 2 (A), 4 (B), 6 (C), and 24 hours (D).   
 Figure 49¬show MRSA with cerium chloride untreated and treated with MNQ and HNQ. 
Cerium chloride reacts with H2O2 to form cerium perhydroxide which shows up as black needle-like 
crystals under TEM, this indicates that there could be generation of reactive oxygen species (ROS). 
These formations can only be seen in the presence of MNQ, it is absent when untreated and treated 
with HNQ. 
   
Figure 49: Transmission electron microscopy of MRSA with cerium chloride; untreated (A) 
and treated with a standardised concentration of MNQ (B), and HNQ (C).   
A  B  C  D  
A  B  C  
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3.3.4 – Antimicrobial Assay with Antioxidants  
 Catalase and Ascorbate are both antioxidants which are able react with H2O2 to reduce 
their negative effects. This assay was carried out to see if the antioxidant activity of catalase and 
ascorbate were able to reduce the efficacy of MNQ as an antimicrobial compound. The presence of 
these antioxidants reduced the activity of MNQ two-fold (Table 29). For example, at 12.5 mg/L of 
MNQ the OD600 increased by 12.31% over 24 hours, when catalase and ascorbate is combined with 
MNQ the OD600 increased by 23.11% and 56.54%, respectively. A negative OD600 result was 
obtained for MNQ treatment at 100 mg/L, this is not uncommon as MNQ is green in colour which 
absorbs light at a lower wavelength than the straw yellow media. At very high concentration the 
green pigment is mixed thoroughly over 24 hours and will reduce the maxima of the absorbance, 
therefore slightly decreasing the OD600 value obtained at 24 hours compared to the initial time 
point. This value can be considered as 0% growth and lower concentrations of MNQ do not have 
this issue.  
Table 29: Minimum inhibitory concentration (MIC) of 2-methoxy-1,4-naphthoquinone 
(MNQ) and in the presence of catalase and ascorbate (n=3).    
MNQ Concentration 
(mg/L) 
MNQ  MNQ with Catalase 
(100 mg/L) 
MNQ with Ascorbate 
(100 mg/L) 
100  -1.30  0.03  0.30  
50  8.52  2.07  0.58  
25  13.03  3.59  13.03  
12.5  12.31  23.11  56.54  
6.25  50.61  95.29  100.46  
3.125  103.95  88.89  109.35  




3.4 – Discussion  
3.4.1 – Proteomics   
  The large-scale analysis of proteins has been used to further understand antibiotics mode 
of action (Bandow et al., 2003) as well as understanding the molecular roles of many active 
compounds including natural products (Lao et al., 2014). Proteomics approaches were employed to 
understand the effects on MNQ on MRSA, however, the regulation of very few proteins were 
affected by MNQ after 6 hours of exposure (Table 25). The low number of proteins changed by MNQ 
could indicate that MoA of MNQ does not impact on protein synthesis and regulation. 
 “Uncharacterised protein 7” was significantly down regulated under MNQ treatment at 6 
hours. It is a helical and transmembrane protein and belongs to a family of cell wall-active antibiotic 
response proteins. These transmembrane proteins are involved in the LiaRS two-component system 
(TCS) which regulates cell envelope stress response especially following the exposure to antibiotics 
such as vancomycin which interfere with the lipid II and undecaprenol cycle (Jordan et al., 2006, 
2007). Both vancomycin and levofloxacin also showed a downregulation of this protein therefore 
this is likely a generic stress response and not useful to decern the MoA of MNQ. 
 The expression of MRSA ribosome was significantly reduced by the presence of MNQ. The 
ribosome is made up of two subunits small (S1-31) and large (L1-44) and one protein of each subunit 
has been affected; S5 at 6 hours and L19 at 0 hours. L19 is known to be located at the interface 
between the small and large subunit and may play a role in the structure and function of 
aminoacyltRNA binding site (Brosius and Arfsten, 1978). Levofloxacin also significantly decreased 
the expression of both S5 and L19 whereas vancomycin significantly increased S5 with no effect of 
L19. Interestingly, the DNA targeting antibiotic, levofloxacin, shows a downregulation of ribosomal 
proteins. This would be expected as ribosomes are produced from DNA in the same way as all other 
proteins within bacteria (Crick, 1958). The upregulation of ribosomal in response to vancomycin is 
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likely a response to the cell wall breaking down. Peptidoglycan fragments are recovered and 
recycled as a part of cell wall biosynthesis; this also serves as a detection mechanism for cell-wall-
targeting antibiotics leading to an upregulation of protective genes (Johnson, Fisher & Mobashery, 
2013), which requires significant ribosomal activity.  
 Cold shock protein CspA was affected both at 0 and 6 hours. and was also significantly 
affected in vancomycin and levofloxacin. As the bacteria were flash frozen in liquid nitrogen and 
stored at -80˚C to halt protein activity, it was thought this process would have been fast enough to 
avoid any protein alterations due to this stress. The significant perturbation of cold shock proteins 
suggests otherwise.  
 DNA-binding protein HU is a part of the histone-like DNA-binding protein family which are 
a set of basic proteins that wrap around DNA stabilising it from denaturation under extreme 
conditions (Tanaka et al., 1984). MNQ decreased the expression of DNA-binding protein HU but 
vancomycin had the opposite effect; significantly increasing the amount of this protein. This 
indicates that MNQ does not inhibit bacterial growth in the same way as vancomycin.  
  Probable malate:quinone-oxidoreductase belongs to the family of proteins called 
malate:quinone-oxidoreductases (MQO). These membrane-associated enzymes are an alternative 
to the NAD-dependant malate dehydrogenase as part of the tricarboxylic acid (TCA) cycle. They play 
a critical role in bacterial survival during oxidative stress. Nitric oxide stress is an important immune 
response utilised by the host to clear a bacterial infection therefore these proteins also play a key 
role in virulence (Spahich et al., 2016.). Both MNQ and levofloxacin negatively affected this protein 
whereas vancomycin increased the amount of this protein. This suggests that MNQ seems to disrupt 
the TCA cycle and similar metabolic pathways likely acting through the generation ROS.  
 Given the low number of proteins and relatively low significance (P<0.1) of the disruption it 
is difficult to draw definite conclusions regarding the MoA of MNQ. This experiment would require 
repetition with different concentrations of MNQ over different periods of time to see a truly 
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significant proteomic impact. The fact that both vancomycin and levofloxacin were shown to effect 
large number of proteins is an indication that this experiment worked well. In addition, the few 
proteins which were affected by MNQ did match with the hypothesis that MNQ bactericidal action 
is brought about via the generation of ROS.   
3.4.2 – Metabolomics  
3.4.2.1 –Metabolomics – Overview of the data  
  When the metabolomics data are considered holistically, which is often done in literature 
(Maifiah et al., 2017; Schelli, Zhong and Zhu, 2017; Zampieri et al., 2017; Baptista et al., 2018), this 
provides broad differences and similarities between treatment groups. Figure 33 to Figure 43 show 
a combination of approaches which provide general information about all antibiotics used and how 
they compare to each other. Figure 32 and Figure 33 show the total number of metabolites affected 
by each antibiotic over 6 hours. The number of metabolites affected by each antibiotic in total and 
at each time point varies greatly. The antibiotics gentamycin, rifampicin, streptomycin and 
vancomycin affect an increasing number of metabolites over time, however MNQ along with 
chloramphenicol, ciprofloxacin, levofloxacin, and nalidixic acid have the largest effect on the 
metabolome of MRSA at the initial time point. This suggest that these antibiotics not only work in 
different ways but at different speeds. As eluded to in the introduction (Figure 24) metabolites are 
the front line in terms of response to a challenge. Metabolites are the first to respond to a change 
in environment, for example the presence of an antibiotic. Whereas proteins and especially DNA 
takes time to react to changes. The 0-hour time was originally to be used as a control time-point 
used for comparisons with later sampling points. However, the 0-hour point it is technically around 
1 minute for each sample as it takes time to add, mix, aliquot and freeze samples, therefore 
significant metabolic effects can take place within this time. This first time point can reveal the true 
metabolic effect of a drug as it shows the primary metabolic effect, whereas later time points would 
show secondary and tertiary reactions as a result of the drugs action. A publication by Zampieri et 
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al., 2018 used methodologies like ours to predict MoA of uncharacterised antimicrobial compounds. 
The research measured the total number of metabolites associated with 7 antibiotic categories; folic 
acid biosynthesis, mycolic acid biosynthesis, cell wall, RNA synthesis, protein synthesis, quinolones, 
and DNA cleavage. The first four of which had the largest number of affected metabolites effected 
at the first time point measured and even protein synthesis could also be argued to have a very 
significant initial response. 
3.4.2.2 –Metabolomics - Statistical analysis   
  PCA is an exploratory statistical procedure often used in metabolomics to draw meaningful 
conclusions between treatment groups (Xia et al., 2015). Figure 34 to Figure 42 show the PCA of all 
antibiotic treatments at each time point. At 0h MNQ has a distinct clustering pattern based on the 
top three principal components (PC) in both positive and negative ionisation. In addition to MNQ, 
chloramphenicol and nalidixic acid both cluster away from the control whereas the other treatments 
do not significantly separate from the control. This result correlates with the total number of 
disturbed metabolites because these three antibiotics have the largest effect at 0h. This indicates 
these antibiotics are having a rapid metabolic effect on the bacteria, these are likely the fastest 
acting antibiotics.  
 As time progresses other antibiotics begin to separate out from the control. MNQ is 
consistently separated from the control at every time point. At 2, 4, and 6-hours vancomycin has 
the most distinct clustering pattern in negative ionisation mode whereas nalidixic acid formed the 
most distinct cluster for positively ionised metabolites across all time points. Of all the antibiotics 
used there are three general targets, DNA, RNA and CW. The hypothesis of this experiment is that 
antibiotics which have similar MoA would show similar metabolic fingerprints, therefore forming 
distinct clusters within a PCA. All time points and treatment groups were combined into these 
groups and a PCA was carried out resulting in Figure 42. There are 3 clear clusters for each MoA and 
MNQ does not cluster with any of these suggesting that MNQ does not target DNA, RNA or the cell 
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wall in the same way these antibiotics do. This is also true for nalidixic acid, which was considered 
to have a DNA targeting MoA, however nalidixic acid points on the PCA are separate from all other 
DNA MoA treatments. Of the three DNA MoA antibiotics; nalidixic acid, ciprofloxacin, and 
levofloxacin, the latter two both second generation fluoroquinolone, whereas nalidixic acid is a first 
generation naphthyridone quinolone. In addition, a much higher dose of nalidixic acid was required 
compared to the more effective fluoroquinolone. As the antibiotic’s concentrations were 
standardised to show the same level of growth inhibition over 6 hours, this higher concentration is 
unlikely to be the cause of this differential clustering. The fact that these small differences were 
clearly shown the PCAs adds confidence to the fact that we are inferring that MNQ works differently 
to all antibiotics tested in this metabolomic data set. 
 By looking at the data collectively we have established MNQ does not affect the 
metabolome of MRSA in the way other antibiotics do, leading us to conclude MNQ has a novel MoA. 
Confidence in this result is backed up by the fact that all other antibiotics cluster together when 
grouped by their MoA, apart from nalidixic acid which seems to be working differently.  
3.4.2.3 –Metabolomics – Pathway mapping  
  To provide further detail to this metabolomic dataset the high-resolution m/z values which 
were identified as significant by the statistical analysis were matched to known metabolite identities 
using R-statistical package. Using R-statistical software, the m/z values were annotated with the 
most likely metabolite ID based on how likely certain adducts are to form and the ppm error. These 
metabolites can then be mapped onto MRSA metabolic pathways to elucidate the true metabolic 
effect of MNQ. The total number of m/z values matched to metabolites which are involved in MRSA 
metabolic pathway are shown in Table 26 separated into distinct metabolic pathways.  
 Amino acid metabolism had the highest number of perturbed metabolites, with at least a 
quarter of all metabolites affected being involved in amino acid metabolism. Carbohydrate 
metabolism was the second with the total number of affected metabolites ranging from 14.6 to 
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27.7%. The two exceptions to this general trend are ciprofloxacin and levofloxacin; which have a 
proportionally larger impact on carbohydrate metabolism. These two antibiotics are 4-quinolones 
which interfere with DNA replication and causing DNA breakage so understandably these antibiotics 
had a lesser effect on amino acid when compared to other antibiotics which target RNA polymerase 
which is directly involved in amino acid utilisation and protein synthesis. However, as we have seen 
previously nalidixic acid does not share the same metabolic fingerprint as the other DNA targeting 
antibiotics. Of all the metabolites perturbed by nalidixic acid 32.4% are involved in amino acid 
metabolism and 19.6% are involved in carbohydrate metabolism, this is patter is like that of RNA 
targeting antibiotics. The structural difference between the quinolone nalidixic acid and the 
fluorinated quinolones ciprofloxacin and levofloxacin could possibly explain the metabolic 
differences. Ciprofloxacin and nalidixic acid are known to affect E. coli in different ways; 
ciprofloxacin is able to kill non-growing cells whereas nalidixic acid cannot (Howard, Pinney and 
Smith, 1993), a resistance mutation within gyrA completely renders nalidixic acid ineffective 
whereas ciprofloxacin remains active (Lewin, Howard and Smith, 1991), and ciprofloxacin becomes 
less active in the presence of chloramphenicol and rifampicin (Chen et al., 1996).  Although these 
differences cannot directly explain the metabolomic differences seen they do suggest that nalidixic 
acid has a very different activity profile to ciprofloxacin.  
 The metabolomic profile of DNA targeting antibiotics was discussed in detail as the 
metabolic profile of MNQs most closely matches that of ciprofloxacin and levofloxacin. MNQ has a 
relatively large effect on carbohydrate metabolism and a lesser effect on amino acids. MNQ also 
shares a similar chemical structure with 4-quinolone antibiotics (Figure 27) as they both possess a 
naphthalene core. This similarity in structure and profile was probed using mcule 1-click docking 
(mcule, Palo Alto) to see how well MNQ fits into the active site of S. aureus DNA gyrase subunit B 
(UniProt: GYRB_STAAU) shown in Table 27 and Figure 43. When docked ciprofloxacin showed the 
highest binding affinity with a docking score of -7.3, followed by levofloxacin with -7. As these are 
second generation quinolone antibiotics it is unsurprising that they have higher binding affinity than 
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that of nalidixic acid which is -6.4. MNQ has similar binding affinity of -6. This is a strong binding 
affinity considering this is compared to drugs which are known to target this protein.   
  This binding affinity combined with the similar metabolomic interference profiles could hint 
that MNQ interferes with DNA synthesis in some way. However, to understand exactly how MNQ 
inhibits the growth of MRSA individual pathway analysis needs to be carried out.   
3.4.2.4 –Metabolomics - Specific Pathway Mapping – TCA cycle  
  MNQ had the third highest proportional impact on carbohydrate metabolism of the 
antibiotics with 24.7% and the second most individual metabolites with 194 significantly influenced 
metabolites within this pathway, this was only surpassed by rifampicin with 195. Therefore, 
carbohydrate metabolism was severely affected by MNQ. The TCA cycle (citrate cycle or Krebs cycle) 
is the primary metabolic pathway for all aerobic processes, it is essential for the complete 
catabolism of non-preferred carbon sources and the subsequent generation of reducing potential 
and biosynthetic intermediates (Vuong et al., 2005). It also plays an important role in 
glycolysis/gluconeogenesis, transamination, deamination and lipogenesis. It’s an important aerobic 
pathway for the final step of oxidation of carbohydrates and fatty acids. The cycle begins with acetyl-
CoA derived from glycolysis; the acetyl group is transferred to oxaloacetate to form citrate. A series 
of reactions causes the oxidation of two carbons from citrate supplying NADH for the use in 
oxidative phosphorylation (Akram, 2014). 
 Figure 44 and Figure 45 shows the regulation of all significantly perturbed TCA cycle 
metabolites over time in comparison to other treatments; MNQ showed a significant upregulation 
of citrate, isocitrate, oxoglutarate, malate, and succinate. We are assured in the identification of 
these TCA cycle metabolites as the same metabolite has been identified more than once due to 
adduct formation. For different m/z values to result in the same metabolite ID increases confidence 
in the identification process. This effect on the TCA cycle is specific to MNQ, no other antibiotics 
tested have the same activity profile a clear indication of the unique action of MNQ. Figure 50 
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depicts the TCA cycle with the 5 metabolites significantly affected by MNQ highlighted. These are 
the central metabolites within this pathway, and they are all upregulated in response to MNQ. NADH 
is a product of the TCA cycle therefore it would be expected also increase, however the opposite is 
true, there is a considerable down regulation of this metabolite.  
 
Figure 50: TCA cycle - metabolites which have been significantly affected by MNQ have been circled 
in red.  
 The literature states that clinical MRSA strains which are exposed to β-lactam antibiotics 
have been found to alter their metabolism to optimise energy production through the TCA cycle. An 
upregulation of TCA related activity was found using transcriptomics and metabolomics which 
suggests the bacteria is increasing its capability to produce more energy and increasing biosynthetic 
capability. These benefits allowed the bacteria to respond to the inhibition of cell wall synthesis by 
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β-lactams (Keaton et al., 2013). MNQ was shown to be the only antibiotic to upregulate all these 
metabolites so this is not generic stress response to an antibiotic, this is a specific response to MNQ. 
The upregulation of the TCA cycle metabolites could be an attempt to compensate for reducing 
compounds such as NADH being depleted. Fenton-mediated hydroxyl radicals which have been 
shown to be produced by many antibiotics irrespective of the molecular target. These radicals result 
in the depletion of NADH (Kohanski et al., 2007), which is demonstrated in the metabolic fingerprint 
of MNQ and the formation of H2O2 was observed using TEM (3.3.3 – Transmission Electron 
Microscopy) 
3.4.2.5 –Metabolomics - Specific Pathway Mapping – Sugar metabolism  
  MNQ also severely affects sugar metabolism (Figure 46 and  
Figure 47). Sugar metabolism is linked to energy metabolism and feed directly into the TCA cycle. 
There’s a significant upregulation of hexose and ribose sugars and their phosphates, as well as deoxy 
ribose and amino sugar phosphates and a down regulation of glucoronate. These changes in sugar 
metabolism are specific to MNQ treatment.  Redox balance is known to be closely involved in sugar 
metabolism (van Dijken and Scheffers, 1986), this supports the hypothesis that the toxic effects of 
MNQ are due to the production of ROS.   
3.4.2.6 –Metabolomics - Specific Pathway Mapping – Lipid metabolism  
  The metabolomics results to this point indicate the antibacterial activity of MNQ is due to 
toxic effect of redox cycling. The production of superoxide radicals required the use of reducing 
agents such as NADH by the bacteria to detoxify the ROS, which were found to be depleted by MNQ. 
This redox cycling is known to be caused by a range of compounds such as catechols, quinones, iron 
chelates, and aromatic nitro compounds causing membrane damage by peroxidative reactions of 
polyunsaturated fatty acids (Kappus and Sies, 1981). Metabolomic data of MRSA in the presence of 
MNQ has shown that there is redox cycling occurring and significant perturbation of lipid 
metabolism (Table 28).  
172 
 
3.4.3 – Transmission Electron Microscopy  
  Metabolomic data revealed that MNQ significantly upregulates TCA cycle metabolites whilst 
downregulating NADH. This would suggest that the redox state of MRSA has been disrupted. This 
oxidative stress caused by MNQ was supported with transmission electron microscopy using cerium 
chloride, which produces black crystals in the presence of hydrogen peroxide (H2O2) (Figure 49) 
(Bestwick et al., 1997). H2O2 is produced by bacteria due to oxidative stress, this can be seen in 
presence of MNQ.  The same experiment was carried out with HNQ yet there was no H2O2 produced 
by the bacteria. This also means that the methoxy group present is crucial to the activity of MNQ.   
3.4.4 – Antimicrobial Assay with Antioxidants  
  Metabolomics and TEM revealed that MNQ affects the growth of MRSA by forming hydroxyl 
radicals and changing with the redox state. This has resulted in the production of H2O2, which can 
be seen in the TEM, however, we do not know for certain if this production is lethal to the bacteria. 
This production could be a relatively harmless by-product of MNQ treatment, and the death of 
bacteria occurs by another mechanism. Therefore, MNQ was combined with the antioxidants 
catalase and ascorbate for a bacterial susceptibility assay. Antioxidants reduce the toxic effects of 
H2O2. If the addition of these compounds reduces the potency of MNQ, this proves the bactericidal 
effect of MNQ is due to the production of ROS. Table 29 shows that MNQ inhibits the growth on 
MNQ to just 12.3% at 12.5 mg/L, in the presence of catalase this increases to 23.1% and 56.54% in 
the presence of ascorbate. This indicates that the production of H2O2 does contribute to the 
inhibitory effect of MNQ.    
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Chapter 4 – General Conclusion   
 Of all the invasive weeds explored to discover new antimicrobial agents, one compound was 
found to be far more active than all others. This compound was identified as 2-methoxy-1,4-
naphthoquinone (MNQ) using mass spectrometry and nuclear magnetic resonance spectroscopy. A 
broad range of biological assays were carried out, finding that MNQ had a broad range of activity 
especially against gram-positive bacteria and the parasite Schistosoma mansoni. As the focus of this 
project was originally targeted at MRSA, many strains with a range of resistance mechanisms were 
assayed, all of which were susceptible to MNQ. 2-hydroxy-1,4-naphthoquinone, which is a structural 
derivative of MNQ lacking a methoxy group was found to be 10x less effective against MRSA 
indicating the importance of the methoxy group.  
 Metabolomic methodologies were developed to discover the mechanism by which MNQ 
inhibits the growth of MRSA. MNQ was found to work differently to other antibiotics and there were 
three major effects on the metabolome of MRSA: i) TCA cycle metabolites were significantly 
upregulated while NADH was down regulated. ii) Sugar metabolism was also significantly affected 
which is closely related to both the TCA cycle and the regulation of NADH. iii) Lipids across all families 
were perturbed by MNQ, which is known to be a side effect of oxidative stress. These all indicate 
that MNQ is interfering with the redox state of MRSA. These results were backed up by TEM showing 
production of hydrogen peroxide and reduction of MNQ potency by the presence of antioxidants. 
These effects are exactly what would be expected by a quinone or other compounds which cause 
superoxide radicals. Although the metabolomic results indicate that MNQ inhibits MRSA by the 
production of superoxide radicals, this does not specifically address the improved potency of the 
methoxy groups. 
  This shows the accuracy and value of metabolomics which has been the least utilised “omic” 
technique (Figure 51). The applications of metabolomics are endless, and this research has shown 
how it can be successfully applied to mode of action studies. With further development, high-
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throughput metabolomics could be used to streamline drug discovery and development leading to 
the approval of more antibiotics and other drugs.  
 
 
Figure 51: Total number of “omics” publications over time using the Google scholar search 
function.  
  As for the development of MNQ into an approved antimicrobial drug the issue with its 
cytotoxicity needs to be addressed. The cytotoxicity results obtained are worrying, however rather 
promisingly MNQ does share many structural similarities to current drugs. Synthetic alterations to 
this structure could yield a potent antimicrobial without the cytotoxicity. The significance of the 
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Appendix 1 -HPLC-PDA-ESI-MS data for I. glandulifera  
 
Figure 52: HPLC-PDA-ESI-MS chromatograms of IG1. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are two peaks of interest 
(green arrow) which show significant UV absorption and consistent molecular ions within the mass 
spectrum.  
 
Figure 53: HPLC-PDA-ESI-MS chromatograms of IG2. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 6 peaks of interest 









Figure 54: HPLC-PDA-ESI-MS chromatograms of IG3. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 5 peaks of interest 
(green arrow) which show significant UV absorption and consistent molecular ions within the mass 
spectrum. 
 
Figure 55: HPLC-PDA-ESI-MS chromatograms of IG4. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 3 peaks of interest 







Figure 56: HPLC-PDA-ESI-MS chromatograms of IG5. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There is 1 peak of interest (green 







Appendix 2 - HPLC-PDA-ESI-MS data for F. japonica 
 
Figure 57: HPLC-PDA-ESI-MS chromatograms of FJ1. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 5 peaks of interest 
(green arrow) which show significant UV absorption and consistent molecular ions within the mass 
spectrum. 
 
Figure 58: HPLC-PDA-ESI-MS chromatograms of FJ2. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 3 peaks of interest 







Figure 59: HPLC-PDA-ESI-MS chromatograms of FJ3. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There is 1 peak of interest (green 
arrow) which shows significant UV absorption and consistent molecular ions within the mass 
spectrum. 
 
Figure 60: HPLC-PDA-ESI-MS chromatograms of FJ4. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There is 1 peak of interest (green 






Figure 61: HPLC-PDA-ESI-MS chromatograms of FJ5. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 3 peaks of interest 





Appendix 3 - HPLC-PDA-ESI-MS data for R. ponticum  
 
Figure 62HPLC-PDA-ESI-MS chromatograms of RP1. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 4 peaks of interest 
(green arrow) which show significant UV absorption and consistent molecular ions within the mass 
spectrum. 
 
Figure 63: HPLC-PDA-ESI-MS chromatograms of RP2. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 11 peaks of interest 









Figure 64: HPLC-PDA-ESI-MS chromatograms of RP3. The top graph represents the total UV 
absorption of the eluting analytes. The bottom graph represents the mass chromatogram of all the 
negatively charged ions detected after eluting from the column. There are 6 peaks of interest 







Appendix 4 – All bacterial strains 
Table 30: List of all aerobic bacterial strains used for susceptibility testing and their mechanism of 
resistance to certain antibiotics  
Strain no. Organism Resistances Mechanism of resistance 
572 Acinetobacter baumannii - - 
NCTC 10661 Burkholderia cepacia - - 
NCTC 12201 Enterococcus faecalis Vancomycin vanA 
ATCC 51299 Enterococcus faecalis Vancomycin vanB 
ATCC 29212 Enterococcus faecalis - - 
ATCC 25922 Escherichia coli - - 
ATCC 35218 Escherichia coli Ampicillin β-lactamase 
NCTC 13353 Escherichia coli 3rd gen cephalosporins CTX-M 
353 Escherichia coli Nitro / Trim - 
Controls Klebsiella pneumoniae Carbapenems NDM 
NCTC 13442 Klebsiella pneumoniae Carbapenems OXA-48 
21856 Klebsiella pneumoniae - - 
ATCC 700603 Klebsiella pneumoniae 4th gen cephalosporins SHV-18 
NCTC 10975 Proteus mirabilis - - 
ATCC 27853 Pseudomonas aeruginosa - - 
8204 Salmonella enteritidis - - 
11051 Staphylococcus aureus Tetracycline - 
ATCC 29213 Staphylococcus aureus - - 
ATCC 33591 Staphylococcus aureus Methicillin mecA (III) 
ATCC 700698 Staphylococcus aureus Vancomycin hVISA 
ATCC BAA-977 Staphylococcus aureus ERY/CLIND MLSB 
H-EMRSA-15 Staphylococcus aureus Methicillin mecA (IV) 
NCTC 12493 Staphylococcus aureus Flucloxacillin mecA 
ST8-USA300 Staphylococcus aureus Methicillin mecA (IV) 
25760 Staphylococcus epidermidis - - 
25495 Staphylococcus epidermidis - - 
NCTC 11047 Staphylococcus epidermidis - - 
19473 Staphylococcus saprophyticus -  - 
Wild strain Staphylococcus saprophyticus - - 
20456 Streptococcus bovis   
21816 Streptococcus bovis - - 
21818 Streptococcus bovis - - 
22358 Streptococcus Group A - - 
22362 Streptococcus Group G - - 
ATCC 49619 Streptococcus pneumoniae - - 
18778 Streptococcus pneumoniae ERY, TET - 
21394 Streptococcus pneumoniae Penicillin PBP 
21395 Streptococcus pneumoniae ERY, CLIND MLSB 
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13121 Streptococcus pneumoniae - - 
13122 Streptococcus pneumoniae - - 
 
Table 31: List of all anaerobic bacterial strains used for susceptibility testing and their mechanism of 
resistance to certain antibiotics 
Strain No. Organism name Ribotype/Resistance mechanism Meropenem susceptibility 
1579 Bacteroides fragilis - Sensitive 
1580 Bacteroides fragilis - Sensitive 
1581 Bacteroides fragilis - Sensitive 
1582 Bacteroides fragilis - Sensitive 
1583 Bacteroides fragilis - Sensitive 
1584 Bacteroides fragilis - Sensitive 
1585 Bacteroides fragilis - Sensitive 
1591 Bacteroides fragilis - Resistant 
1592 Bacteroides fragilis - Sensitive 
1593 Bacteroides fragilis - Sensitive 
1594 Bacteroides fragilis - Sensitive 
1595 Bacteroides fragilis - Resistant 
1596 Bacteroides fragilis - Sensitive 
1597 Bacteroides fragilis - Sensitive 
1598 Bacteroides fragilis - Sensitive 
1599 Bacteroides fragilis - Sensitive 
1600 Bacteroides fragilis - Sensitive 
1601 Bacteroides fragilis - Sensitive 
1602 Bacteroides fragilis - Sensitive 
13350 Bacteroides fragilis Met R Sensitive 
ATCC 25285 Bacteroides fragilis - Sensitive 
R43812 Clostridium difficile Ribotype 001 Sensitive 
R43874 Clostridium difficile Ribotype 027 Sensitive 
R43875 Clostridium difficile Ribotype 001 Sensitive 
R43883 Clostridium difficile Ribotype 014 Sensitive 
R43935 Clostridium difficile Ribotype 001 Sensitive 
R43942 Clostridium difficile Ribotype 078 Sensitive 
R43943 Clostridium difficile Ribotype 001 Sensitive 
R43968 Clostridium difficile Ribotype 001 Sensitive 
R43997 Clostridium difficile Ribotype 078 Sensitive 
R43998 Clostridium difficile Ribotype 078 Sensitive 
R44000 Clostridium difficile Ribotype 014 Sensitive 
R44002 Clostridium difficile Ribotype 014 Sensitive 
R44003 Clostridium difficile Ribotype 014 Sensitive 
R44004 Clostridium difficile Ribotype 078 Sensitive 
R44007 Clostridium difficile Ribotype 078 Sensitive 







Appendix 5 – R-statistical package script 
# PIPsearches of ecmdb metabolite database Jasen Finch 12/10/2017 
# Database downloaded in JSON format and converted to csv 
##### Functions ##### 
 
ecmdbQueryPIP <- function(add, mz, ppm = 5, adducts = adducts, DB = DB){ 
   
  rule <- adducts$Rule[adducts$Name == add] 
  mass <- ppmRange(mz, ppm) 
  mass <- map(mass, calcM, adduct = add) 
  DB <- DB %>% filter(moldb_mono_mass > mass$lower & moldb_mono_mass < mass$upper) %>% 
    rename(Nch = moldb_formal_charge, 
           Nacc = moldb_acceptor_count, 
           Ndon = moldb_donor_count 
           ) %>% 
    mutate(Ionisation = eval(parse(text = rule))) %>% 
    filter(Ionisation == T) %>% 
    mutate(Adduct = add,`Measured m/z` = mz) 
   




ecmdbPIPsearch <- function(mz, ppm = 5, mode = 'n', adducts = adducts, DB = DB){ 
  if (mode == "p") { 
    adductList <- adducts$Name[adducts$Nelec < 0] 
  } 
  if (mode == "n") { 
    adductList <- adducts$Name[adducts$Nelec > 0] 
  } 
  if (mode == "ne") { 
    adductList <- c("M") 
  } 
   
  res <- map(adductList,ecmdbQueryPIP,mz = mz, ppm = ppm, adducts = adducts, DB = DB) %>% 
    bind_rows() %>% 
    select(id:moldb_mono_mass,Adduct:`Measured m/z`) %>% 
    rename(`Accurate Mass` = moldb_mono_mass) 
     
  if (nrow(res) > 0) { 
    res <- res %>% 
      rowwise() %>% 
      mutate(`Theoretical m/z` = calcMZ(`Accurate Mass`,Adduct), PPMerror = ppmError(`Measured 
m/z`,`Theoretical m/z`)) 
  } else { 
    res <- res %>% 
      bind_cols(tibble(`Theoretical m/z` = numeric(), PPMerror = numeric())) 
  } 
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  return(res) 
} 
 
########## Script starts here ############# 
 
## library load 
packages <- c('magrittr', 
              'purrr', 
              'dplyr', 
              'mzAnnotation', 
              'parallel' 
) 
lapply(packages,library,character.only = T) 
 
## Database and adduct preperation 
# Set DBpath to the location of ecmdb.csv 
DBpath <- 'C:/Users/dmf/Documents/ecmdb.csv' 
 
DB <- DBpath %>% 





adducts <- Adducts %>% 




# Change mode and ppm threshold for searches accordingly 
Mode <- 'n' 
PPM <- 3 
 
# set mzPath to the location of mz.csv 
# mz.csv should contain a single column of masses with the heading "mz"  
mzPath <- 'C:/Users/dmf/Documents/mz.csv' 
MZ <- read_csv(mzPath) 
 
clus <- makeCluster(detectCores())  
clusterExport(clus,varlist = c(ls('package:magrittr'), 
                               ls('package:purrr'), 
                               'ecmdbQueryPIP', 
                               ls('package:mzAnnotation'), 
                               ls('package:dplyr') 
                               )) 
PIPhits <- parLapply(clus,MZ$mz,ecmdbPIPsearch,ppm = PPM,mode = Mode,adducts = adducts,DB = DB) 
%>% 
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